SEC Filing | Protalix BioTherapeutics

View:

1
Filed Pursuant to Rule 424(b)(3)
Registration No. 333-48677

EMBASSY ACQUISITION CORP.
1428 BRICKELL AVENUE, SUITE 105
MIAMI, FLORIDA 33131

March 26, 1998

Dear Fellow Shareholder:

I am pleased to enclose information relating to a Special Meeting of
Shareholders of Embassy Acquisition Corp. ("Embassy") to be held at NationsBank
Tower Auditorium, 100 SE 2nd Street, 19th Floor, Miami, Florida 33131 at 9:00
a.m. E.D.T. on April 16, 1998. At the Special Meeting of Shareholders you will
be asked:

1. To consider and vote upon a proposal to approve an Agreement and
Plan of Merger and Reorganization dated as of October 30, 1997 (the "Merger
Agreement") by and between Embassy and Orthodontix, Inc., a Florida
corporation ("Orthodontix"), providing for, among other things, (i) the
merger of Orthodontix Acquisition Corp., a Florida corporation and wholly
owned subsidiary corporation of Embassy ("Embassy Sub") with and into
Orthodontix (the "Merger"), and (ii) an amendment to Embassy's Articles of
Incorporation to change Embassy's name to "Orthodontix, Inc.";

2. To consider and vote upon a proposal to approve an amendment to
Embassy's Articles of Incorporation to provide for an authorized class of
Preferred Stock consisting of 100,000,000 shares, par value $.0001 per
share, with rights, preferences and designations of such shares to be
determined by the Board of Directors of Embassy; and

3. To consider and vote upon a proposal to approve the 1997 Embassy
Acquisition Corp. Stock Option Plan.

If the Merger is not consummated, the Embassy Articles of Incorporation
will not be amended and restated, and the 1997 Embassy Acquisition Corp. Stock
Option Plan will not be implemented, notwithstanding shareholder approval of
such proposals.

As a result of the Merger: (i) Embassy's name will be changed to
"Orthodontix, Inc."; (ii) Orthodontix will become a wholly-owned subsidiary
corporation of Embassy; (iii) Embassy will issue an aggregate of approximately
3,487,940 shares, par value $.0001 per share, of Embassy Common Stock (the
"Merger Stock") to the current owners of all of the outstanding shares of
capital stock of Orthodontix, and in exchange for the acquisition of
substantially all the assets of 27 orthodontic practices, which will then
constitute approximately 57.9% of the then outstanding shares of capital stock
of Embassy, without giving effect to (a) the issuance of 120,000 shares of
Embassy Common Stock issuable upon the exercise of certain warrants held by
affiliates of Barron Chase Securities, Inc. (the "Underwriter Warrants"); or (b)
the issuance of 959,944 shares of Embassy Common Stock issuable upon the
exercise of certain stock options granted to certain persons, based on an
assumed Average Price of $8.5625 per share (the "Closing Stock Options"); and
(iv) designees of Orthodontix, Inc. will comprise four of the seven members of
the Board of Directors of Embassy. None of the shares of Embassy Common Stock
currently outstanding will be converted or otherwise modified in the Merger and
all of such shares will continue to be outstanding capital stock of Embassy
after the Merger. A copy of the Merger Agreement is attached as Appendix A to,
and is summarized in, the accompanying Proxy Statement/Prospectus.

The Board of Directors of Embassy has fixed March 24, 1998 as the record
date for the determination of shareholders entitled to notice of and to vote at
the Special Meeting of Shareholders. The affirmative vote of the holders of a
majority of all of the outstanding Embassy Common Stock entitled to vote at the
Special Meeting is necessary to approve and adopt the Merger, assuming that less
than 30% of the shares of Embassy Common Stock held by non-affiliated
shareholders are voted against approval of the Merger. The holders of Embassy
Common Stock are entitled to certain redemption rights. These redemption rights
are more fully described in the attached Proxy Statement/Prospectus.

Enclosed is a Notice of Special Meeting of Shareholders of Embassy and a
Proxy Statement/Prospectus containing detailed information concerning the Merger
Agreement and the transactions contemplated thereby. Whether or not you plan to
attend the Special Meeting of Shareholders, we urge you to read this material
carefully. Your vote is important. In order to ensure that your vote is
represented at the Special Meeting of
2

Shareholders, please indicate your vote on the Proxy form, date and sign it, and
return it in the enclosed postage prepaid envelope. A prompt response is
appreciated. If you are able to attend the Special Meeting of Shareholders, you
may revoke your Proxy and vote in person if you wish.

The Board of Directors of Embassy unanimously recommends that you vote FOR
the approval and adoption of the proposals described above.

Very truly yours,

Glenn L. Halpryn, President
3

EMBASSY ACQUISITION CORP.
1428 BRICKELL AVENUE, SUITE 105
MIAMI, FLORIDA 33131

---------------------

NOTICE OF SPECIAL MEETING OF SHAREHOLDERS
TO BE HELD ON APRIL 16, 1998

NOTICE IS HEREBY GIVEN that a Special Meeting of Shareholders (the "Special
Meeting") of Embassy Acquisition Corp., a Florida corporation ("Embassy"), will
be held on April 16, 1998, commencing at 9:00 A.M., local time, at NationsBank
Tower Auditorium, 100 SE 2nd Street, 19th Floor, Miami, Florida 33131, for the
following purposes:

1. The Merger. To consider and vote upon the following interrelated
matters (collectively, the "Merger") as a single proposal:

(i) to approve and adopt a certain Agreement and Plan of Merger and
Reorganization, dated as of October 30, 1997 (the "Merger Agreement"), by
and between Embassy and Orthodontix, Inc. a Florida corporation
("Orthodontix"), providing for, among other things, the merger of
Orthodontix Acquisition Corp., a Florida corporation and wholly owned
subsidiary corporation of Embassy ("Embassy Sub"), with and into
Orthodontix; and

(ii) to approve an amendment to Embassy's Articles of Incorporation to
change Embassy's name to "Orthodontix, Inc.";

2. Authorization to Issue Preferred Stock. To consider and vote upon a
proposal to amend and restate Embassy's Articles of Incorporation to provide for
an authorized class of Preferred Stock consisting of 100,000,000 shares, par
value $.0001 per share (the "Preferred Stock"), with rights, preferences and
designations of such shares to be determined by the Board of Directors of
Embassy (the "Preferred Stock Amendment");

3. 1997 Stock Option Plan. To consider and vote upon a proposal to approve
the 1997 Embassy Acquisition Corp. Stock Option Plan (the "Stock Option Plan
Proposal"); and

4. Other Business. To transact any other business that may properly come
before the Special Meeting or any adjournment or postponement thereof.

As a result of the Merger (i) Embassy's name will be changed to
"Orthodontix, Inc."; (ii) Orthodontix will become a wholly-owned subsidiary
corporation of Embassy; (iii) Embassy will issue an aggregate of approximately
3,487,940 shares of common stock, par value $.0001 per share, (the "Embassy
Common Stock") to the owners of all of the outstanding shares of capital stock
of Orthodontix, and in exchange for the acquisition of substantially all the
assets of 27 orthodontic practices, which will then constitute approximately
57.9% of the then outstanding shares without giving effect to (a) the issuance
of 120,000 shares of Embassy Common Stock issuable upon the exercise of certain
warrants held by affiliates of Barron Chase Securities, Inc. (the "Underwriter
Warrants"); or (b) the issuance of 959,944 shares of Embassy Common Stock
issuable upon the exercise of certain stock options granted to certain persons
(the "Closing Stock Options"); and (iv) designees of Orthodontix, Inc. will
comprise four of the seven members of the Board of Directors of Embassy. None of
the shares of Embassy Common Stock currently outstanding will be converted or
otherwise modified in the Merger and all of such shares will continue to be
outstanding capital stock of Embassy after the Merger. A copy of the Merger
Agreement and the Form of Restated Articles of Incorporation of Embassy are
attached to the accompanying Proxy Statement/Prospectus as Appendices A and B,
respectively, and are incorporated herein by reference.

CONCURRENTLY WITH THE CLOSING OF THE MERGER, EMBASSY WILL ACQUIRE IN
SEPARATE TRANSACTIONS (THE "PRACTICE ACQUISITIONS") SUBSTANTIALLY ALL THE
TANGIBLE AND INTANGIBLE ASSETS AND ASSUME CERTAIN LIABILITIES OF 27 ORTHODONTIC
PRACTICES (COLLECTIVELY, THE "FOUNDING PRACTICES") IN EXCHANGE FOR CASH AND
SHARES OF EMBASSY COMMON STOCK (IN ACCORDANCE WITH STAFF AC-
4

COUNTING BULLETIN NO. 48). THE NUMBER OF SHARES OF EMBASSY COMMON STOCK
TO BE ISSUED IN EACH ACQUISITION WILL DEPEND ON THE PRICE OF THE EMBASSY COMMON
STOCK. THE NUMBER OF SHARES WILL DEPEND ON THE AVERAGE OF THE CLOSING BID AND
ASK PRICE, AS REPORTED ON THE OTC ELECTRONIC BULLETIN BOARD OF EMBASSY COMMON
STOCK FOR THE 15 TRADING DAYS IMMEDIATELY PRECEDING THE DATE OF THE CLOSING OF
THE PRACTICE ACQUISITIONS (THE "AVERAGE PRICE"). THE DISCLOSURES HEREIN RELATING
TO THE EMBASSY COMMON STOCK ISSUED IN CONNECTION WITH THE PRACTICE ACQUISITIONS
ARE ESTIMATED, BASED ON AN ASSUMED AVERAGE PRICE OF $8.5625 PER SHARE (THE
MIDPOINT OF THE CLOSING BID AND ASK PRICE, AS REPORTED ON THE OTC ELECTRONIC
BULLETIN BOARD OF EMBASSY COMMON STOCK FOR THE 15 TRADING DAYS IMMEDIATELY
PRECEDING THE DATE HEREOF).

SHAREHOLDER APPROVAL AND ADOPTION OF THE MERGER WILL RESULT IN A CHANGE OF
THE MAJORITY EQUITY OWNERSHIP, THE BUSINESS AND MANAGEMENT OF EMBASSY.

The Board of Directors of Embassy has fixed March 24, 1998 as the record
date for the determination of shareholders entitled to notice of and to vote at
the Special Meeting. The affirmative vote of the holders of a majority of all of
the outstanding Embassy Common Stock entitled to vote at the Special Meeting is
necessary to approve and adopt the Merger, assuming that less than 30% of the
shares of Embassy Common Stock held by non-affiliated shareholders are voted
against approval of the Merger. HOLDERS OF EMBASSY COMMON STOCK ARE NOT ENTITLED
TO APPRAISAL RIGHTS UNDER FLORIDA LAW IN CONNECTION WITH THE MERGER BUT WILL BE
ENTITLED TO CERTAIN REDEMPTION RIGHTS. These Redemption Rights are more fully
described in the attached Proxy Statement/Prospectus.

Whether or not you plan to attend the Special Meeting, please complete,
date and sign the accompanying proxy card and mail it promptly in the enclosed
pre-addressed envelope, which requires no postage if mailed in the United
States.

THE EMBASSY BOARD UNANIMOUSLY RECOMMENDS THAT THE EMBASSY SHAREHOLDERS VOTE
"FOR" THE PROPOSAL TO APPROVE AND ADOPT THE MERGER, THE PREFERRED STOCK
AMENDMENT AND THE STOCK OPTION PLAN PROPOSAL.

Ronald M. Stein, Secretary

Miami, Florida
March 26, 1998.
5

TABLE OF CONTENTS

PAGE
----

INTRODUCTION................................................ 1

AVAILABLE INFORMATION....................................... 4

SUMMARY..................................................... 5
The Parties............................................... 5
The Merger................................................ 5
Background................................................ 6
Risk Factors.............................................. 6
Special Meeting of Embassy Shareholders................... 6
Required Vote............................................. 6
Recommendations of the Boards of Directors and Reasons for
the Merger............................................. 7
Interests of Certain Persons in the Merger................ 7
Closing; Effective Date................................... 8
Conditions to the Merger.................................. 8
Right to Terminate, Amendment............................. 8
Delivery of Stock Certificates............................ 8
Comparison of Rights of Embassy Shareholders and
Orthodontix Shareholders............................... 8
Redemption Rights......................................... 9
Appraisal Rights.......................................... 9
Accounting Treatment...................................... 9
Certain Tax Consequences of the Merger.................... 9
Resale of Embassy Common Stock by Affiliates.............. 10
Certain Regulatory Matters................................ 10
Operations After the Merger............................... 10
Security Ownership of Management.......................... 10
Market Prices............................................. 10

RISK FACTORS................................................ 11
Risks Relating to Orthodontix............................. 11
Risks Relating to Embassy................................. 14

THE SPECIAL MEETING......................................... 17
Introduction.............................................. 17
Purposes of Meeting....................................... 17
Date, Time and Place; Record Date......................... 18
Voting Rights............................................. 18
Solicitation of Proxies................................... 19

PROPOSAL 1: THE MERGER...................................... 20
General................................................... 20
Background of the Merger.................................. 20
Recommendations of the Boards of Directors and Reasons for
the Merger............................................. 22
The Merger Agreement...................................... 24
Effective Date............................................ 26
Interests of Certain Persons in the Merger................ 26
Exchange of Stock Certificates............................ 28
No Fractional Shares...................................... 28
Absence of Appraisal Rights............................... 28
Redemption Rights......................................... 28
Accounting Treatment...................................... 29
Certain Tax Consequences of the Merger.................... 29

(i)
6

PAGE
----

Restrictions on Sales by Affiliates....................... 29
Certain Regulatory Matters................................ 31
Operations After the Merger............................... 31

PROPOSAL 2: RESTATEMENT OF THE ARTICLES OF INCORPORATION OF
EMBASSY................................................... 32
Authorization to Issue Preferred Stock.................... 32

PROPOSAL 3: RATIFICATION AND APPROVAL OF THE 1997 EMBASSY
ACQUISITION CORP. STOCK OPTION PLAN....................... 34
Description of the Stock Option Plan...................... 34
Federal Income Tax Consequences........................... 35
Options Outstanding....................................... 35
Recommendation of the Board of Directors.................. 36

PRICE RANGES OF EMBASSY'S SECURITIES........................ 36

MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION OF
EMBASSY................................................... 37

MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION OF
ORTHODONTIX............................................... 38
Overview.................................................. 38
Administrative Services Agreements........................ 38
Service Agreements and PA Contractor Employment
Agreements............................................. 39
Practice Acquisitions..................................... 40
Results of Operations..................................... 40
Liquidity and Capital Resources........................... 40
Year 2000 Computer Compliance............................. 40

BUSINESS OF ORTHODONTIX..................................... 41
General................................................... 41
The Orthodontic Industry.................................. 41
Operating Strategy........................................ 42
Growth Strategy........................................... 43
Affiliated Practice Operations and Locations.............. 44
Affiliated Orthodontist, PA Contractor and Other
Contractual Relationships.............................. 45
Government Regulation..................................... 45
Competition............................................... 46
Employees................................................. 46
Properties................................................ 46
Intellectual Property..................................... 47
Litigation and Insurance.................................. 47

MANAGEMENT OF ORTHODONTIX................................... 47
Executive Officers and Directors.......................... 47
Compensation of Officers and Directors.................... 48
Advisory Board............................................ 48
Anticipated Employment Arrangements....................... 49

CERTAIN TRANSACTIONS RELATING TO ORTHODONTIX................ 49

PRINCIPAL SHAREHOLDERS OF ORTHODONTIX....................... 52

DESCRIPTION OF ORTHODONTIX' SECURITIES...................... 53

BUSINESS OF EMBASSY......................................... 53

(ii)
7

PAGE
----

MANAGEMENT OF EMBASSY....................................... 53
Executive Officers and Directors.......................... 53
Compensation of Officers and Directors.................... 55

CERTAIN TRANSACTIONS RELATING TO EMBASSY.................... 55

PRINCIPAL SHAREHOLDERS OF EMBASSY........................... 56

DESCRIPTION OF EMBASSY'S SECURITIES......................... 57
General................................................... 57
Common Stock.............................................. 58
Preferred Stock........................................... 58
Transfer Agent............................................ 58
Underwriter Warrants...................................... 58

COMPARISON OF RIGHTS OF EMBASSY SHAREHOLDERS AND ORTHODONTIX
SHAREHOLDERS.............................................. 59

LEGAL MATTERS............................................... 59

EXPERTS..................................................... 59

INDEX TO FINANCIAL STATEMENTS............................... F-1

APPENDICES.................................................. A-1
Appendix A: Merger Agreement.............................. A-1
Appendix B: Restated Articles of Incorporation............ B-1

(iii)
8

EMBASSY ACQUISITION CORP.
PROXY STATEMENT AND PROSPECTUS

3,487,940 SHARES OF COMMON STOCK

INTRODUCTION

This Proxy Statement and Prospectus ("Proxy Statement/Prospectus") is being
furnished to the shareholders (the "Embassy Shareholders") of common stock, par
value $.0001 per share (the "Embassy Common Stock") of Embassy Acquisition
Corp., a Florida corporation ("Embassy") in connection with the solicitation of
proxies by the Board of Directors of Embassy (the "Embassy Board") from such
holders for use at a Special Meeting of Shareholders of Embassy (the "Special
Meeting") to be held on April 16, 1998 at 9:00 local time at NationsBank Tower
Auditorium, 100 SE 2nd Street, 19th Floor, Miami, Florida 33131, and any
adjournments or postponements thereof.

At the Special Meeting, Embassy Shareholders will be asked to consider and
vote upon a proposal to approve and adopt an Agreement and Plan of Merger and
Reorganization, dated as of October 30, 1997 (the "Merger Agreement"), providing
for the merger (the "Merger") of Orthodontix Acquisition Corp., a Florida
corporation wholly owned by Embassy ("Embassy Sub"), with and into Orthodontix,
Inc., a Florida corporation ("Orthodontix"). A copy of the Merger Agreement is
attached as Appendix A hereto and is incorporated herein by reference.

This Proxy Statement/Prospectus also constitutes a prospectus of Embassy
with respect to 3,487,940 shares of Embassy Common Stock to be issued to
shareholders of Orthodontix pursuant to the Merger Agreement. This Proxy
Statement/Prospectus, the enclosed Notice of Special Meeting of Shareholders and
the form of proxy are first being mailed to the Embassy Shareholders on or about
March 26, 1998.

In addition, at the Special Meeting, Embassy Shareholders will be asked to
consider and vote upon a proposal to amend and restate Embassy's Articles of
Incorporation to provide for an authorized class of Preferred Stock consisting
of 100,000,000 shares, par value $.0001 per share (the "Preferred Stock"), with
rights, preferences and designations of such shares to be determined by the
Embassy Board (the "Preferred Stock Amendment"); and a proposal to ratify and
approve the 1997 Embassy Acquisition Corp. Stock Option Plan (the "Stock Option
Plan"). The Form of Restated Articles of Incorporation of Embassy (the "Restated
Articles") is attached hereto as Appendix B and is incorporated herein by
reference.

As a result of the Merger and the transactions contemplated thereby, all as
more fully set forth in the Merger Agreement (i) Embassy's name will be changed
to "Orthodontix, Inc." (the "Name Change"); (ii) Orthodontix will become a
wholly-owned subsidiary corporation of Embassy; (iii) Embassy will issue that
amount of shares of par value $.0001 per share, of Embassy Common Stock (the
"Merger Stock"), to the current owners of all of the outstanding shares of
capital stock of Orthodontix and in connection with the Practice Acquisitions
(hereinafter defined), which will constitute approximately 57.9% of the then
outstanding shares of capital stock of Embassy, without giving effect to (a) the
issuance of 120,000 shares of Embassy Common Stock issuable upon the exercise of
certain warrants held by affiliates of Barron Chase Securities, Inc. (the
"Underwriter Warrants"); or (b) the issuance of 959,944 shares of Embassy Common
Stock issuable upon the exercise of certain stock options granted to certain
persons, based on an assumed Average Price of $8.5625 per share (the "Closing
Stock Options"); and (iv) designees of Orthodontix will comprise four of the
seven members of the Embassy Board. For additional information relating to the
Closing Stock Options, See "Proposal 1: THE MERGER -- Interests of Certain
Persons."

CONCURRENTLY WITH THE CLOSING OF THE MERGER, THE ACQUISITION (THE "PRACTICE
ACQUISITIONS") OF SUBSTANTIALLY ALL THE TANGIBLE AND INTANGIBLE ASSETS AND THE
ASSUMPTION OF CERTAIN LIABILITIES OF 27 ORTHODONTIC PRACTICES (COLLECTIVELY, THE
"FOUNDING PRACTICES") WILL BE CONSUMMATED IN
9

EXCHANGE FOR CASH AND SHARES OF EMBASSY COMMON STOCK IN ACCORDANCE WITH STAFF
ACCOUNTING BULLETIN NO. 48.

THE FOLLOWING SUMMARY IS QUALIFIED IN ITS ENTIRETY BY THE MORE DETAILED
INFORMATION AND FINANCIAL STATEMENTS, INCLUDING THE NOTES THERETO, APPEARING
ELSEWHERE IN THIS PROXY STATEMENT/PROSPECTUS. UNLESS OTHERWISE INDICATED, THE
INFORMATION IN THIS PROXY STATEMENT/PROSPECTUS GIVES EFFECT TO THE PRACTICE
ACQUISITIONS.

THE MERGER WILL RESULT IN A CHANGE-IN-CONTROL OF EMBASSY, WHEREBY, AMONG
OTHER THINGS, THE SHAREHOLDERS OF ORTHODONTIX WILL BECOME THE CONTROLLING
SHAREHOLDERS AND PRINCIPAL EXECUTIVE OFFICERS AND DIRECTORS OF EMBASSY
SUBSEQUENT TO THE CONSUMMATION OF THE MERGER.

THE CONSUMMATION OF THE MERGER IS SUBJECT TO SEVERAL CONDITIONS, INCLUDING
THE APPROVAL AND ADOPTION OF THE MERGER BY THE EMBASSY SHAREHOLDERS AND LESS
THAN 30% OF THE OUTSTANDING EMBASSY COMMON STOCK HELD BY NON-AFFILIATED EMBASSY
SHAREHOLDERS ACTUALLY VOTING AGAINST THE MERGER. EMBASSY'S DIRECTORS AND
EXECUTIVE OFFICERS, COLLECTIVELY HOLDING AN AGGREGATE OF APPROXIMATELY 30.7% OF
THE OUTSTANDING EMBASSY COMMON STOCK BEFORE GIVING EFFECT TO THE MERGER, HAVE
AGREED, WITH RESPECT TO THE PROPOSAL TO APPROVE THE MERGER, TO VOTE THEIR
RESPECTIVE SHARES OF EMBASSY COMMON STOCK IN ACCORDANCE WITH THE VOTE OF THE
MAJORITY OF THE NON-AFFILIATED EMBASSY SHAREHOLDERS.

UNLESS OTHERWISE INDICATED, THE INDUSTRY INFORMATION USED IN THIS PROXY
STATEMENT/PROSPECTUS IS DERIVED FROM THE 1995 JOURNAL OF CLINICAL ORTHODONTISTS
ORTHODONTIC PRACTICE STUDY (THE "JCO STUDY") AND RELATES TO 1994 UNLESS
OTHERWISE INDICATED. PARTS I AND II OF THE 1997 JOURNAL OF CLINICAL
ORTHODONTISTS ORTHODONTIC PRACTICE STUDY (THE "1997 STUDY"), WHICH CONTAIN
CERTAIN COMPARABLE INFORMATION FOR 1995 AND 1996, HAVE RECENTLY BECOME AVAILABLE
AND ARE CITED HEREIN. THE REMAINDER OF THE 1997 STUDY IS NOT CURRENTLY
AVAILABLE. THE INFORMATION COMPILED IN THE JCO STUDY AND THE 1997 STUDY RELATES
TO ORTHODONTISTS WHO HAVE COMPLETED ACCREDITED GRADUATE ORTHODONTIC TRAINING
PROGRAMS AND DOES NOT INCLUDE GENERAL DENTISTS WHO ALSO PERFORM CERTAIN
ORTHODONTIC SERVICES.

SEE "RISK FACTORS" FOR CERTAIN INFORMATION THAT SHOULD BE CONSIDERED BY
EMBASSY SHAREHOLDERS IN VOTING UPON THE MERGER, THE PREFERRED STOCK AMENDMENT,
AND THE STOCK OPTION PLAN.

No person is authorized to give any information or to make any
representations other than those contained in this Proxy Statement/Prospectus,
and if given or made, such information or representations should not be relied
upon as having been authorized. This Proxy Statement/Prospectus does not
constitute the solicitation of a proxy in any jurisdiction to or from any person
to whom or from whom it is unlawful to make such proxy solicitation in such
jurisdiction. Neither the delivery of this Proxy Statement/Prospectus nor any
distribution of securities pursuant to this Proxy Statement/Prospectus shall,
under any circumstances, create any implication that there has been no change in
the information set forth herein or in the affairs of Embassy or Orthodontix
since the date of this Proxy Statement/Prospectus. However, if any material
change occurs during the period that this Proxy Statement/Prospectus is required
to be delivered, this Proxy Statement/Prospectus will be amended and
supplemented accordingly. All information regarding Embassy in this Proxy
Statement/Prospectus has been supplied by Embassy, and all information regarding
Orthodontix has been supplied by Orthodontix.

The Embassy Board knows of no matters that will be presented for
consideration at the Meeting other than those matters set forth in the Notice of
Special Meeting of Shareholders. If any other matters are properly presented at
the Meeting, the persons named in the enclosed proxy and acting thereunder will
have

2
10

authority to vote on such matters, to the extent permitted by the rules of the
Securities and Exchange Commission (the "Commission"), in accordance with the
judgement of the persons voting such proxies.

THE SECURITIES TO WHICH THIS PROXY STATEMENT/PROSPECTUS RELATE HAVE NOT
BEEN APPROVED OR DISAPPROVED BY THE SECURITIES AND EXCHANGE COMMISSION OR ANY
STATE SECURITIES COMMISSION, NOR HAS THE SECURITIES AND EXCHANGE COMMISSION OR
ANY STATE SECURITIES COMMISSION PASSED UPON THE ACCURACY OR ADEQUACY OF THIS
PROXY STATEMENT/PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL
OFFENSE.

The last reported closing bid price of Embassy Common Stock on the OTC
Bulletin Board on March 25, 1998 was $8.75 per share.

The date of this Proxy Statement/Prospectus is March 26, 1998.

3
11

AVAILABLE INFORMATION

Embassy is subject to the information requirements of the Securities
Exchange Act of 1934, as amended, (the "Exchange Act") and in accordance
therewith is required to file periodic reports, proxy statements and other
information with the Commission pursuant to the Exchange Act relating to its
business, financial statements and other matters. Such reports, proxy and
information statements and other information are available for inspection and
copying at the Commission's principal office, Room 1024, Judiciary Plaza at 450
Fifth Street, N.W., Washington, D.C. 20549; the Northeast Regional Office of the
Commission at 7 World Trade Center, Suite 1300, New York, New York 10048; and
the Midwest Regional office of the Commission, Citicorp Center, 500 West Madison
Street, Suite 1400, Chicago, Illinois 60611. Copies of such material may be
obtained upon payment of the fees prescribed by the Commission from the Public
Reference Section of the Commission, 450 Fifth Street, N.W., Washington, D.C.
20549. Such documents may also be obtained through the website maintained by the
Commission at http://www.sec.gov.

Embassy has filed with the Commission a registration statement (the
"Registration Statement") under the Securities Act of 1933, as amended (the
"Securities Act"), on Form S-4 with respect to the securities offered hereby.
This Proxy Statement/Prospectus also constitutes the Prospectus of Embassy filed
as part of the Registration Statement and does not contain all of the
information set forth in the Registration Statement and the exhibits thereto,
certain parts of which are omitted in accordance with the rules of the
Commission. Statements made in this Proxy Statement/Prospectus as to the
contents of any contract, agreement, or other document referred to are not
necessarily complete; with respect to each such contract, agreement or other
document filed as an exhibit to the Registration Statement, reference is made to
the exhibit for a more complete description of the matter involved, and each
such statement shall be qualified in its entirety by such reference. The
Registration Statement and any amendments thereto, including exhibits filed as
part thereof, are available for inspection and copying at the Commission's
offices as described above.

PRIVATE SECURITIES LITIGATION REFORM ACT SAFE HARBOR STATEMENT. When used
in this Proxy Statement/Prospectus, the words "estimate," "project," "intend,"
"expect" and similar expressions are intended to identify forward-looking
statements. Such statements are subject to risks and uncertainties that could
cause actual results to differ materially from those contemplated in such
forward-looking statements. For a discussion of such risks, see "RISK FACTORS."
Readers are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. Embassy does not undertake
any obligation to publicly release any revisions to these forward-looking
statements to reflect events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events.

[This Space Intentionally Left Blank]

4
12

SUMMARY

The following is a brief summary of certain significant matters discussed
elsewhere in this Proxy Statement/Prospectus. The information contained in this
summary is qualified in its entirety by, and should be read in conjunction with,
the detailed information and financial statements, including the notes thereto,
appearing elsewhere in this Proxy Statement/Prospectus and the documents
incorporated herein by reference. The reader is cautioned that forward-looking
statements are contained in this summary and in other sections of this Proxy
Statement/Prospectus. All forward-looking statements are necessarily speculative
and there are certain risks and uncertainties that could cause actual events or
results to differ materially from those referred to in such forward-looking
statements. Capitalized terms used and not otherwise defined in this summary
have the meanings given to them elsewhere in this Proxy Statement/Prospectus.

THE PARTIES

Embassy. Embassy was formed in November 1995 to serve as a vehicle to
effect a merger, exchange of capital stock, asset acquisition or other similar
business combination (a "Business Combination") with a business (an "Acquired
Business"). In April 1996, Embassy consummated an initial public offering of its
equity securities (the "IPO") from which it derived net proceeds of
approximately $7,052,000 (the "Net Proceeds"). As per the terms of its
prospectus dated April 2, 1996, $6,800,767 of the Net Proceeds, representing 90%
of the Net Proceeds (inclusive of interest earned thereon) was held in escrow at
September 30, 1997 pending the consummation of a Business Combination and will
be released to Embassy upon consummation of the Merger. The balance of the Net
Proceeds, less net operating expenses to date, is currently held by Embassy and
is being used in Embassy's pursuit of the Merger. Other than its IPO and the
pursuit of a Business Combination, Embassy has not engaged in any business to
date. Embassy's executive offices are located at 1428 Brickell Avenue, Suite
105, Miami, Florida 33131 and its telephone number is (305) 374-6700. See
"BUSINESS OF EMBASSY."

Orthodontix. Orthodontix was organized in August 1996 to provide practice
management services to orthodontic practices. Concurrently with the consummation
of the Merger, the Founding Practices will transfer certain operating assets and
liabilities to Embassy in exchange for cash and shares of Embassy Common Stock.
Immediately subsequent to the acquisition of the Founding Practices, Embassy
will provide practice management services to the Founding Practices pursuant to
long-term administrative services agreements with separately organized
affiliated professional associations (collectively, the "PA Contractors"). The
PA Contractors directly employ orthodontists or affiliate with other separately
formed professional associations owned by practicing orthodontists pursuant to
service agreements ranging from terms of two to ten years (the "Practitioner
PAs"). In those practices where the PA Contractors do not directly employ
orthodontists, the Practitioner PAs directly employ orthodontists. In all cases,
Orthodontix directly employs all non-orthodontic personnel and subject to
applicable law directly owns the tangible equipment and other assets utilized in
the practices. Unless the context otherwise requires, references to: (i)
"Affiliated Practices" include the Founding Practices and any orthodontic
practice which enters into a similar arrangement with Orthodontix whereby it is
provided practice management services by Orthodontix, with orthodontic services
provided by the "Affiliated Orthodontists"; and (ii) "Affiliated Orthodontists"
include orthodontists directly employed by the PA Contractors or the
Practitioner PAs. Orthodontix' executive offices are located at 2222 Ponce de
Leon Boulevard, Suite 300, Coral Gables, Florida 33134 and its telephone number
is (305) 446-8661.

THE MERGER

Subject to the approval of the Merger Agreement by the Embassy Shareholders
and certain other conditions, on the date the Merger becomes effective (the
"Effective Date"): (i) Embassy Sub will be merged with and into Orthodontix and
Orthodontix will become a wholly-owned subsidiary of Embassy; (ii) each
outstanding share of Orthodontix common stock, par value $.0001 per share (the
"Orthodontix Common Stock") will be converted into the right to receive one
share of Embassy Common Stock; (iii) the name of Embassy will be changed to
Orthodontix, Inc.; and (iv) designees of Orthodontix will comprise four of the
seven members of the Embassy Board.

5
13

On the Effective Date, the holders of all the outstanding Orthodontix
Common Stock will receive in the aggregate, 3,487,940 shares of Embassy Common
Stock (the "Merger Stock"), which will then constitute approximately 57.9% of
the then outstanding shares of Common Stock of Embassy. Assuming the issuance of
1,079,944 shares of Embassy Common Stock issuable subsequent to the Merger upon
the (a) exercise of the Underwriter Warrants (120,000 shares) and (b) the
exercise of the Closing Stock Options (959,944 shares), the percentage to be
owned by the current Embassy shareholders would be 40.0% of the outstanding
Embassy Common Stock.

BACKGROUND

For a detailed description of the analysis and negotiations conducted by
the parties in connection with the Merger, See "PROPOSAL 1: THE
MERGER -- Background."

RISK FACTORS

Embassy Shareholders should carefully consider certain risk factors in
evaluating the Merger. See "RISK FACTORS" beginning on page 11.

SPECIAL MEETING OF EMBASSY SHAREHOLDERS

The Special Meeting will be held at 9:00 A.M. local time, on April 16,
1998, at the NationsBank Tower Auditorium, 100 Southeast 2nd Street, 19th Floor,
Miami, Florida, 33131. At the Special Meeting, Embassy Shareholders will be
asked to consider and vote upon: (i) the proposal to approve and adopt the
Merger Agreement and the transactions contemplated thereby; (ii) the proposal to
approve the Preferred Stock Amendment and (ii) the proposal to ratify and
approve the Stock Option Plan, as discussed elsewhere herein and such other
business as may properly come before the Embassy Special Meeting. The Embassy
Board has fixed the close of business on March 24, 1998 as the record date (the
"Embassy Record Date") for the determination of holders of Embassy Common Stock
entitled to notice of and to vote at the Special Meeting. See "THE SPECIAL
MEETING."

THE EMBASSY BOARD, WITHOUT DISSENT OR ABSTENTION, HAS APPROVED THE MERGER
AND RECOMMENDS THAT THE EMBASSY SHAREHOLDERS VOTE "FOR" THE PROPOSAL TO APPROVE
AND ADOPT THE MERGER, THE PREFERRED STOCK AMENDMENT AND THE STOCK OPTION PLAN
PROPOSAL. SEE "PROPOSAL 1: THE MERGER -- RECOMMENDATIONS OF THE BOARD OF
DIRECTORS AND REASONS FOR THE MERGER -- EMBASSY."

REQUIRED VOTE

Orthodontix. The Merger Agreement and the transactions contemplated
thereby have heretofore been approved and adopted by the holders of all
outstanding shares of Orthodontix Common Stock.

Embassy. The presence, either in person or by proxy, of the holders of a
majority of the outstanding shares of Embassy Common Stock entitled to vote at
the Special Meeting is necessary to constitute a quorum at the Special Meeting.
The affirmative vote of the holders of a majority of the outstanding shares of
Embassy Common Stock entitled to vote is necessary to approve and adopt the
Merger. Embassy's directors and executive officers, collectively holding an
aggregate of approximately 30.7% of the outstanding shares of Embassy Common
Stock before giving effect to the Merger, have agreed, with respect to the
Merger, to vote their respective shares of Embassy Common Stock in accordance
with the vote of the majority in interest of all non-affiliated Embassy
Shareholders. Consequently, if a majority of outstanding Embassy Common Stock
held and voted by non-affiliated persons is voted in favor of the Merger, the
current directors and executive officers of Embassy will vote their shares of
Embassy Common Stock in favor of the Merger. In the event, however, that holders
of 30% or more in interest of all non-affiliated Embassy Shareholders vote
against approval of the Merger, Embassy will not consummate the Merger. The
proposals to adopt the Preferred Stock Amendment and the Stock Option Plan
require the affirmative vote of a majority of the shares of Embassy Common Stock
present and entitled to vote at the Embassy Special Meeting. See "THE SPECIAL
MEETING -- Voting Rights" and "PROPOSAL 1: THE MERGER -- Redemption Rights."

6
14

RECOMMENDATIONS OF THE BOARDS OF DIRECTORS AND REASONS FOR THE MERGER

Orthodontix. On October 30, 1997, the Board of Directors of Orthodontix
(the "Orthodontix Board") without dissent or abstention, approved the Merger.
For a discussion of the factors considered by the Orthodontix Board in reaching
such decision, see "PROPOSAL 1: THE MERGER -- Recommendations of the Boards of
Directors and Reasons for the Merger -- Orthodontix."

Embassy. On October 30, 1997, the Embassy Board, without dissent or
abstention, approved the Merger. The Embassy Board recommends that the Embassy
Shareholders vote "FOR" approval and adoption of the Merger. The recommendation
of the Embassy Board is based upon its belief that the Merger will provide an
opportunity for the Embassy Shareholders to share in the expansion of
Orthodontix' market share in an industry which appears to be growing. The
Embassy Board believes that the Merger is fair to, and in the best interests of,
Embassy and the Embassy Shareholders. For a discussion of the factors considered
by the Embassy Board in making its recommendation, see "PROPOSAL 1: THE
MERGER -- Recommendations of the Boards of Directors and Reasons for the
Merger -- Embassy."

INTERESTS OF CERTAIN PERSONS IN THE MERGER

Upon consummation of the Merger, Orthodontix will be a wholly-owned
subsidiary of Embassy. F.W. Mort Guilford, the sole director of Orthodontix
immediately prior to the Effective Date, will continue to be the sole director
of Orthodontix. Additionally, and pursuant to the terms of the Merger Agreement,
after the Effective Date, Embassy and Orthodontix have agreed to cause the
following persons to be elected to the Embassy Board: (i) Stephen J. Dresnick,
M.D., (ii) Stephen Grussmark, D.D.S., M.S.D., (iii) F.W. Mort Guilford, (iv)
Glenn L. Halpryn, (v) William Thompson, D.D.S., (vi) Mel Gottlieb, and (vii)
Gary Gerson.

Upon the closing of the Merger, Drs. Dresnick, Grussmark, and Thompson and
Messrs. Guilford, Halpryn, Gottlieb and Gerson will own approximately 2,133,639
shares of Embassy Common Stock (assuming the exercise of 390,000 currently
exercisable stock options held by such individuals to be outstanding following
the consummation of the Merger), representing in the aggregate approximately
33.0% of the total shares of Embassy Common Stock to be outstanding after the
Merger (assuming the exercise of all then currently exercisable options,
warrants and other rights to purchase shares of Embassy Common Stock).
Additionally, the executive officers of Orthodontix immediately prior to the
Effective Date will be the initial executive officers of Embassy and Orthodontix
subsequent to the Merger.

In consideration for Dr. Dresnick's efforts in the negotiation of the
Merger on behalf of Embassy, on the Effective Date, Dr. Dresnick shall be
granted the option to purchase, for a period of five years from the Effective
Date, 200,000 shares of Embassy Common Stock at a per share purchase price of
$8.00 (the "Dresnick Options"). In addition, Mr. Guilford, President and Chief
Operating Officer of Orthodontix will be granted the option for a period of five
years from the Effective Date to purchase at a per share purchase price equal to
the average of the closing bid and ask price per share of Embassy Common Stock
as reported on the OTC Bulletin Board 15 trading days immediately preceding the
date of the Closing (the "Average Price") 150,000 shares (the "Guilford
Options"). Richard L. Alfonso, Vice President -- Operations of Orthodontix, will
be granted on the Effective Date the option to purchase at a per share purchase
price equal to the Average Price 25,000 shares (the "Alfonso Options"), 20% of
which shares may be purchased commencing on the Effective Date through the date
which is 60 months from the Effective Date (the "60 Month Date"), an additional
20% of which may be purchased commencing on the date which is 12 months from the
Effective Date through the 60 Month Date, an additional 20% of which may be
purchased commencing on the date which is 24 months from the Effective Date
through the 60 Month Date, an additional 20% of which may be purchased
commencing on the date which is 36 months from the Effective Date through the 60
Month Date, and the remainder of which may be purchased commencing on the date
which is 48 months from the Effective Date through the 60 Month Date. In the
event Mr. Alfonso resigns or is terminated for cause by Orthodontix from his
employment with Orthodontix, the Alfonso Options shall terminate. In addition,
Dr. William Thompson, who upon the closing of the Merger shall be a member of
the Board of Directors of Embassy, shall be granted the option to purchase for a
period of three years from the Effective Date, 40,000 shares of

7
15

Embassy Common Stock at a per share purchase price equal to 80% of the Average
Price (the "William Thompson Options").

CLOSING; EFFECTIVE DATE

The closing of the transactions contemplated by the Merger Agreement (the
"Closing") will take place no later than the fifth business day immediately
following the date on which the last of the conditions set forth in the Merger
Agreement is satisfied or waived, or at such other time as Embassy and
Orthodontix agree (the "Closing Date"). After all the conditions set forth in
the Merger Agreement have been satisfied or waived, the Merger will become
effective on such date as Articles of Merger, together with a Plan of Merger
reflecting the Merger, shall be accepted for filing by the Secretary of State of
Florida (the "Effective Date"). Such filing will be made simultaneously with or
as soon as practicable after the closing of the transactions contemplated by the
Merger Agreement. See "PROPOSAL 1: THE MERGER -- The Merger Agreement and --
Effective Date."

CONDITIONS TO THE MERGER

The respective obligations of Embassy and of Orthodontix to effect the
Merger are subject to a number of conditions, any or all of which may be waived
by the party for whom such condition was established, including, among others:
(i) the Practice Acquisitions shall have been consummated; (ii) the Merger shall
have been approved and adopted by the Embassy Shareholders, and no more than 30%
in interest of the Embassy Common Stock held by Embassy Shareholders actually
vote against the Merger; (iii) no preliminary or permanent injunction or other
order or decree by any federal or state court or any action by any state or
federal governmental agency preventing the consummation of the Merger shall have
been issued or taken and remain in effect; and (iv) all consents, orders and
approvals legally required shall have been obtained and be in effect on the
Effective Date. A copy of the Merger Agreement is attached hereto as Appendix A
to this Proxy Statement/Prospectus.

RIGHT TO TERMINATE, AMENDMENT

The Merger Agreement may be terminated (i) at any time by the mutual
consent of the parties; (ii) unilaterally by either Embassy or Orthodontix if
the Merger has not been consummated prior to May 1, 1998, unless such date is
extended by mutual consent of the parties; or (iii) unilaterally by either
Embassy or Orthodontix if the other is unable to satisfy any of its pre-closing
covenants and obligations under the Merger Agreement. See "PROPOSAL 1: THE
MERGER -- The Merger Agreement -- Termination." Subject to compliance with
applicable law, the Merger Agreement may be amended at any time prior to or
after its approval by the Embassy Shareholders only by a written agreement
executed by Embassy and Orthodontix. See "PROPOSAL 1: THE MERGER -- The Merger
Agreement -- Amendment."

DELIVERY OF STOCK CERTIFICATES

On the Effective Date, the shareholders of Orthodontix (the "Orthodontix
Shareholders") will receive certificates representing the Merger Stock.

COMPARISON OF RIGHTS OF EMBASSY SHAREHOLDERS AND ORTHODONTIX SHAREHOLDERS

The rights of Embassy Shareholders are currently governed by applicable
Florida law, the Embassy Articles of Incorporation and Embassy Bylaws. Holders
of Embassy Common Stock immediately prior to the Effective Date will continue as
Embassy Shareholders subsequent to the Effective Date, and although their
ownership in Embassy will suffer significant dilution, their rights as Embassy
Shareholders will remain substantially unchanged and will continue to be
governed by applicable Florida law, the Embassy Articles of Incorporation, as
amended, and the Embassy Bylaws from and after the Effective Date. See "RISK
FACTORS -- Certain Provisions of Embassy's Articles of Incorporation."

8
16

EMBASSY SHAREHOLDERS WILL NOT BE REQUIRED TO SURRENDER CERTIFICATES
EVIDENCING SHARES OF EMBASSY COMMON STOCK FOLLOWING THE APPROVAL AND ADOPTION OF
THE MERGER AGREEMENT AND THE SUBSEQUENT IMPLEMENTATION OF THE MERGER.

REDEMPTION RIGHTS

Each non-affiliated Embassy Shareholder as of the Embassy Record Date will
have the right until April 15, 1998 to offer his or her shares of Embassy Common
Stock to Embassy for redemption (the "Redemption") at a price equal to
approximately $5.35 per share as of September 30, 1997 (the "Redemption Value").
As per the terms of Embassy's prospectus dated April 2, 1996, the Redemption
Value is equal to Embassy's book value divided by the number of shares of
Embassy Common Stock held by all non-affiliated Embassy Shareholders, as
determined by Embassy and reviewed by its independent public accountants,
calculated as of the Embassy Record Date. If less than 30% in interest of
Embassy Common Stock held by non-affiliated Embassy Shareholders who vote
against approval of the Merger also elect to have their shares of Embassy Common
Stock redeemed, and if the Merger is consummated, Embassy will redeem shares of
Embassy Common Stock at the Redemption Value from those Embassy Shareholders who
affirmatively requested such redemption and who actually voted against approval
of the Merger. If 30% or more in interest of Embassy Common Stock held by
non-affiliated Embassy Shareholders actually vote against approval of the
Merger, the proposed Merger will be terminated, Embassy will not proceed with
the Merger and will not redeem such shares. See PROPOSAL 1: THE
MERGER -- Redemption Rights."

A non-affiliated Embassy Shareholder wishing to exercise his or her
redemption rights (i) must deliver to Embassy, prior to or at the Special
Meeting but before the vote is taken on the Merger, a written objection to the
Merger (the "Notice of Election"), which shall include a notice of his or her
election to redeem his or her Embassy Common Stock, his or her name and
residence address, the number of shares of Embassy Common Stock which he or she
owns and demand for payment of the Redemption Value of his or her shares of
Embassy Common Stock (which Notice of Election must be in addition to and
separate from any proxy or vote against the Merger); and (ii) must vote against
the Merger. A proxy directing such vote for an abstention, even if accompanied
by a Notice of Election, will not meet the requirements for exercise of the
redemption rights. A nonaffiliated Embassy Shareholder who elects to redeem his
or her shares of Embassy Common Stock may not redeem less than all of the shares
of Embassy Common Stock beneficially owned by such Embassy Shareholder as of the
Embassy Record Date. If a Shareholder votes against the Merger but specifically
chooses not to redeem his shares of Embassy Common Stock, such shareholder will
continue to be a shareholder of Embassy. See "PROPOSAL 1: THE
MERGER -- Redemption Rights."

APPRAISAL RIGHTS

Holders of Embassy Common Stock will not be entitled to appraisal rights in
connection with the Merger. See "PROPOSAL 1: THE MERGER -- Absence of Appraisal
Rights." However, see "PROPOSAL 1: THE MERGER -- Redemption Rights."

ACCOUNTING TREATMENT

For accounting and financial reporting purposes, the Merger will be treated
as a capital transaction equivalent to the issuance of stock by Orthodontix for
Embassy's net monetary assets of approximately $7.4 million as of September 30,
1997, accompanied by a recapitalization of Orthodontix. See "PROPOSAL 1: THE
MERGER -- Accounting Treatment."

CERTAIN TAX CONSEQUENCES OF THE MERGER

The Merger will be treated as a "reorganization" for federal income tax
purposes. Accordingly, other than with respect to the Redemption, (i) Embassy
will not recognize any gain or loss in the Merger; and (ii) the Embassy
Shareholders will not recognize any gain or loss in the Merger. See "PROPOSAL 1:
THE MERGER -- Certain Tax Consequences of the Merger."

9
17

RESALE OF EMBASSY COMMON STOCK BY AFFILIATES

The shares of Merger Stock to be issued to Orthodontix Shareholders in
connection with the Merger have been registered under the Securities Act.
Subject to certain lock-up agreements described below, all shares of Merger
Stock to be issued in connection with the Merger will be freely transferable by
Orthodontix Shareholders not deemed to be "Affiliates" (as such term is defined
in the Securities Act) of Orthodontix at the time of the Special Meeting. The
Merger Agreement contemplates that all of the holders of the shares of Merger
Stock will, prior to the consummation of the Merger, have entered into lock-up
agreements with Embassy to the effect that such holders shall not sell, transfer
or otherwise dispose of shares of Merger Stock received pursuant to the Merger
for specified periods of time. See "PROPOSAL 1: THE MERGER -- Restrictions on
Sales by Affiliates."

CERTAIN REGULATORY MATTERS

Except for certain required notifications and closing and post-closing
filings, consummation of the Merger is not subject to any regulatory approvals.
Although no assurance can be given, Embassy believes that the Merger can be
effected in compliance with all federal and state regulations. See "PROPOSAL 1:
THE MERGER -- Certain Regulatory Matters."

OPERATIONS AFTER THE MERGER

As a result of the Merger, Orthodontix will be a wholly-owned subsidiary
corporation of Embassy. Embassy's Articles of Incorporation will be amended on
the Effective Date to, among other things, change Embassy's name to
"Orthodontix, Inc." In accordance with the Merger Agreement, all of Embassy's
executive officers will resign effective on the Effective Date, to be replaced
by Orthodontix' current executive officers. See "PROPOSAL 1: THE
MERGER -- Operations After the Merger -- Executive Officers and Directors" and
"MANAGEMENT OF ORTHODONTIX -- Executive Officers and Directors."

SECURITY OWNERSHIP OF MANAGEMENT

As of the Record Date, the directors and executive officers of Embassy as a
group had the power to vote approximately 30.71% of the issued and outstanding
shares of Embassy Common Stock entitled to vote at the Special Meeting.
Embassy's directors and executive officers have agreed, with respect to the
Merger, to vote their respective shares of Embassy Common Stock in accordance
with the vote of the majority in interest of all non-affiliated Embassy
Shareholders.

MARKET PRICES

Embassy's Common Stock has been quoted in the over-the-counter market under
the symbol "MBCA" since April 2, 1996. There is no established trading market
for the shares of Embassy Common Stock and, to the extent there has been any
trading in the shares of Embassy Common Stock, it has been thin and sporadic.
There can be no assurances that an established trading market for the shares of
Embassy Common Stock will develop. Orthodontix Common Stock is owned of record
by nine shareholders and there is no established public trading market therefor.

On May 5, 1997 (the last day prior to the public announcement of the letter
of intent relating to the Merger that the Embassy Common Stock was quoted), the
last reported closing bid price of the Embassy Common Stock was $9.25.

On November 6, 1997 (the last day prior to the public announcement of the
execution of the Merger Agreement that the Embassy Common Stock was quoted), the
last reported closing bid price of the Embassy Common Stock was $8.00.

On March 25, 1998 (the last day prior to the date of this Proxy
Statement/Prospectus that the Embassy Common Stock was quoted), the last
reported closing bid price of the Embassy Common Stock was $8.75. On that date,
there were 46 record holders of Embassy Common Stock, inclusive of those
brokerage firms and/or clearing houses holding shares of Embassy Common Stock
for their clientele (with each such brokerage house and/or clearing house being
considered as one holder). See "PRICE RANGES OF EMBASSY'S SECURITIES."

10
18

RISK FACTORS

The business to be conducted by Embassy subsequent to the consummation of
the Merger involves certain elements of risk, including, but not limited to, the
several factors discussed below.

In addition to the other information contained in this Proxy
Statement/Prospectus, Embassy Shareholders should review carefully the following
considerations regarding the business of Orthodontix in deciding whether to vote
in favor of approval of the Merger.

RISKS RELATING TO ORTHODONTIX

Absence of Combined Operating History. Orthodontix was organized in August
1996 to provide practice management services to orthodontic practices.
Concurrently with the consummation of the Merger, substantially all the tangible
and intangible assets, and certain liabilities of the Founding Practices will be
acquired in exchange for cash and shares of Embassy Common Stock. Immediately
following the acquisition of the Founding Practices, Embassy will provide
practice management services to the Founding Practices. The Founding Practices
have been operating as separate, independent entities and there can be no
assurance that in the process of integrating management and administrative
functions, the management of Orthodontix will be able to operate the Founding
Practices successfully, manage the Founding Practices' operations effectively,
achieve any cost savings as a result of the consolidation of the Practice
Acquisitions or implement the necessary systems and procedures to manage the
Founding Practices on a profitable basis. In addition, the management group of
Orthodontix has recently been assembled and there can be no assurance that such
persons will be able to effectively oversee the implementation of Orthodontix'
operating, growth, acquisition and business strategies. The inability of
Orthodontix to successfully integrate or operate the Founding Practices, or
delays, complications and expenses in implementing and operating the necessary
systems, any of which could have a material adverse effect on Orthodontix'
business, financial condition and results of operations and make it unlikely
that Orthodontix' acquisition program will be successful. See "CERTAIN
TRANSACTIONS RELATING TO ORTHODONTIX," "MANAGEMENT'S DISCUSSION AND ANALYSIS OR
PLAN OF OPERATION OF ORTHODONTIX" and "MANAGEMENT OF ORTHODONTIX."

Dependence on Affiliated Orthodontists. Orthodontix will receive fees for
practice management services provided to the Affiliated Practices under
administrative services agreements, but does not employ orthodontists or control
or own the practices of the Affiliated Orthodontists. Orthodontix' revenue is
dependent on revenue generated by the Affiliated Practices, which in turn is
largely dependent on the efforts of the Affiliated Orthodontists and, therefore,
the performance of Affiliated Orthodontists is essential to Orthodontix'
success. The service agreements with the Practitioner PAs and the Affiliated
Orthodontists have terms ranging from two to ten years with automatic renewal
terms, subject to prior termination by the Affiliated Orthodontist. Any material
loss of revenue by the Affiliated Orthodontists, termination of such service or
employment agreements, or violation of any noncompete arrangements contained
therein, could have a material adverse effect on Orthodontix' business,
financial condition and results of operations. See "MANAGEMENT'S DISCUSSION AND
ANALYSIS OR PLAN OF OPERATION OF ORTHODONTIX" and "BUSINESS OF
ORTHODONTIX -- Services of Orthodontix and -- Affiliated Orthodontists, PA
Contractor and Other Contractual Relationships."

Risks Related to Additional Affiliations and Growth Strategy. One of
Orthodontix' primary business strategies is to increase revenue and expand the
markets it serves beyond the Founding Practices by acquiring certain operating
assets of and entering into agreements to provide practice management services
to additional orthodontic practices. Competition for such affiliations has
increased significantly in recent years and, as a result, there may be fewer
candidates available for affiliation with Orthodontix. There can be no assurance
that Orthodontix will be able to identify additional practices or contract with
such practices on favorable terms. Furthermore, such arrangements involve a
number of risks, including diversion of management's attention, dependence on
retaining, hiring and training key personnel, and risks associated with the
assumption of certain contingent legal liabilities, some or all of which could
have a material adverse effect on Orthodontix' business, financial condition and
results of operations. To the extent that Orthodontix is unable to enter into
affiliations

11
19

with additional orthodontic practices, its ability to expand its operations and
increase its revenues to the degree desired would be reduced significantly and
would have a material adverse effect on Orthodontix' business, financial
condition and results of operations. In addition, future acquisitions accounted
for as purchases may result in substantial annual noncash amortization charges
for intangible assets in Orthodontix' statements of operations. See "BUSINESS OF
ORTHODONTIX -- Operating Strategy and -- Growth Strategy."

Risks Related to Orthodontix' Affiliation Strategy. Orthodontix intends to
finance future affiliations with cash, the issuance of shares of common stock or
the issuance of indebtedness as consideration. In the event that the Embassy
Common Stock does not maintain a sufficient market value, or potential
acquisition candidates are unwilling to accept Embassy Common Stock as partial
consideration for their practices, Orthodontix may be required to use its cash
resources, if available, to initiate and maintain its acquisition program. If
Orthodontix lacks sufficient cash resources to pursue acquisitions, its growth
could be limited unless it is able to obtain additional capital through debt or
equity financing. There can be no assurance that Orthodontix will be able to
obtain such financing if and when it is needed or that, if available, such
financing can be obtained on favorable terms. The inability to obtain such
financing could have a material adverse effect on Orthodontix' business,
financial condition and results of operations. Furthermore, issuing shares of
Embassy Common Stock as consideration for (or in order to provide financing for)
future acquisitions could result in significant dilution to existing
shareholders. See "MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION OF
ORTHODONTIX -- Liquidity and Capital Resources" and "BUSINESS OF
ORTHODONTIX -- Growth Strategy."

Risks Related to Orthodontix' Ability to Continue Internal Growth. Certain
of the Founding Practices have experienced significant growth in the past,
principally through growth of operations of existing orthodontic offices and the
opening of new offices. There can be no assurance that Orthodontix will be able
to expand its market presence in its current locations or successfully enter
other markets by providing financial resources to the Affiliated Practices
required for opening new orthodontic offices. Such offices may incur substantial
costs, delays or other operational or financial problems. The ability of
Orthodontix to continue its growth will depend on a number of factors, including
the availability of working capital to support such growth, existing and
emerging competition and Orthodontix' ability to maintain profitability while
facing pricing pressures and rising overhead costs. Orthodontix must also manage
costs in a changing regulatory environment, adapt its infrastructure and systems
to accommodate growth, and recruit and train additional qualified personnel. See
"MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION OF
ORTHODONTIX -- Liquidity and Capital Resources" and "BUSINESS OF
ORTHODONTIX -- Operating Strategy and -- Growth Strategy."

Risks Related to Changes in Government Regulation. The orthodontic
industry and orthodontic practices are regulated extensively at the state and
federal levels. Orthodontix will not engage in or control the practice of
orthodontics by the Affiliated Orthodontists as required by certain regulatory
requirements directly applicable to the orthodontists and their practices. The
laws of many states prohibit non-orthodontic entities (such as Orthodontix) from
practicing orthodontics, owning all or certain assets of an orthodontic
practice, employing orthodontists or controlling the content of an
orthodontist's advertisements. The laws of many states also prohibit
orthodontists from paying any portion of fees received for orthodontic services
in consideration for the referral of a patient. In addition, many states impose
limits on the tasks that may be delegated by an orthodontist to other staff
members. There can be no assurance that any review of Orthodontix' business
relationships by regulatory authorities or the courts will not result in
determinations that could adversely affect the operations of Orthodontix or that
the regulatory environment will not change to restrict Orthodontix' existing or
future operations. These laws and their interpretations vary from state to state
and are enforced by regulatory authorities with broad discretion. There can be
no assurance that the legality of Orthodontix' arrangements with the Affiliated
Practices and Affiliated Orthodontists will not be successfully challenged or
that enforceability of the provisions thereof will not be limited. See "BUSINESS
OF ORTHODONTIX." The laws and regulations of certain states in which Orthodontix
may seek to expand may require Orthodontix to change the form of relationships
entered into with orthodontists in a manner which may restrict Orthodontix'
operations in those states or may prevent Orthodontix from acquiring the assets
of orthodontic practices in those states. In addition, there can be no assurance
that the laws and regulations of

12
20

states in which the Founding Practices presently maintain operations will not
change or be interpreted in the future to either restrict or adversely affect
Orthodontix' relationships with Affiliated Practices or Affiliated Orthodontists
in those states. See "BUSINESS OF ORTHODONTIX -- Government Regulation."

Risks Related to Possible Future Health Care Reform. The United States
Congress as well as state legislatures have considered various health care
reform proposals, including comprehensive revisions to the current health care
system. It is not possible to predict which, if any, proposal that has been or
will be considered will be adopted. There can be no assurances that the
healthcare regulatory environment will not change so as to restrict the existing
operations of, impose additional requirements on or limit the expansion of
Orthodontix. Costs of compliance with changes in government regulations may not
be subject to recovery by Orthodontix through price increases.

Dependence on Enforceability of Operative Agreements. To effect the
consummation of the Practice Acquisitions, Orthodontix requires that the
Founding Practices and the Affiliated Orthodontists execute the following
agreements (collectively, the "Operative Agreements"): (i) an agreement and plan
of reorganization by and between the Founding Practice and Orthodontix; and (ii)
a service agreement by and between the PA Contractor and the Practitioner PAs
(the "Service Agreement") or an employment agreement between the Affiliated
Orthodontist and the PA Contractor (the "PA Contractor Employment Agreement");
and (iii) an employment agreement between the Affiliated Orthodontist and the
Practitioner PAs (the "Practitioner PA Employment Agreement") in those cases
where the employment agreement has not been entered between the PA Contractor
and the Affiliated Orthodontist. The consummation of the Practice Acquisitions
and the subsequent viability of Orthodontix are dependent on the initial and
continuing enforceability of the Operative Agreements. While Orthodontix has
attempted to structure the Operative Agreements in accordance with applicable
law, there can be no assurance that the enforceability of certain non-compete
and other provisions will not be successfully challenged. See "BUSINESS OF
ORTHODONTIX."

Dependence on Key Personnel. The success of Orthodontix is dependent upon
the continued services and management experience of F. W. Mort Guilford,
President and Chief Operating Officer. The loss of the services of Mr. Guilford
could have a material adverse effect upon Orthodontix' business, financial
condition and results of operations. Orthodontix carries no "key man" life
insurance policy on Mr. Guilford. See "MANAGEMENT OF ORTHODONTIX."

Risks Related to Competition. The business of providing orthodontic
services is highly competitive in each market in which Orthodontix operates.
Each of Orthodontix' Affiliated Orthodontists faces competition from other
orthodontists or general dentists in the communities served, some of whom have
more established practices in the market. Orthodontix is aware of several other
companies currently developing, consolidating and managing orthodontic practices
throughout much of the United States, and Orthodontix may encounter substantial
competition from those entities, as well as new market entrants. Other
competitors involved in managing multiple practices may have greater marketing,
financial and other resources and more established operations than Orthodontix.
Orthodontix expects that the level of competition with regional or national
management concerns will remain high in the future, which could limit
Orthodontix' ability to maintain or increase its market share or maintain or
increase gross margins, either of which could have a material adverse effect on
Orthodontix' business, financial condition and results of operations. See
"BUSINESS OF ORTHODONTIX -- Competition."

Liability Risks Associated with Providing Orthodontic Services. Each of
the Affiliated Orthodontists provides orthodontic services to the public and may
be exposed to the risk of professional liability and other claims. Claims
relating to orthodontic treatment, temporomandibular joint syndrome-related
claims and claims for failure to diagnose periodontal disease, if successful,
could result in substantial damage awards to the claimants which may exceed the
limits of any applicable insurance coverage of the Affiliated Practice and,
potentially, Orthodontix as an affiliate of the Affiliated Practice. Each of the
Affiliated Practices or Orthodontix on its behalf will be required to maintain
certain levels of general liability and malpractice insurance.

Orthodontix does not engage in the practice of orthodontics. Orthodontix
will not control the practice of orthodontics by its Affiliated Orthodontists or
the compliance with regulatory and other requirements directly
13
21

applicable to the Affiliated Orthodontists and the Affiliated Practices.
Although Orthodontix intends to maintain liability insurance for itself (with
limits and retention amounts to be negotiated), and intends to be named as an
additional insured party on the liability insurance policies of the Affiliated
Orthodontists (where permitted by insurers and applicable state law), successful
malpractice claims against Orthodontix or the Affiliated Orthodontists could
have a material adverse effect on Orthodontix' business, financial condition and
results of operations. In addition, there can be no assurance that claims not
covered by Orthodontix' insurance (e.g., claims for punitive damages) will not
arise. See "BUSINESS OF ORTHODONTIX -- Litigation and Insurance." Claims against
Orthodontix, the Affiliated Practices and/or the Affiliated Orthodontists,
regardless of their merit or eventual outcome, may also have a material adverse
effect on the ability to attract patients to Affiliated Practices. Furthermore,
because insurance policies must be renewed annually, there can be no assurance
that Orthodontix, the Affiliated Practices and/or the Affiliated Orthodontists,
will be able to obtain liability insurance coverage in the future on acceptable
terms, if at all.

State Laws Regarding Prohibition of Corporate Practice of Orthodontics.
The laws of many states prohibit business corporations, such as Orthodontix,
from exercising control over the orthodontic judgments or decisions of
orthodontists and from engaging in certain financial arrangements, such as fee
splitting with orthodontists. These laws and their interpretations vary from
state to state and are enforced by both the courts and regulatory authorities,
each with broad discretion. Expansion into certain jurisdictions may require
structural and organizational modifications of Orthodontix' form of relationship
with practices. Orthodontix strives to establish affiliations and related
arrangements with Affiliated Practices that achieve the substance of ownership,
control and operation, to the maximum extent practicable in accordance with
applicable state law. Although Orthodontix believes that it is in compliance
with applicable state laws and regulations relating to the corporate practice of
orthodontics, there can be no assurances that regulatory authorities or other
parties will not assert that Orthodontix is engaged in the unlawful corporate
practice of orthodontics in such states or that the management and
administration fees paid to Orthodontix by the PA Contractors constitute
unlawful fee splitting or the unlawful corporate practice of orthodontics. If
such a claim were successfully asserted, Orthodontix and the Affiliated
Orthodontists could be subject to civil and criminal penalties and Orthodontix
could be required to restructure its contractual arrangements. Such penalties or
the inability of Orthodontix to successfully restructure its relationships to
comply with such laws could have a material adverse effect on Orthodontix'
financial condition and results of operations. See "BUSINESS OF ORTHODONTIX --
Government Regulation."

RISKS RELATING TO EMBASSY

Benefits to Embassy's Officers and Directors. Subsequent to the
consummation of the Merger, the current officers and directors of Embassy, Dr.
Dresnick and Messrs. Halpryn, Stein, Brumfield, and Marshak, shall each own
2.7%, 5.5%, 2.8%, 1.0%, and 1.0% of Embassy Common Stock of Embassy without
giving effect to the issuance of 1,079,944 shares of Embassy Common Stock upon
the exercise of the Underwriter Warrants or the Closing Stock Options.

Dilution. Current Embassy Shareholders will incur an immediate dilution in
the net tangible book value of $2.23 per share of Embassy Common Stock.

Control by Certain Shareholders. Following the consummation of the Merger,
the Orthodontix Shareholders, by virtue of their direct ownership, will
collectively own approximately 57.9% of the outstanding Embassy Common Stock,
without giving effect to the issuance of shares of Embassy Common Stock upon the
exercise of the Underwriter Warrants or the Closing Stock Options. Accordingly,
such persons, as a result of their ownership of the Merger Stock will be able to
control the election of the Embassy Board and thereby direct the policies of
Embassy. Simultaneous with the consummation of the Merger, the current directors
and executive officers of Embassy, who, after the Merger and without taking into
account the sale of any of the shares of Embassy Common Stock they may sell,
will collectively own approximately 12.9% of the then outstanding Embassy Common
Stock, without giving effect to the issuance of 120,000 shares of Embassy Common
Stock upon the exercise of the Underwriter Warrants or the 959,944 shares of
Embassy Common Stock upon the exercise of the Closing Stock Options. Upon the
Effective Date, the Embassy Board shall consist of (i) Dr. Dresnick, (ii) Dr.
Grussmark, (iii) Mr. Guilford, (iv) Mr. Halpryn, (v) Dr. Thompson,
14
22

(vi) Mr. Gottlieb and (vii) Gary Gerson who will exercise control over Embassy's
affairs. See "MANAGEMENT OF ORTHODONTIX," "PRINCIPAL SHAREHOLDERS OF
ORTHODONTIX" and "DESCRIPTION OF ORTHODONTIX' SECURITIES."

In addition, certain Affiliated Orthodontists, officers, directors and
existing shareholders of Orthodontix and Dr. Dresnick will be granted the right
to acquire an aggregate of 959,944 shares of Common Stock upon the exercise of
Closing Stock Options. The exercise of these Closing Stock Options will result
in further increasing the holders' of such shares control over Embassy's
affairs. In the event all of the these Closing Stock Options are exercised such
persons would own approximately 65.3% of the then outstanding shares of Embassy
Common Stock (assuming no other issuances of capital stock). See "DESCRIPTION OF
EMBASSY'S SECURITIES."

Shares Eligible for Future Sale. Upon consummation of the Merger,
6,027,940 shares of Embassy Common Stock are expected to be outstanding,
exclusive of shares of Embassy Common Stock issuable upon exercise of the
Underwriter Warrants and Closing Stock Options.

Resale of Embassy Common Stock by Affiliates. The shares of Merger Stock
to be issued to Orthodontix Shareholders in connection with the Merger have been
registered under the Securities Act, and, subject to applicable law and certain
lock-up agreements described below, will be freely transferable under the
Securities Act, except for shares issued to any person who may be deemed an
"Affiliate" (as defined below) of Orthodontix within the meaning of Rule 145
under the Securities Act ("Rule 145"). "Affiliates" are generally defined as
persons who control, are controlled by, or are under common control with
Orthodontix at the time of the Special Meeting (generally, directors, certain
executive officers and major shareholders). Affiliates of Orthodontix may not
sell their shares of Embassy Common Stock acquired in connection with the
Merger, except pursuant to an effective registration statement under the
Securities Act covering such shares or in compliance with Rule 145 or another
applicable exemption from the registration requirements of the Securities Act.
In general, under Rule 145, for one year following the Effective Date, an
Affiliate (together with certain related persons) would be entitled to sell
shares of Embassy Common Stock acquired in connection with the Merger only
through unsolicited "broker transactions" or in transactions directly with a
"market maker," as such terms are defined in Rule 144 under the Securities Act.
Additionally, the number of shares to be sold by an Affiliate (together with
certain related persons and certain persons acting in concert) during such
one-year period within any three-month period for purposes of Rule 145 may not
exceed the greater of 1% of the outstanding shares of Embassy Common Stock or
the average weekly trading volume of such stock during the four calendar weeks
preceding such sale. Rule 145 would remain available to Affiliates only if
Embassy remained current with its information filings with the Commission under
the Exchange Act. One year after the Effective Date, an Affiliate would be able
to sell such Embassy Common Stock without such manner of sale or volume
limitations, provided that Embassy was current with its Exchange Act information
filings and such Affiliate was not then an Affiliate of Embassy. Two years after
the Effective Date, an Affiliate would be able to sell such shares of Embassy
Common Stock without any restrictions provided such Affiliate has not been an
Affiliate of Embassy for at least three months prior thereto.

Under the terms of a lock-up agreement between each of the Affiliated
Orthodontists who are issued Merger Stock (the "Practitioner Holders") and
Embassy, all of the shares of Merger Stock to be issued to the Practitioner
Holders in connection with acquisition of the Affiliated Practices as well as
shares underlying stock options received by the Practitioner Holders (the
"Practitioner Merger Stock") will not be permitted to be sold, transferred or
otherwise disposed of for a period of six months from the Effective Date.
Thereafter, the Practitioner Holders will not be permitted to sell, transfer or
otherwise dispose of the Practitioner Merger Stock other than in amounts equal
to: (i) 20% of the Practitioner Holder's Practitioner Merger Stock during the
period of time commencing on the 181st day and ending on the 270th day after the
Effective Date; (ii) 40% of the Practitioner Holder's Practitioner Merger Stock
during the period of time commencing on the 271st day and ending on the 365th
day following the Effective Date; (iii) 60% of the Practitioner Holder's Merger
Stock during the period of time commencing on the 366th day and ending on the
456th day following the Effective Date, and thereafter the Practitioner Holders'
Practitioner Merger Stock will be transferable by the Practitioner Holders not
deemed to be "Affiliates" of Embassy subject to applicable law. Affiliates are

15
23

generally defined as persons who control, are controlled by, or under common
control with Embassy (generally certain executive officers, directors and
principal shareholders).

Under the terms of a lock-up agreement executed by each of the Orthodontix
Shareholders who receive Merger Stock other than the Practitioner Holders (the
"Non-Practitioner Holders"), the Non-Practitioner Holders are not permitted to
sell, transfer or otherwise dispose of any shares of Embassy Common Stock
received in connection with the Merger or issuable upon exercise of any stock
options for a period of 15 months from the Effective Date. Thereafter, such
persons, not affiliates of Embassy, will be able to sell, transfer or otherwise
dispose of such shares subject to applicable law.

Under the terms of a lock-up agreement executed by each of Dr. Dresnick and
Messrs. Halpryn, Stein, and Brumfield, they are not permitted to sell, transfer,
or otherwise dispose of any shares of Embassy Common Stock currently owned by
them or issuable upon exercise of any stock options for a period of six months
following the Effective Date. Thereafter, for a period of nine months, Dr.
Dresnick and Mr. Halpryn will only be permitted to sell, transfer or otherwise
dispose of their shares in 20% increments per quarter. Under the terms of a
lock-up agreement executed by Mr. Marshak, he is only permitted to sell,
transfer, or otherwise dispose of 20,000 shares of Embassy Common Stock
currently owned by him or issuable upon exercise of any stock options for a
period of six months following the Effective Date, subject to applicable law.
The sale of any of these shares could have an adverse effect on the future
market price of Embassy Common Stock. See "PROPOSAL 1: THE
MERGER -- Restrictions on Sales by Affiliates" and "-- Interests of Certain
Persons in the Merger."

While no assurances can be made, it is contemplated that subsequent to the
Effective Date, Embassy expects to file a Registration Statement on Form S-8
(the "S-8 Registration Statement") covering the resale of the shares of Embassy
Common Stock issuable upon exercise of options to be granted under the Stock
Option Plan (assuming it is approved) (the "S-8 Registration Statement"). The
effect of filing such S-8 Registration Statement is that, subject to applicable
law, upon the effectiveness of the S-8 Registration Statement, the shares of
Embassy Common Stock underlying stock options to be granted under the Stock
Option Plan, when properly issued, will be freely transferable under the
Securities Act in accordance with the terms and conditions of the Stock Option
Plan. See "STOCK OPTION PLAN PROPOSAL."

Volatility of Stock Price. Prior to the Merger, there has been no public
market for the equity securities of Orthodontix and there can be no assurances
that an active trading market for the Embassy Common Stock will develop or be
sustained subsequent to the Merger. The market price of the Embassy Common Stock
could be subject to significant fluctuations in response to Embassy's operating
results and other factors. In addition, the stock market in recent years has
experienced extreme price and volume fluctuations that either have been
unrelated or disproportionate to the operating performance of companies. These
fluctuations, as well as general economic and market conditions, may adversely
affect the market price of the Embassy Common Stock.

No Dividends. Embassy has never paid cash dividends on its Common Stock
and does not anticipate paying any cash dividends in the foreseeable future.
Embassy intends to reinvest any funds that might otherwise be available for the
payment of dividends in further development of its business following the
Merger. See "PROPOSAL 1: THE MERGER -- Operations after the Merger -- Dividends"
and "DESCRIPTION OF EMBASSY'S SECURITIES."

OTC Bulletin Board. The Embassy Common Stock is currently quoted on the
OTC Bulletin Board under the symbol "MBCA." There is currently no established
trading market for the shares of Embassy Common Stock and there can be no
assurances that an established trading market will develop.

Certain Provisions of Embassy's Articles of Incorporation. Embassy's
Articles of Incorporation provide, among other things, that (i) officers and
directors of Embassy will be indemnified to the fullest extent permitted under
Florida law; and (ii) Embassy has elected not to be governed by Sections
607.0901 and 607.0902 of the Florida Business Corporation Act and other laws
relating thereto (the "Anti-Takeover Sections").

16
24

As a result of Embassy's election not to be governed by the Anti-Takeover
Sections, Embassy will not be subject to the provisions of Florida law which
provides that certain transactions between Embassy and an "interested
shareholder" or any affiliate of the "interested shareholder" be approved by
two-thirds of Embassy's outstanding shares. An "interested shareholder" as
defined in Section 607.0901 of the Florida Business Corporation Act is any
person who is the beneficial owner of more than 10% of the outstanding shares of
Embassy who is entitled to vote generally in the election of directors. Since
neither Orthodontix nor any of its shareholders own 10% or more of the
outstanding Embassy Common Stock, these provisions of the Anti-Takeover Sections
would, nevertheless, not impact the Merger or the required role thereon. In
addition, because of Embassy's election not to be governed by the Anti-Takeover
Sections, Embassy will not be subject to the provisions of Florida law which
provide that a person who acquires shares in an issuing public corporation in
excess of certain specified thresholds will generally not have any voting rights
with respect to such shares unless the voting rights are approved by a majority
of the shares entitled to vote, excluding the interested shares.

Authorization of Preferred Stock. The Embassy Shareholders are being asked
to consider and vote upon a proposal to amend and restate Embassy's Articles of
Incorporation to provide for an authorized class of Preferred Stock, consisting
of 100,000,000 shares, par value $.0001 per share (the "Preferred Stock"), with
rights, preferences and designations of such shares to be determined by the
Board of Directors (the "Preferred Stock Amendment"). Accordingly, if Embassy
becomes authorized to issue the Preferred Stock, the Embassy Board will be
empowered, without shareholder approval, to issue the Preferred Stock with
dividend, liquidation, conversion, voting or other rights which could adversely
affect the voting power or other rights of the holders of Embassy Common Stock.
In the event of issuance, the Preferred Stock could be utilized, under certain
circumstances, as a method of discouraging and delaying or preventing a change
of control of Embassy. Although Embassy has no present intention to issue any
shares of Preferred Stock, there can be no assurances that Embassy will not do
so in the future. See, "PROPOSAL 2 -- RESTATEMENT OF THE ARTICLES OF
INCORPORATION OF EMBASSY."

THE SPECIAL MEETING

INTRODUCTION

This Proxy Statement/Prospectus is provided by the Embassy Board to the
Embassy Shareholders in connection with the Special Meeting of Shareholders of
Embassy and any adjournments or postponements thereof. The Special Meeting will
be held on the date, at the time and in the location, and will be held to
consider the matters set forth below.

The Embassy Board is soliciting proxies hereby for use at the Special
Meeting. A form of proxy is being provided to the Embassy Shareholders with this
Proxy Statement/Prospectus. Information with respect to the execution and the
revocation of proxies is provided under "Voting Rights."

PURPOSES OF MEETING

At the Special Meeting, Embassy Shareholders eligible to vote will be asked
to consider and vote upon a proposal to approve the (1) Merger, including the
Name Change; (2) Preferred Stock Amendment; and (3) Stock Option Plan Proposal.
Copies of the Merger Agreement and the proposed Restated Articles are attached
as Appendices A and B, respectively, to this Proxy Statement/Prospectus and are
incorporated herein by reference.

THE EMBASSY BOARD, WITHOUT DISSENT OR ABSTENTION HAS APPROVED THE MERGER,
THE PREFERRED STOCK AMENDMENT AND THE STOCK OPTION PLAN PROPOSAL, AND RECOMMENDS
THAT THE EMBASSY SHAREHOLDERS VOTE "FOR" THE PROPOSAL TO APPROVE AND ADOPT THE
MERGER, INCLUDING THE NAME CHANGE, THE PREFERRED STOCK AMENDMENT, AND THE STOCK
OPTION PLAN.

17
25

DATE, TIME AND PLACE; RECORD DATE

The Special Meeting is scheduled to be held at 9:00 A.M., local time, on
April 16, 1998, at NationsBank Tower Auditorium, 100 SE 2nd Street, 19th Floor,
Miami, Florida 33131. The Embassy Board has fixed the close of business on March
24, 1998 as the record date (the "Embassy Record Date") for the determination of
holders of Embassy Common Stock entitled to notice of and to vote at the Embassy
Special Meeting. As of the date of this Proxy Statement/Prospectus, there are
2,540,000 shares of Embassy Common Stock (held by 46 persons of record)
outstanding and entitled to vote. Each share of Embassy Common Stock is entitled
to one vote.

VOTING RIGHTS

The presence, either in person or by proxy, of the holders of a majority of
the outstanding shares of Embassy Common Stock entitled to vote at the Special
Meeting is necessary to constitute a quorum at the Special Meeting. If a proxy
is marked as "Abstain" on any matter, or specific instructions are given that no
vote be cast on any specific matter (other than a broker which holds shares in
street name for its customers) (a "Specified Non-Vote"), the shares represented
by proxy will not be voted on such matter. Abstentions and Specified Non-Votes
will be included within the number of shares present at the Special Meeting and
entitled to vote for purposes of determining whether such matter has been
authorized and accordingly will have the same effect as a negative vote. A duly
executed but unmarked proxy (other than a broker which holds shares in street
name for its customers) will be voted "FOR" the approval and adoption of the
proposals, as indicated in the accompanying Proxy Card. Abstentions are counted
for purposes of determining the presence or absence of a quorum for the
transaction of business. The affirmative vote of the holders of at least a
majority of Embassy Common Stock entitled to vote thereon is required to approve
and adopt the Merger, including the Name Change. The affirmative vote of a
majority of the shares of Embassy Common Stock voting in person or by proxy at
the Special Meeting is required to approve and adopt the Preferred Stock
Amendment and the Stock Option Plan Proposal. Among the conditions precedent to
the Merger is that less than 30% of the outstanding Embassy Common Stock held by
non-affiliated shareholders is voted against approval of the Merger. See
"PROPOSAL 1: THE MERGER -- Conditions to the Merger." Holders of record of
Embassy Common Stock on the Embassy Record Date are entitled to vote on the
proposals to be presented to the Embassy Shareholders at the Special Meeting.

Embassy's directors and executive officers collectively holding an
aggregate of approximately 30.7% of the outstanding shares of Embassy Common
Stock before giving effect to the Merger, have agreed, with respect to the
proposal to approve the Merger, to vote their respective shares of Embassy
Common Stock in accordance with the vote of the majority of all non-affiliated
Embassy Shareholders. Consequently, if a majority of outstanding Embassy Common
Stock held and voted by non-affiliated persons is voted in favor of the Merger,
the current directors and executive officers of Embassy will vote their shares
of Embassy Common Stock in favor of the Merger, the Preferred Stock Amendment
and the Stock Option Plan Proposal.

If an Embassy Shareholder attends the Special Meeting, he or she may vote
by ballot. However, many of the Embassy Shareholders may be unable to attend the
Special Meeting. Therefore, the Embassy Board is soliciting proxies so that each
holder of Embassy Common Stock on the Embassy Record Date has the opportunity to
vote on the proposals to be considered at the Special Meeting. When a proxy card
is returned properly signed and dated, the shares represented thereby will be
voted in accordance with the instructions on the proxy card. If an Embassy
Shareholder does not return a signed proxy card, his or her shares will not be
voted. Embassy Shareholders are urged to mark the box on the proxy card to
indicate how their shares are to be voted. If an Embassy Shareholder (other than
a broker which holds shares in street name for its customers) returns a signed
proxy card, but does not indicate how his or her shares are to be voted, the
shares represented by the proxy card will be voted FOR approval and adoption of
the Merger, the Preferred Stock Amendment and the Stock Option Plan Proposal. If
a signed proxy card is returned by an Embassy Shareholder and expressly reflects
an abstention upon any proposal, the shares evidenced thereby will be counted
towards the quorum necessary to convene the Special Meeting, noted in the
immediately preceding paragraph, but will not be counted towards the requisite
affirmative vote upon such proposal mandated by applicable Florida law. If a
signed proxy card is returned by a broker with no indication of how shares are
to be
18
26

voted, the shares evidenced thereby will not be counted towards a quorum and
will have no effect on the vote for such proposals. The proxy card also confers
discretionary authority on the individuals appointed by the Embassy Board and
named on the proxy card to vote the shares represented thereby on any other
matter that is properly presented for action at the Special Meeting.

Any Embassy Shareholder who executes and returns a proxy card may revoke
such proxy at any time before it is voted by (i) notifying in writing the
Secretary of Embassy, at 1428 Brickell Avenue, Suite 105, Miami, Florida 33131;
(ii) granting a subsequent proxy; or (iii) appearing in person and voting at the
Special Meeting. Attendance at the Special Meeting will not in and of itself
constitute revocation of a proxy.

IF THE MERGER IS NOT APPROVED BY THE REQUISITE VOTE IMPOSED BY APPLICABLE
FLORIDA LAW OR IF SO APPROVED, BUT 30% OR MORE IN INTEREST OF ALL NON-AFFILIATED
EMBASSY SHAREHOLDERS ACTUALLY VOTE AGAINST APPROVAL OF THE MERGER, THE MERGER
AGREEMENT WILL BE TERMINATED AND THE PROPOSED MERGER ABANDONED. SEE "PROPOSAL 1:
THE MERGER -- REDEMPTION RIGHTS."

SOLICITATION OF PROXIES

Embassy will bear all of the expenses in connection with printing and
mailing this Proxy Statement/ Prospectus. The costs of solicitation of proxies
also will be borne by Embassy. Embassy will reimburse brokers, fiduciaries,
custodians and other nominees for reasonable out-of-pocket expenses incurred in
sending this Proxy Statement/Prospectus and other proxy materials to, and
obtaining instructions relating to such materials from, beneficial owners of
Embassy Common Stock. Embassy Shareholder proxies may be solicited by directors,
executive officers or regular employees of Embassy, in person, by letter or by
telephone, telegram or telefax.

Embassy has retained American Stock Transfer & Trust Company, Embassy's
transfer agent, to assist it in the solicitation of proxies. Embassy shall
reimburse such firm for its firm's accountable expenses.

[This Space Intentionally Left Blank]

19
27

PROPOSAL 1: THE MERGER

GENERAL

The following is a brief summary of certain aspects of the Merger. This
summary does not purport to be complete and is qualified in its entirety by
reference to the Merger Agreement, which is attached to this Proxy
Statement/Prospectus as Appendix A and is incorporated herein by reference.

On the Effective Date, Embassy Sub will be merged with and into
Orthodontix. As a result of the Merger, Orthodontix will become a wholly-owned
subsidiary corporation of Embassy. The Articles of Incorporation of Embassy will
be amended on the Effective Date to change, among other things, Embassy's name
to "Orthodontix, Inc." After the Merger is consummated, the Embassy Board will
be comprised of seven members, four of which shall be designated by Orthodontix.

BACKGROUND OF THE MERGER

As discussed under "BUSINESS OF EMBASSY" elsewhere herein, Embassy was
formed in November 1995 to serve as a vehicle to effect a merger, exchange of
capital stock, asset acquisition or other similar business combination (a
"Business Combination") with an operating business (an "Acquired Business").
Embassy's business objective has been to seek to effect a Business Combination
with an Acquired Business which Embassy believes has growth potential.

Following the consummation of Embassy's initial public offering of its
equity securities in April 1996 (the "IPO"), from which Embassy derived net
proceeds of approximately $7,052,000 (the "Net Proceeds"), Embassy's executive
officers commenced a search for a prospective Acquired Business. Approximately
90% of such Net Proceeds were placed in escrow immediately following the IPO, to
be released therefrom either upon consummation of a Business Combination or if
required to facilitate a Business Combination, as applicable. The balance of the
Net Proceeds, less net operating expenses to date, is currently held by Embassy.

Excluding Orthodontix, during the period from April 1996 through May 5,
1997, Embassy's executive officers evaluated approximately 75 prospective
Acquired Businesses in varied fields of endeavor. Serious consideration was
given to effecting a Business Combination with two of such prospective Acquired
Businesses engaged in, respectively, providing security services and promoting
and producing musical and theatrical live entertainment (collectively, the
"Other Two Candidates").

In evaluating each prospective Acquired Business, Embassy's executive
officers considered, among other factors, all or a majority of the following:

- costs associated with effecting the Business Combination;

- equity interest in and opportunity for control of the prospective
Acquired Business;

- growth potential of the prospective Acquired Business and the industry
in which it operates;

- experience and skill of management and availability of additional
necessary personnel of the prospective Acquired Business;

- capital requirements of the prospective Acquired Business;

- competitive position of the prospective Acquired Business;

- stage of development of the product, process or service of the
prospective Acquired Business;

- degree of current or potential market acceptance of the product,
process or service of the prospective Acquired Business;

- proprietary features and degree of intellectual property or other
protection of the product, process or service of the prospective
Acquired Business; and

- regulatory environment of the industry in which the prospective
Acquired Business operates.

20
28

The Other Two Candidates, which were accorded serious consideration by
Embassy's executive officers, were rejected prior to reaching an agreement in
principle for a Business Combination. The primary reasons for rejection of the
Other Two Candidates were as follows:

- Intense competition and uncertainties attendant to an industry which
appears to be becoming increasingly dominated by large consolidating
firms.

- Severe fluctuations in operating results and relative uncertainty of
market taste.

In November 1996, Dr. Grussmark, a personal friend of Dr. Dresnick,
informed Dr. Dresnick that he, along with Mr. Guilford, had commenced the
development of Orthodontix, an orthodontic practice management firm. At a
meeting held on November 26, 1996 attended by Dr. Dresnick, Mr. Halpryn and Mr.
Guilford, Dr. Dresnick informed Mr. Halpryn of his discussion with Dr. Grussmark
and his business objectives regarding Orthodontix. In January 1997, Dr.
Grussmark communicated to Dr. Dresnick the status of the development of
Orthodontix, including preliminary feedback that he had received from
orthodontists whom Dr. Grussmark had targeted to become affiliated with
Orthodontix. In January 1997, Mr. Guilford requested that Dr. Dresnick, Mr.
Halpryn and he meet to discuss whether Embassy would be interested in pursuing a
transaction with Orthodontix. At a meeting on January 17, 1997, Mr. Guilford,
Mr. Halpryn and Dr. Dresnick discussed preliminarily whether Embassy might
consider a business combination with Orthodontix. At this meeting, the structure
and preliminary business plan of Orthodontix was presented by Mr. Guilford to
Dr. Dresnick and Mr. Halpryn. No meetings between Embassy and Orthodontix took
place between the January 17, 1997 meeting and April 10, 1997. On April 10,
1997, Dr. Dresnick telephoned Mr. Guilford regarding the status of development
of Orthodontix and specifically requested how many orthodontic practices had
agreed to be acquired by Orthodontix at that point in time. This matter was
further discussed at a meeting between Dr. Dresnick and Mr. Guilford on April
16, 1997. Dr. Dresnick inquired and Mr. Guilford responded as to the status of
pending practice acquisitions and the overall development of Orthodontix at that
point. On April 24, 1997, Dr. Dresnick informed Mr. Halpryn of his meeting with
Mr. Guilford and suggested that Mr. Halpryn and Mr. Guilford meet regarding a
possible business combination between Embassy and Orthodontix. On April 28,
1997, Mr. Guilford and Mr. Halpryn met concerning the possible business
combination. At this April 28, 1997 meeting, Mr. Guilford informed Mr. Halpryn
of his assessment of the orthodontic practice management industry, where he
thought Orthodontix might fit within that industry, and the growth potential of
Orthodontix. On April 30, 1997, the members of the Embassy Board were informed
by Mr. Halpryn of his meeting with Mr. Guilford. Thereafter, the members of the
Embassy Board spoke among themselves regarding pursuing an initial meeting for
the purpose of gathering financial and other information regarding Orthodontix.
The Embassy Board ultimately concluded that such a meeting should be scheduled.
A meeting was held on May 1, 1997, at which time the members of the Embassy
Board met with Mr. Guilford for the purpose of receiving an introduction to the
background of Mr. Guilford and Dr. Grussmark and gaining insight into
Orthodontix' operations and prospects. This initial meeting lasted several hours
and topics concerning the orthodontics practice management services industry in
general, Orthodontix' position within the industry and the potential for
expansion of Orthodontix' operations were discussed. Shortly thereafter, Mr.
Guilford distributed certain written materials, including financial information
and product literature regarding Orthodontix and certain publicly available
information regarding Orthodontix' competitors. Discussions included
Orthodontix' (i) financial status, (ii) existing banking relationships, (iii)
competitors, and (iv) rapid growth, as well as the possible impact of what
appeared to the Embassy Board to be increasing competition on Orthodontix'
prospects. Later that same week, Mr. Guilford met with Dr. Dresnick, wherein he
discussed whether Dr. Dresnick would have an ongoing role in a possible combined
company. Dr. Dresnick informed Mr. Guilford that he would, if requested to do
so, serve as Chairman of the combined company.

The following week, Mr. Halpryn and Mr. Stein, both directors of Embassy
spoke via telephone to several orthodontist acquaintances, all of whom are
unaffiliated with Embassy and Orthodontix, as to their views concerning the
future of the delivery of orthodontic services generally and the concept of
practice management or orthodontic practices. Messrs. Halpryn and Stein
generally understood from such acquaintances that, from the orthodontist's
perspective, there existed growth prospects for businesses engaged in providing
practice management services to orthodontic practices.

21
29

On May 2, 1997, all of the members of the Embassy Board met with Mr.
Guilford to assess the Orthodontix information theretofore received. At a May 5,
1997 meeting among the members of the Embassy Board, the fundamental terms of
the Merger were reached, subject to the preparation of an appropriate letter of
intent (the "Letter of Intent").

A Letter of Intent was executed on the morning of May 6, 1997. Embassy and
Orthodontix announced their execution of the Letter of Intent by a joint press
release later that day. Pursuant to the Letter of Intent, among other things,
Orthodontix represented to Embassy that at the closing of the business
combination, if any, the Practices acquired would, in the aggregate, have
generated gross revenue (unaudited) of no less than $20.0 million for the year
ended December 31, 1996. In addition, the Letter of Intent provided that if a
definitive agreement had not been executed by 5:00 P.M. Eastern Standard Time on
August 30, 1997 (the "Termination Date") the Letter of Intent would
automatically terminate.

Subsequent thereto, Embassy commenced its initial "due diligence" review of
Orthodontix and the preparation of the Merger Agreement and related
documentation. Meetings in these regards were held among the principals of
Embassy and Orthodontix and, in certain instances with their respective
professional advisors, on several occasions in June, July and August, 1997. Of
particular concern to Embassy was whether Orthodontix had entered into
agreements to acquire a sufficient number of orthodontic practices. On August
30, 1997, at a meeting between the Embassy Board and Mr. Guilford, Mr. Guilford
requested that Embassy extend the Termination Date primarily because, although
Orthodontix had understandings to acquire certain orthodontic practices,
Orthodontix had not, at that point entered into definitive agreements with
practices which had generated in the aggregate $20.0 million in practice revenue
as of December 31, 1996. On August 30, 1997, Embassy and Orthodontix entered
into an amendment to the Letter of Intent providing for the Termination Date to
be extended until October 30, 1997.

On October 10, 1997, Dr. Dresnick and Mr. Guilford met regarding the status
of Orthodontix' execution of definitive acquisition agreements with practices.
Dr. Dresnick informed Mr. Halpryn of his conversation with Mr. Guilford. On
October 27, 1997, the material terms of the Merger Agreement were reviewed by
the Embassy Board. Following discussions, the Embassy Board voted without
dissent or abstention to approve and adopt the Merger Agreement and the
transactions contemplated thereby, but subject to the negotiation and execution
of a definitive version of the Merger Agreement.

On October 27, 1997, representatives of Embassy and Orthodontix, together
with their respective counsel, agreed to finalize the terms of the Merger
Agreement. The Merger Agreement was then entered into by Embassy and Orthodontix
on November 7, 1997 and announced that day through a joint press release issued
by Embassy and Orthodontix.

The material difference between the Letter of Intent and the Merger
Agreement is that pursuant to the Merger Agreement, Orthodontix represented that
at the closing of the business combination, if any, Orthodontix will provide
practice management services to orthodontic practices which in the aggregate
generated at least $15 million in revenue as of December 31, 1996. This change
was made to accommodate Orthodontix, to secure the business combination for
Embassy and to avoid any further delay in the execution of the Merger Agreement.

RECOMMENDATIONS OF THE BOARDS OF DIRECTORS AND REASONS FOR THE MERGER

Embassy. The Embassy Board has determined that the Merger is in the best
interests of Embassy and the Embassy Shareholders. The Embassy Board without
dissent or abstention approved and adopted the Merger Agreement and the
transactions contemplated thereby and recommends that the Embassy Shareholders
vote for approval and adoption of the Merger Agreement and the transactions
contemplated thereby.

22
30

Embassy Shareholders, as determined by Embassy and audited by its independent
public accountants, calculated as of the Embassy Record Date. If less than 30%
in interest of Embassy Common Stock held by non-affiliated Embassy Shareholders
who vote against approval of the Merger also elect to have their shares of
Embassy Common Stock redeemed, and if the Merger is consummated, Embassy will
redeem shares of Embassy Common Stock at the Redemption Value from those Embassy
Shareholders who affirmatively requested such redemption and who actually voted
against approval of the Merger. If 30% or more in interest of Embassy Common
Stock held by non-affiliated Embassy Shareholders actually vote against approval
of the Merger, the proposed Merger will be terminated, Embassy will not proceed
with the Merger and will not redeem such shares. See "PROPOSAL 1: THE
MERGER -- Redemption Rights."

The Embassy Board concluded that a business combination with Orthodontix
was a better alternative than the other companies that had been theretofore
evaluated by Embassy as possible candidates for a business combination because
of Embassy's belief that Orthodontix would provide a higher net income per share
and more attractive growth prospects due to management's business plan to grow
primarily through acquisition of additional orthodontic practices and Embassy's
belief that investors have generally been receptive to orthodontic practice
management companies. Furthermore, Embassy believes that Orthodontix is
positioned to increase its market share and withstand competitive pressure more
ably once it is a public company. With respect to the other factors listed
above, Embassy believed (i) the costs associated with effecting a business
combination with Orthodontix or the Other Two Candidates were substantially
similar; (ii) neither Orthodontix nor the Other Two Candidates was agreeable to
relinquishing control; (iii) Orthodontix' growth potential was greater than that
of the Other Two Candidates due to Embassy's belief that Orthodontix' business
had greater market appeal than that of the Other Two Candidates; (iv)
Orthodontix' management's experience and skill, when combined with Dr.
Dresnick's agreement to serve as Chairman of the combined company was equivalent
to that of the management of the Other Two Candidates; and (v) the capital
requirements of Orthodontix were less than that of the Other Two Candidates
because the Other Two Candidates had significant debt. The Embassy Board gave
considerable weight to the experience of Dr. Dresnick in the practice management
field and concluded that Dr. Dresnick's experience combined with the industry in
which Orthodontix will engage presented the best opportunity of the business
combination candidates evaluated by the Embassy Board. Consequently, the Embassy
Board has determined that the Merger is in the best interests of the Embassy
Shareholders. In addition, the Embassy Board considered the dilutive effect the
Merger would have on the Embassy Shareholders.

With respect to the valuation of Orthodontix, the Embassy Board considered
the Founding Practices' pre-tax profit (unaudited), anticipated growth over a
five-year period, comparable price earnings ratios of public companies
competitive with Orthodontix. There is no established trading market for
Orthodontix securities.

In considering whether or not to approve the Merger, the Embassy Board
reviewed all of the criteria for a prospective Acquired Business as set forth
under "Background of the Merger" elsewhere herein, excluding only the
opportunity for acquiring operating control of Orthodontix in view of management
of Orthodontix' unwillingness to relinquish such control and the Embassy Board's
lack of expertise in these regards. Significant import was given by the Embassy
Board to Dr. Dresnick's agreement to serve as Chairman of the combined company.
The Embassy Board concluded that a Business Combination with Orthodontix would
satisfy Embassy's business objective of effecting a Business Combination which
afforded the possibility of growth potential. See "RISK FACTORS" and "BUSINESS
OF ORTHODONTIX."

Consideration was given by the Embassy Board to securing an opinion (a
"Fairness Opinion") of an independent investment banker or other financial
advisor to the effect that the Merger would be fair, from a financial point of
view, to the Embassy Shareholders. The Embassy Board decided not to obtain a
Fairness Opinion due to the fact that the Merger requires the approval of a
majority of the outstanding Embassy Common Stock entitled to vote at the Special
Meeting and accordingly, the vote of the executive officers and directors of
Embassy in the Merger is effectively neutralized by their agreement to vote
consistent with the vote of a majority of the non-affiliated Embassy
Shareholders and that each non-affiliated Embassy Shareholder will have certain
redemption rights with respect to the Merger. In addition, the cost and expense
of procuring a Fairness Opinion factored into the Embassy Board's decision not
to obtain a Fairness Opinion.

23
31

Furthermore, the Embassy Board took note of the fact that no Embassy executive
officer, director or principal shareholder is to become a salaried employee of
Orthodontix subsequent to the consummation of the Merger.

Orthodontix. The Orthodontix Board has determined that the Merger is in
the best interests of Orthodontix and its shareholders. The Orthodontix Board
and all its shareholders, without dissent or abstention have approved and
adopted the Merger Agreement and the transactions contemplated thereby.

In considering the Merger, the Orthodontix Board noted that the Merger
would afford Orthodontix access to approximately $7.0 million (after payment of
Embassy's expenses in consummating the Merger), and that Embassy's status as a
company whose securities are publicly traded would afford Embassy's post-Merger
management the opportunity to utilize Embassy's authorized but unissued
securities to attempt to acquire other orthodontic practices rather than expend
its cash resources for any such purpose, in each instance without the
anticipated uncertainty attendant to Orthodontix' own public offering of
securities and the possibility that any such offering might not be successfully
consummated in view of then prevailing market conditions or, alternatively, the
negotiation and uncertain consummation of additional commercial lending
arrangements. The Orthodontix Board also took into account the fact that if all
of the Underwriter Warrants were to be exercised subsequent to the Merger, as to
which there can be no assurances, Embassy would derive proceeds of approximately
$936,000 upon the exercise of the Underwriter Warrants. In addition, the
Orthodontix Board also noted that the current public market for Embassy Common
Stock would afford potential liquidity for the Embassy Common Stock to be
acquired by the Orthodontix Shareholders in exchange for the Orthodontix Common
Stock.

THE MERGER AGREEMENT

Set forth below is a description of the material provisions of the Merger
Agreement. This description does not purport to be complete and is qualified in
its entirety by reference to the full text of the Merger Agreement, which is
attached as Appendix A to this Proxy Statement/Prospectus. As discussed below,
the Merger will be effected by the merger of Embassy Sub with and into
Orthodontix. To effect the Merger, Embassy formed Embassy Sub as a wholly-owned
subsidiary.

General. Upon consummation of the Merger, the Orthodontix Shareholders,
including the persons receiving Merger Stock in connection with the Practice
Acquisitions, will own approximately 57.9% of the then outstanding shares of
Embassy Common Stock. Upon the exercise of the Underwriter Warrants, an
aggregate of 6,147,940 shares of Embassy Common Stock will be outstanding upon
consummation of the Merger, without giving effect to the issuance of 959,944
shares of Embassy Common Stock upon the exercise of the Closing Stock Options.

None of the shares of Embassy Common Stock then outstanding on the
Effective Date will be converted or otherwise modified in the Merger and all of
such shares will continue to be outstanding capital stock of Embassy after the
Effective Date. The Merger Agreement also provides that the Articles of
Incorporation of Embassy will be amended on the Effective Date to change
Embassy's name to "Orthodontix, Inc." and to revise Embassy's authorized capital
stock to include the Preferred Stock.

The Merger Agreement also provides that on the Effective Date the Embassy
Board shall consist of (i) Dr. Dresnick, (ii) Dr. Grussmark, (iii) Mr. Guilford,
(iv) Mr. Halpryn, (v) Dr. Thompson, (vi) Mr. Gottlieb and (vii) Mr. Gerson.

Closing. The closing of the transactions contemplated by the Merger
Agreement (the "Closing") will take place no later than the fifth business day
immediately following the date on which the last of the conditions set forth in
the Merger Agreement is satisfied or waived, or at such other time as Embassy
and Orthodontix agree (the "Closing Date").

Representations and Warranties. The Merger Agreement contains various
representations and warranties of Orthodontix and Embassy relating to, among
other things: (i) each of Embassy's and Orthodontix' organization and similar
corporate matters; (ii) each of Embassy's and Orthodontix' capital structure;
(iii) the authorization, execution, delivery, performance and enforceability of
the Merger Agreement and related documentation; (iv) title to assets and
properties; (v) the absence of any governmental or regulatory
24
32

authorization, consent or approval required to consummate the Merger; (vi) the
documents and reports filed by Embassy with the Commission, including this Proxy
Statement/Prospectus; (vii) the absence of certain liabilities; (viii) the
absence of certain material events, changes or defaults; (ix) litigation; (x)
the accuracy of the information provided by Orthodontix and Embassy; (xi)
intellectual property of Orthodontix; (xii) compliance with laws and material
agreements; (xiii) taxes; (xiv) environmental matters; (xv) certain accounting
matters; and (xv) employee matters.

Certain Covenants. Pursuant to the Merger Agreement, Orthodontix has
agreed that, during the period from the date of the Merger Agreement until the
Closing Date, except as permitted by the Merger Agreement (including those
provisions set forth or described in this Proxy Statement/Prospectus) or as
consented to in writing by Embassy, Orthodontix will, among other things: (i)
use reasonable efforts to cause the Founding Practices to be operated and
maintained in the usual and ordinary course of business and in material
compliance with the terms of the Agreement, and to preserve the goodwill and
business relationships with suppliers, customers and others; (ii) use reasonable
efforts to cause the Founding Practices not to dispose of any material assets or
properties other than in the ordinary course of business; and (iii) not declare
any dividend or other distribution, sell or issue, redeem or otherwise acquire
any shares of its capital stock or other securities.

Pursuant to the Merger Agreement, Embassy has agreed that, during the
period from the date of the Merger Agreement until the Closing Date or the
earlier termination of the Merger Agreement, except as permitted by the Merger
Agreement or consented to in writing by Orthodontix, Embassy will, among other
things, (i) conduct its business in the ordinary and usual course and in
material compliance with the Merger Agreement; (ii) not declare any dividend or
other distribution, sell or issue, redeem or otherwise acquire any shares of its
capital stock or other securities other than with respect to the Underwriter
Warrants; and (iii) not make any payments or incur costs aggregating more than
$30,000, exclusive of costs relating to the transactions contemplated by the
Merger Agreement or costs relating to shares offered for redemption pursuant to
this Proxy Statement/Prospectus.

No Solicitation of Other Transactions. The Merger Agreement provides that
Orthodontix, its officers, directors, representatives and agents will not
solicit any proposal or offer to acquire all or any substantial part of the
business or capital stock of Orthodontix or any of its subsidiaries from any
person other than Embassy. The Merger Agreement also provides for similar
restrictions on Embassy and its officers, directors, representatives and agents.

Indemnification. The Merger Agreement provides indemnification to
Orthodontix and Embassy for any costs or expenses, judgments, fines, losses,
claims, damages, liabilities and amounts paid in settlement arising out of,
relating to or in connection with any misrepresentation or breach of
representations, warranties or covenants contained in the Merger Agreement.

Conditions to the Merger. The respective obligations of Embassy and of
Orthodontix to effect the Merger are subject to a number of conditions, any or
all of which may be waived by the party for whom the condition was established,
including among others: (i) Orthodontix shall have consummated the Practice
Acquisitions on the Effective Date; (ii) the Merger shall have been approved and
adopted by the Embassy Shareholders, and no more than 30% in interest of the
Embassy Common Stock held by Embassy Shareholders actually vote against the
Merger; (iii) no preliminary or permanent injunction or other order or decree by
any federal or state court or any action by any state or federal governmental
agency preventing the consummation of the Merger shall have been issued or taken
and remain in effect; and (iv) all consents, orders and approvals legally
required shall have been obtained and be in effect on the Effective Date.

In addition to the conditions set forth above, the obligations of Embassy
to effect the Merger are subject to the following conditions, any or all of
which may be waived by Embassy: (i) Orthodontix shall have performed in all
material respects its agreements contained in the Merger Agreement and all
representations and warranties of Orthodontix contained in the Merger Agreement
shall be true and correct in all material respects on and as of the date made
and the Closing Date (as defined in the Merger Agreement); (ii) the receipt of a
written opinion from counsel to Orthodontix as to certain matters; (iii) the
absence of material adverse changes in the business, operations, properties,
assets, condition (financial or otherwise), results of
25
33

operations or prospects of Orthodontix; (iv) Orthodontix' capitalization shall
be as set forth in the Merger Agreement; and (v) the receipt of all consents,
orders and approvals required to consummate the Merger.

In addition to the conditions set forth in the first paragraph of this
subsection, the obligations of Orthodontix to effect the Merger are subject to
the following conditions, any or all of which may be waived by Orthodontix: (i)
Embassy shall have cash assets of no less than $7.2 million as of the Closing;
(ii) Embassy shall have performed in all material respects its agreements
contained in the Merger Agreement and all representations and warranties of
Embassy contained in the Merger Agreement shall be true and correct in all
material respects on and as of the date made and the Closing Date; (iii)
Embassy's outstanding securities shall be unchanged in amount except as
contemplated by the Merger Agreement; and (iv) an application to have the
Embassy Common Stock quoted on the Nasdaq SmallCap Stock Market shall have been
filed by Embassy.

Termination. The Merger Agreement may be terminated prior to the Closing
Date, whether before or after approval by the Embassy Shareholders: (i) at any
time by the mutual consent of the Boards of Directors of Embassy and of
Orthodontix; (ii) by either Orthodontix or Embassy after May 1, 1998 if the
Merger shall not have been consummated on or before such date (so long as the
party terminating has not breached its obligations under the Merger Agreement),
unless such date is extended by mutual consent of the parties; or (iii) by
either Orthodontix or Embassy if the other party is unable to satisfy any
condition to the obligations of that party (other than by reason of a breach by
that party of its obligations under the Merger Agreement).

In the event of termination of the Merger Agreement by either Orthodontix
or Embassy as provided above, the Merger Agreement shall become void and there
will be no further obligation on the part of any of Orthodontix or Embassy
except for certain nondisclosure obligations, unless such termination arises
from a willful breach of the Merger Agreement.

Expenses. The Merger Agreement provides that, whether or not the
transactions contemplated by Merger are consummated, Orthodontix and Embassy
shall each pay its own expenses incident to the negotiation, preparation and
carrying out of the Merger Agreement, including all fees and expenses of its
counsel and accountants for actions taken pursuant to the Merger Agreement.

Amendment. Subject to applicable law, the Merger Agreement may not be
amended except by the written agreement of Orthodontix and Embassy. Under
applicable law, neither Orthodontix nor Embassy may amend the Merger Agreement
subsequent to obtaining approval of their respective shareholders if such
amendments would: (i) alter or change the amount or kind of shares, securities,
cash, property and/or rights to be received in exchange for shares of such
corporation; (ii) alter or change any term of the Articles of Incorporation of
Embassy following the Merger; or (iii) alter or change any of the terms and
conditions of the Merger Agreement if such alteration or change would adversely
affect the Embassy Shareholders.

EFFECTIVE DATE

The Merger will become effective on such date as Articles of Merger
together with a Plan of Merger reflecting the Merger shall be accepted for
filing by the Secretary of State of Florida. Such filing will be made
simultaneously with or as soon as practicable after the Closing.

INTERESTS OF CERTAIN PERSONS IN THE MERGER

Embassy has agreed to cause Dr. Grussmark, Mr. Guilford, Dr. Thompson and
Mr. Gerson to be elected as directors of Embassy, such election to become
effective on the Effective Date. Such persons will comprise four of the seven
members of the Embassy Board after the Merger and, consequently, will then
control the business and affairs of Embassy. In consideration for Dr. Dresnick's
efforts in the negotiation of the Merger on behalf of Embassy, on the Effective
Date, Dr. Dresnick shall be granted the option to purchase, for a period of five
years from the Effective Date, 200,000 shares of Common Stock, at a per share
purchase price of $8.00 (the "Dresnick Options").

In addition, Mr. Guilford, the President and Chief Operating Officer of
Orthodontix will be granted the option for a period of five years from the
Effective Date, to purchase at a per share purchase price equal to the
26
34

Average Price 150,000 shares. Richard L. Alfonso, Vice President -- Operations
of Orthodontix, will be granted on the Effective Date the option to purchase at
a per share purchase price equal to the Average Price 25,000 shares (the
"Alfonso Options"), 20% of which shares may be purchased commencing on the
Effective Date through the date which is 60 months from the Effective Date (the
"60 Month Date"), an additional 20% of which may be purchased commencing on the
date which is 12 months from the Effective Date through the 60 Month Date, an
additional 20% of which may be purchased commencing on the date which is 24
months from the Effective Date through the 60 Month Date, an additional 20% of
which may be purchased commencing on the date which is 36 months from the
Effective Date through the 60 Month Date, and the remainder of which may be
purchased commencing on the date which is 48 months from the Effective Date
through the 60 Month Date. In the event Mr. Alfonso resigns or is terminated for
cause by Orthodontix from his employment with Orthodontix, the Alfonso Options
shall terminate.

On the Effective Date, William Thompson, D.D.S., who will become a director
of Embassy upon the closing of the Merger, shall be granted the option to
acquire for a period of three years from the Effective Date, 40,000 shares of
Common Stock at a purchase price equal to 80% of the Average Price (the "William
Thompson Options").

In connection with the Merger, in addition to the Dresnick Options, the
Guilford Options, the Alfonso Options and the William Thompson Options, on the
Effective Date, members of the law firm of Berman Wolfe & Rennert, P.A., counsel
to Embassy, Jack Greenman, and Ed Strongin, both advisors to Orthodontix, shall
be granted options to acquire an aggregate of 50,000, 50,000 and 10,000 shares
of Common Stock, respectively, at any time and from time to time for a period of
five years from the Effective Date at the per share purchase price equal to the
Average Price (collectively the "Merger Options"). In addition, in connection
with the Practice Acquisitions, options to acquire 327,444 shares of Common
Stock at the Average Price per share, based on an assumed Average Price of
$8.5625 per share, shall be granted to five Affiliated Orthodontists (the
"Affiliated Orthodontists Options"). The Affiliated Orthodontists Options shall
be granted to (i) John A. Benkovich, III, D.D.S., M.S., (ii) Clifford Marks,
D.D.S., (iii) Bradley A. Taylor, D.M.D., (iv) Ronald Taylor, D.M.D., M.S., and
(v) Roger Taylor, D.M.D., as follows:

On the Effective Date, Dr. Benkovich shall be granted the option to acquire
an aggregate of 40,000 shares of Common Stock, at a per share purchase price
equal to the Average Price, the exerciseability of which is subject to his
generating certain levels of revenue from his orthodontic practice.

On the Effective Date, Dr. Marks shall be granted the option to acquire for
a period of three years from the Effective Date, 20,000 shares of Common Stock
at a per share purchase price equal to 80% of the Average Price.

On the Effective Date, Dr. Bradley Taylor shall be granted the option to
acquire, in the aggregate, that amount of shares of Common Stock equal to the
quotient obtained by dividing 1,340,000 by the Average Price, at a per share
purchase price equal to the Average Price, the exerciseability of which is
subject to his generating certain levels of revenue from his orthodontic
practice.

On the Effective Date, Dr. Ronald Taylor shall be granted the option to
acquire, in the aggregate 50% of that amount of shares of Common Stock equal to
the quotient obtained by dividing 950,000 by the Average Price, at a per share
purchase price equal to the Average Price, the exerciseability of which is
subject to his generating certain levels of revenue from his orthodontic
practice.

On the Effective Date, Dr. Roger Taylor shall be granted the option to
acquire, in the aggregate, 50% of that amount of shares of Common Stock equal to
the quotient obtained by dividing 950,000 by the Average Price, the
exerciseability of which is subject to his generating certain levels of revenue
from his orthodontic practice.

The Dresnick Options, the Guilford Options, the Alfonso Options, the
William Thompson Options, the Merger Options, and the Affiliated Orthodontists
Options, together with options to be granted to 13 Affiliated Orthodontists in
connection with their tenure on the Advisory Board (the "Advisory Board
Options") are collectively referred to herein as the "Closing Stock Options."
See "MANAGEMENT OF ORTHODONTIX -- Advisory Board."
27
35

EXCHANGE OF STOCK CERTIFICATES

Any stock certificate that, prior to the Effective Date, represented
outstanding shares of Orthodontix Common Stock will, on the Effective Date and
prior to surrender, be deemed to evidence ownership of the Merger Stock for
which such shares of Orthodontix Common Stock were exchanged in the Merger. From
and after the Effective Date, certificates representing Embassy Common Stock
will continue to represent such securities and will not be exchanged,
notwithstanding the Name Change of Embassy to "Orthodontix, Inc."

NO FRACTIONAL SHARES

No certificates or scrip for fractional shares of Embassy Common Stock will
be issued in connection with the Merger.

ABSENCE OF APPRAISAL RIGHTS

Florida law does not afford appraisal rights to the Embassy Shareholders
with respect to the Merger. However, see "Redemption Rights" below.

REDEMPTION RIGHTS

Each non-affiliated Embassy Shareholder as of the Embassy Record Date will
have the right until April 15, 1998 to offer his or her shares of Embassy Common
Stock for redemption (the "Redemption") at a price equal to approximately $5.35
per share as of September 30, 1997 (the "Redemption Value"). The Redemption
Value is equal to Embassy's book value divided by the number of shares of
Embassy Common Stock held by all non-affiliated Embassy Shareholders, as
determined by Embassy and audited by its independent public accountants,
calculated as of the Embassy Record Date. If less than 30% in interest of
Embassy Common Stock held by non-affiliated Embassy Shareholders who vote
against approval of the Merger, and the Merger is consummated, Embassy will
redeem shares of Embassy Common Stock at the Redemption Value from those Embassy
Shareholders who affirmatively requested such redemption and who actually voted
against approval of the Merger. If 30% or more in interest of Embassy Common
Stock held by non-affiliated Embassy Shareholders actually vote against approval
of the Merger, the proposed Merger will be terminated, Embassy will not proceed
with the Merger and will not redeem any shares.

A non-affiliated Embassy Shareholder wishing to exercise his or her
redemption rights (i) must deliver to Embassy, prior to or at the Special
Meeting but before the vote is taken on the Merger, a written objection to the
Merger (the "Notice of Election"), which shall include a notice of his or her
election to redeem his or her Embassy Common Stock, his or her name and
residence address, the number of shares of Embassy Common Stock which he or she
owns and demand for payment of the Redemption Value of his or her shares of
Embassy Common Stock (which Notice of Election must be in addition to and
separate from any proxy or vote against the Merger); and (ii) must vote against
the Merger. A vote against the Merger, in person or by proxy, will in and of
itself not constitute a written objection to the Merger satisfying the
requirements for exercise of the redemption rights. In addition, a proxy
directing such vote for an abstention, even if accompanied by a Notice of
Election, will not meet the requirements for exercise of the redemption rights.
A non-affiliated Embassy Shareholder, who elects to redeem his or her shares of
Embassy Common Stock, may not redeem less than all of the shares of Embassy
Common Stock beneficially owned by such Embassy Shareholder as of the Embassy
Record Date. Embassy Shareholders, who timely file a Notice of Election and who
vote their Embassy Common Stock against the Merger, are hereinafter referred to
as "Redeeming Shareholders."

ALL NOTICES OF ELECTION SHOULD BE ADDRESSED TO EMBASSY ACQUISITION CORP.,
1428 BRICKELL AVENUE, SUITE 105, MIAMI, FLORIDA 33131, ATTENTION: GLENN HALPRYN.

28
36

On the Effective Date, each Redeeming Shareholder will cease to have any of
the rights of an Embassy Shareholder, except the right to be paid the Redemption
Value for his or her shares of Embassy Common Stock. To maintain his or her
position as a Redeeming Shareholder, each Embassy Shareholder must submit the
certificate representing his or her shares of Embassy Common Stock to Embassy or
its transfer agent as noted below. A Notice of Election may be withdrawn by an
Embassy Shareholder, with the written consent of Embassy, prior to 20 days
following the Effective Date.

Within 10 days after the date on which the Embassy Shareholders approve the
Merger, Embassy will send written notice of such approval ("Notice of Approval
of Merger"), including the per share Redemption Value, by certified or
registered mail to each Embassy Shareholder who filed a Notice of Election and
who voted his shares against adoption of the Merger. Within 20 days following
the date of mailing of the Notice of Approval of Merger, Redeeming Shareholders
must submit certificates representing their shares of Embassy Common Stock to
Embassy or its transfer agent. Within 30 days following the date of mailing of
the Notice of Approval of Merger, Embassy will pay each Redeeming Shareholder
who has submitted the certificates representing his or her shares of Embassy
Common Stock to Embassy or its transfer agent, the Redemption Value for such
shares. ANY REDEEMING SHAREHOLDER WHO FAILS TO SUBMIT HIS OR HER CERTIFICATES
REPRESENTING EMBASSY COMMON STOCK WITHIN 20 DAYS FOLLOWING THE DATE OF MAILING
OF THE NOTICE OF APPROVAL OF MERGER SHALL LOSE HIS REDEMPTION RIGHTS.

ACCOUNTING TREATMENT

Embassy and Orthodontix believe that the Merger will be treated as a
capital transaction equivalent to the issuance of stock by Orthodontix for
Embassy's net monetary assets of approximately $7.4 million as of September 30,
1997, accompanied by a recapitalization of Orthodontix.

In accordance with Staff Accounting Bulletin No. 48, "Transfers of
Nonmonetary Assets by Promoters and Shareholders" ("SAB 48"), the acquisition of
the tangible and intangible assets and assumption of certain liabilities of the
Founding Practices from certain promoters of the transaction (the orthodontists
who own the Founding Practices) will be accounted for by Orthodontix, at the
transferor's historical cost basis. The Orthodontix Common Stock being issued in
connection with the acquisition of the Founding Practices will be recorded at
the historical net book value of the net assets being acquired, net of
liabilities assumed, as reflected on the books of the Founding Practices.

CERTAIN TAX CONSEQUENCES OF THE MERGER

The Merger is intended to be a "reorganization" for federal income tax
purposes under Section 368 of the Internal Revenue Code of 1986, as amended (the
"Code"). As a consequence, other than with respect to the Redemption: (i)
Embassy will not recognize any gain or loss in the Merger; and (ii) the Embassy
Shareholders will not recognize any gain or loss in the Merger.

THE TAX DISCUSSION SET FORTH ABOVE IS INCLUDED FOR GENERAL INFORMATION ONLY
AND IS BASED UPON PRESENT LAW. EACH EMBASSY SHAREHOLDER SHOULD CONSULT HIS OR
HER TAX ADVISOR AS TO THE SPECIFIC TAX CONSEQUENCES OF THE MERGER, INCLUDING THE
APPLICATION AND EFFECT OF FEDERAL STATE, LOCAL AND OTHER TAX LAWS AND THE
POSSIBLE EFFECTS OF CHANGES IN FEDERAL LAW OR OTHER TAX LAWS.

RESTRICTIONS ON SALES BY AFFILIATES

The shares of Merger Stock to be issued to Orthodontix Shareholders in
connection with the Merger have been registered under the Securities Act, and,
subject to applicable law and certain lock-up agreements described below, will
be freely transferable under the Securities Act, except for shares issued to any
person who may be deemed an "Affiliate" (as defined below) of Orthodontix within
the meaning of Rule 145 under the Securities Act ("Rule 145"). "Affiliates" are
generally defined as persons who control, are controlled by, or are under common
control with Orthodontix at the time of the Special Meeting (generally,
directors, certain executive officers and major shareholders). Affiliates of
Orthodontix may not sell their shares of
29
37

Embassy Common Stock acquired in connection with the Merger, except pursuant to
an effective registration statement under the Securities Act covering such
shares or in compliance with Rule 145 or another applicable exemption from the
registration requirements of the Securities Act. In general, under Rule 145, for
one year following the Effective Date, an Affiliate (together with certain
related persons) would be entitled to sell shares of Embassy Common Stock
acquired in connection with the Merger only through unsolicited "broker
transactions" or in transactions directly with a "market maker," as such terms
are defined in Rule 144 under the Securities Act. Additionally, the number of
shares to be sold by an Affiliate (together with certain related persons and
certain persons acting in concert) during such one-year period within any
three-month period for purposes of Rule 145 may not exceed the greater of 1% of
the outstanding shares of Embassy Common Stock or the average weekly trading
volume of such stock during the four calendar weeks preceding such sale. Rule
145 would remain available to Affiliates only if Embassy remained current with
its information filings with the Commission under the Exchange Act. One year
after the Effective Date, an Affiliate would be able to sell such Embassy Common
Stock without such manner of sale or volume limitations, provided that Embassy
was current with its Exchange Act information filings and such Affiliate was not
then an Affiliate of Embassy. Two years after the Effective Date, an Affiliate
would be able to sell such shares of Embassy Common Stock without any
restrictions provided such Affiliate has not been an Affiliate of Embassy for at
least three months prior thereto.

Under the terms of a lock-up agreement between each of the Affiliated
Orthodontists who are issued Merger Stock (the "Practitioner Holders") and
Embassy, all of the shares of Merger Stock to be issued to the Practitioner
Holders in connection with acquisition of the Affiliated Practices as well as
shares underlying stock options received by the Practitioner Holders (the
"Practitioner Merger Stock") will not be permitted to be sold, transferred or
otherwise disposed of for a period of six months from the Effective Date.
Thereafter, the Practitioner Holders will not be permitted to sell, transfer or
otherwise dispose of the Practitioner Merger Stock other than in amounts equal
to: (i) 20% of the Practitioner Holder's Practitioner Merger Stock during the
period of time commencing on the 181st day and ending on the 270th day after the
Effective Date; (ii) 40% of the Practitioner Holder's Practitioner Merger Stock
during the period of time commencing on the 271st day and ending on the 365th
day following the Effective Date; and (iii) 60% of the Practitioner Holder's
Merger Stock during the period of time commencing on the 366th day and ending on
the 456th day following the Effective Date, and thereafter the Practitioner
Holders' Practitioner Merger Stock will be transferable by the Practitioner
Holders not deemed to be "Affiliates" of Embassy subject to applicable law.
Affiliates are generally defined as persons who control, are controlled by, or
under common control with Embassy (generally certain executive officers,
directors and principal shareholders).

While no assurances can be made, it is contemplated that subsequent to the
Effective Date, Embassy expects to file a registration statement on Form S-8
(the "S-8 Registration Statement") covering the resale of the shares of Embassy
Common Stock issuable upon exercise of options to be granted under the Stock
Option Plan (assuming it is approved) (the "S-8 Registration Statement"). The
effect of filing such S-8 Registration Statement is that, subject to applicable
law, upon the effectiveness of the S-8 Registration Statement, the
30
38

shares of Embassy Common Stock underlying stock options to be granted under the
Stock Option Plan, when properly issued, will be freely transferable under the
Securities Act in accordance with the terms and conditions of the Stock Option
Plan.

CERTAIN REGULATORY MATTERS

No federal or state regulatory requirements remain to be complied with in
connection with the Merger, except for certain required notifications and
closing and post-closing filings.

OPERATIONS AFTER THE MERGER

General. As a result of the Merger, Orthodontix will become a wholly-owned
subsidiary corporation of Embassy. The Articles of Incorporation of Embassy will
be amended on the Effective Date to, among other things, change Embassy's name
to "Orthodontix, Inc."

Directors and Executive Officers. In accordance with the Merger Agreement,
all members of the Embassy Board will, immediately prior to the Effective Date,
resign from the Embassy Board, other than Dr. Dresnick and Mr. Halpryn and,
following the Merger, the Embassy Board shall elect four new members of the
Embassy Board selected by Orthodontix, namely, Mr. Guilford, Dr. Grussmark, Dr.
Thompson and Mr. Gerson and one new member selected by Embassy, namely, Mr.
Gottlieb. In addition, all of Embassy's executive officers will resign effective
on the Effective Date, to be replaced by Orthodontix' current executive
officers. See "MANAGEMENT OF ORTHODONTIX -- Executive Officers and Directors."

Dividends. Embassy does not presently intend to pay any cash dividends for
the foreseeable future, as all available cash will be utilized to further the
growth of Embassy's business subsequent to the Effective Date and for the
proximate future thereafter. The payment of any subsequent cash dividends will
be in the discretion of the Embassy Board and will be dependent upon Embassy's
results of operations, financial condition, and other factors deemed relevant by
the Embassy Board. See "DESCRIPTION OF EMBASSY'S SECURITIES."

THE PROPOSAL TO APPROVE THE MERGER REQUIRES THE AFFIRMATIVE VOTE OF A
MAJORITY OF THE OUTSTANDING EMBASSY SHARES HELD BY NONAFFILIATED SHAREHOLDERS
AND NO MORE THAN 30% IN INTEREST OF THE EMBASSY COMMON STOCK HELD BY
NON-AFFILIATED SHAREHOLDERS ACTUALLY VOTE AGAINST THE MERGER. UNLESS OTHERWISE
SPECIFIED BY SUCH SHAREHOLDER, A VOTE AGAINST THE MERGER WILL NOT CONSTITUTE A
REQUEST BY SUCH SHAREHOLDER FOR REDEMPTION OF HIS SHARES. IF A SHAREHOLDER VOTES
AGAINST THE MERGER BUT SPECIFICALLY CHOOSES NOT TO REDEEM HIS SHARES, SUCH
SHAREHOLDER WILL CONTINUE TO BE A SHAREHOLDER OF EMBASSY. THE EMBASSY BOARD
BELIEVES THAT APPROVAL OF THE MERGER IS IN THE BEST INTERESTS OF EMBASSY AND THE
EMBASSY SHAREHOLDERS AND UNANIMOUSLY RECOMMEND A VOTE FOR APPROVAL AND ADOPTION
OF THE MERGER.

31
39

PROPOSAL 2: RESTATEMENT OF THE
ARTICLES OF INCORPORATION OF EMBASSY

The Embassy Shareholders are being asked to consider and vote upon a
proposal to amend and restate Embassy's Articles of Incorporation (the "Restated
Articles") to provide for (i) an authorized class of Preferred Stock, consisting
of 100,000,000 shares, par value $.0001 per share (the "Preferred Stock"), with
rights, preferences and designations to be determined by the Embassy Board (the
"Preferred Stock Amendment"); and (ii) a change in the corporate name from
Embassy Acquisition Corp. to "Orthodontix, Inc."

The following summary of the Preferred Stock Amendment is, in all respects,
qualified and amplified by the actual language of the Restated Articles, a copy
of which is attached as Appendix B to this Proxy Statement/Prospectus.

AUTHORIZATION TO ISSUE PREFERRED STOCK

Under Florida law and under the terms of the proposed Restated Articles of
Embassy, preferred stock may be issued in series established from time to time
by the Board of Directors. In this connection, the Board of Directors has broad
discretion to set the terms of the Preferred Stock, and, if it decided to, may
fix for each series, without further shareholder approval (i) the rate of
dividend; (ii) the price at and the terms and conditions on which shares may be
redeemed; (iii) the amount payable upon shares in the event of voluntary or
involuntary liquidation; (iv) sinking fund provisions, if any, for the
redemption or purchase of shares; (v) the terms and conditions on which shares
may be converted, if the shares of any series are issued with the privilege of
conversion; and (vi) voting rights, if any.

The Embassy Board may fix the number of votes to which each share of
Preferred Stock is entitled, or deny voting rights to the shares of any series,
except to the extent voting rights are expressly granted by applicable law.
Depending upon the terms of voting rights granted to any series of Preferred
Stock, issuance thereof could result in a reduction in the voting power of the
holders of Common Stock or other Preferred Stock.

It is not possible to state the actual effect of the authorization of the
Preferred Stock or other classes of stock upon the rights of holders of Embassy
Common Stock until the Embassy Board determines the respective rights of the
holders of one or more series of the Preferred Stock. However, such effects
might include, without limitation: (a) restrictions on dividends on Common stock
if Preferred Stock is issued with a preferential (and possibly cumulative)
dividend right and dividends on the Preferred Stock are in arrears; (b)
substantial dilution of the voting power of the Common Stock to the extent that
the Preferred Stock has voting rights or to the extent that any Preferred Stock
is given conversion rights into Common Stock; and (c) the holders of Common
Stock not being entitled to share in Embassy's assets upon liquidation or
dissolution until satisfaction of any liquidation preference granted to the
Preferred Stock, which the Embassy Board may set at its discretion. The Embassy
Board could also authorize holders of the Preferred Stock to vote, either
separately as a class or with the holders of Common Stock, on any merger, sale
or exchange of assets by Embassy or other extraordinary corporate transaction.
Shares of Preferred Stock could even be privately placed with purchasers who
might ally themselves with the Embassy Board in opposing a hostile takeover bid,
diluting the stock ownership or voting power of persons seeking to obtain
control of Embassy. The Preferred Stock could be utilized, under certain
circumstances, as a method of discouraging, delaying or preventing a change in
control of Embassy, thereby having an anti-takeover effect. The ability to issue
Preferred Stock could be beneficial to management in a hostile tender offer
while it may have an adverse impact on shareholders who may want to participate
in such a tender offer.

In addition, Embassy may be affected to the extent that Preferred Stock is
issued which is, by its terms, redeemable, either at the option of Embassy or
the holders of Preferred Stock, in accordance with such terms and conditions as
may be designated by the Board of Directors in creating such series. The amount
payable by Embassy upon redemption of the Preferred Stock will be the redemption
price fixed for the shares of each series by the Board of Directors and may also
include payment of all accumulated and unpaid dividends. There are many other
potential effects not mentioned here.
32
40

Although Embassy does not presently intend to issue any of the additional
shares of Preferred Stock to be authorized, this approval is being sought in
order to allow the Embassy Board to authorize the issuance of such shares when
opportunities arise without delay, which would result from holding a meeting of
the Embassy Shareholders to authorize the issuance of such additional shares.

In approving the proposed Restated Articles of Embassy, Embassy
Shareholders will also be authorizing the Embassy Board to take all such actions
and execute and/or file all such documents as the Board deems necessary or
appropriate to effectuate the purposes of the proposed Restated Articles,
including, without limitation, the making of any technical or non-material
changes to the Restated Articles. Furthermore, the Embassy Board reserves the
right, notwithstanding approval of the proposed Restated Articles by the Embassy
Shareholders, at any time prior to the filing of the Restated Articles, with the
Secretary of State of Florida, to terminate all or any part of the provisions
made a part of the Restated Articles and all transactions contemplated by or
incident thereto.

THE PROPOSAL TO AMEND AND RESTATE THE ARTICLES REQUIRES THE AFFIRMATIVE
VOTE OF A MAJORITY OF THE SHARES OF EMBASSY COMMON STOCK VOTING IN PERSON OR BY
PROXY AT THE SPECIAL MEETING. THE EMBASSY BOARD BELIEVES THAT APPROVAL OF THE
RESTATED ARTICLES IS IN THE BEST INTERESTS OF EMBASSY AND THE EMBASSY
SHAREHOLDERS AND UNANIMOUSLY RECOMMENDS A VOTE FOR APPROVAL.

[This Space Intentionally Left Blank]

33
41

PROPOSAL 3: RATIFICATION AND APPROVAL OF THE
1997 EMBASSY ACQUISITION CORP. STOCK OPTION PLAN

The Embassy Shareholders are being asked to consider the proposal to ratify
and approve the 1997 Embassy Acquisition Corp. Stock Option Plan (the "Stock
Option Plan"). The following summary of the Stock Option Plan is, in all
respects, qualified and amplified by the actual language of the Stock Option
Plan.

DESCRIPTION OF THE STOCK OPTION PLAN

The Stock Option Plan was unanimously approved by the Embassy Board in
November 1997 to become effective on the Effective Date, to provide Embassy with
an effective means to attract, retain and motivate persons affiliated with
Embassy. The Stock Option Plan is designed to comply with the requirements of
Section 16(b) the Exchange Act. A maximum of 500,000 shares of Embassy Common
Stock (the "Option Shares") may be issued under the Stock Option Plan. No
options may be granted under the Plan after November 18, 2007. Pursuant to the
Merger Agreement, Embassy shall file with the Commission a Registration
Statement on Form S-8 (the "Form S-8") covering the Option Shares. The effect of
filing the Form S-8 is that, subject to applicable law, the Option Shares when
properly issued by Embassy, shall be freely tradeable securities.

The Stock Option Plan is to be administered by a compensation and stock
option committee of the Embassy Board (the "Committee"), which, under the terms
of the Stock Option Plan, must consist of at least two "Non-Employee Directors,
within the meaning of Rule 16b-3 promulgated by the Commission under the
Exchange Act. The Committee has the authority to interpret the provisions of the
Stock Option Plan and to make all determinations deemed necessary or advisable
for its administration. On the Effective Date, Mr. Gottlieb and Mr. Gerson shall
serve on the Committee.

The Stock Option Plan provides for the issuance of incentive stock options
within the meaning of Section 422 of the Internal Revenue Code of 1986 (the
"Code") and non-qualified stock options not intended to meet the requirements of
Section 422 of the Code. Incentive stock options may be granted to employees of
Embassy and its subsidiaries, and non-qualified stock options may be granted to
employees, directors, independent contractors and agents of Embassy and its
subsidiaries. Subject to the Stock Option Plan, the Committee determines the
persons to whom grants are made and the vesting, timing, amounts and other terms
of such grants. An optionee may not receive incentive stock options exercisable
in one calendar year for shares with a fair market value on the date of grant in
excess of $100,000. No quantity limitations apply to the grant of nonqualified
stock options.

The exercise price of options may not be less than the fair market value of
the Embassy Common Stock on the date of grant, except that the exercise price of
any incentive stock option granted to the holder of more than 10% of the
outstanding Embassy Common Stock may not be less than 110% of the fair market
value of the Embassy Common Stock on the date of grant. The term of each option
may not exceed ten years, except the term of any incentive stock option granted
to the holder of more than 10% of the outstanding Embassy Common Stock may not
exceed five years. The Stock Option Plan sets forth additional provisions with
respect to the exercise of options by optionees upon the termination of their
employment and upon their death.

The number of shares of Embassy Common Stock covered by outstanding
options, the number of shares of Embassy Common Stock available for issuance
under the Stock Option Plan, and the exercise price per share of outstanding
options, are proportionately adjusted for any increase or decrease in the number
of issued shares of Embassy Common Stock resulting from a stock split or stock
dividend. In the event of a merger, sale of all or substantially all of the
assets or other "change in control" of Embassy (as defined in the Stock Option
Plan), all stock options will become immediately exercisable.

The Committee may amend or terminate the Stock Option Plan, except that
shareholder approval is required to increase the number of shares of Embassy
Common Stock subject to the Stock Option Plan, to change the class of persons
eligible to participate in the Stock Option Plan, or to materially increase the
benefits accruing to participants under the Stock Option Plan.

34
42

FEDERAL INCOME TAX CONSEQUENCES

Incentive Stock Options. It is intended that certain options granted under
the Stock Option Plan will qualify as "incentive stock options" to the degree
possible under the Code. This means that the optionee will not realize taxable
income upon the grant or exercise of the option subject to compliance with the
Code. However, any excess of the fair market value of the option stock on the
date of exercise over the option price will constitute an item of adjustment for
purposes of the alternative minimum tax and may cause the optionee to incur a
liability for such tax in the year of exercise.

If the optionee holds the stock purchased on exercise of the option until
at least (a) one year after it is purchased and (b) two years after the option
is granted, any profit or loss recognized on disposition of the stock will be
treated as capital gain or loss. If, however, the optionee disposes of the stock
within either the one or two-year period, the optionee generally will be
required to include in ordinary taxable income upon disposition of the stock an
amount equal to the lesser of (a) the amount, if any, by which the fair market
value of such stock on the date the option was exercised exceeded the option
price, or (b) the amount, if any, by which the amount realized from such
disposition exceeds the option price; any additional gain would be long-term or
short-term capital gain, depending upon how long the stock was held. But, for
certain dispositions of stock made within either the one or two-year period by
way of gift or by way of sale to a person or entity related to the optionee, the
optionee may be required to include in ordinary taxable income the full amount
described in (a), regardless of the amount realized from such disposition.

The one and two-year requirements do not apply to the disposition of stock
after an optionee's death by (a) the optionee's estate or (b) a person who
acquires the right to exercise the option by reason of the optionee's death. In
such cases, the stock may be disposed of any time after receipt and receive
preferential tax treatment subject to the general holding period rules for
capital gains.

Options granted under the Stock Option Plan may be exercised by the
transfer to Embassy of shares of Embassy's Common Stock with a fair market value
equal to the option's exercise price. If the optionee transfers incentive stock
option shares to Embassy before both the one and two-year holding periods have
expired, the transfer will be treated as a disposition of such shares with the
tax consequences described above. If the shares so transferred are not incentive
stock option shares or, if they are such shares and both the one and two-year
periods have expired, such transfer to Embassy will not be a taxable event.

Generally, Embassy will not be entitled to any tax deduction in connection
with the grant or exercise of an incentive stock option. If, however, the
optionee disposes of stock acquired upon exercise of an option before the one
and two-year periods have expired, Embassy will be entitled to deduct, when the
optionee disposes of the stock, any amount the optionee is required to include
in ordinary taxable income.

Non-Qualified Stock Options. The grant by Embassy of non-qualified stock
options is not a taxable event to the optionee. Generally, an optionee
recognizes ordinary income on the date unrestricted option shares are issued to
him pursuant to the exercise of the option in an amount equal to the "spread" or
the excess of the fair market value of the shares on that date over the exercise
price. Any further gain or loss on disposition of the shares will be capital
gain or loss if the shares are held by the optionee for investment.

In certain circumstances, Embassy will be entitled to deduct, as an
expense, for federal income tax purposes any amount the optionee is required to
include in ordinary income at the time such amount is so includable, provided
that such amount is not deemed to be an "excess parachute payment" (i.e.,
payment payable upon a change of control of Embassy that is in excess of
reasonable compensation).

OPTIONS OUTSTANDING

As of the date of this Proxy Statement/Prospectus, no options have been
granted under the Stock Option Plan. However, in connection with the Merger,
Closing Stock Options to purchase approximately 959,944 shares of Embassy Common
Stock shall be outstanding as of the Closing Date.

35
43

RECOMMENDATION OF THE BOARD OF DIRECTORS

The Embassy Board believes that the best interests of Embassy will be
served by Embassy implementing the Stock Option Plan. The Embassy Board believes
that awards made under the Stock Option Plan will enable Embassy to better
compete for qualified personnel, to retain such personnel in the employ of
Embassy, and to motivate such personnel and align their long-term interests with
those of the Embassy Shareholders. To remain competitive in attracting and
retaining qualified personnel and to continue to provide such personnel proper
motivation and incentives, the Embassy Board believes that the proposal to
ratify and approve the Stock Option Plan should be approved.

THE BOARD OF DIRECTORS RECOMMENDS THAT THE EMBASSY SHAREHOLDERS VOTE FOR
THE PROPOSAL TO RATIFY AND APPROVE THE STOCK OPTION PLAN.

PRICE RANGES OF EMBASSY'S SECURITIES

Embassy's Common Stock, par value $.0001 per share, has been quoted in the
over-the-counter market under the symbol "MBCA" since April 2, 1996. The
following table shows the reported low bid and high bid quotations for the
Embassy Common Stock for the periods indicated below. The high and low bid
prices for the periods indicated are interdealer prices, without retail mark-up,
mark-down or commissions and may not necessarily represent actual transactions.
These quotations have been obtained from the OTC Bulletin Board.

LOW BID HIGH BID
(PER SHARE) (PER SHARE)
----------- -----------

1996
April 2 through June 30................................... $6.00 $6.25
Third Quarter............................................. $6.00 $6.25
Fourth Quarter............................................ $6.00 $6.25
1997
First Quarter............................................. $6.00 $8.375
Second Quarter............................................ $7.125 $9.25
Third Quarter............................................. $8.00 $8.00
Fourth Quarter............................................ $5.25 $8.75
1998
January 1 through March 25, 1998.......................... $8.00 $8.75

On May 5, 1997 (the last day prior to the public announcement of the letter
of intent relating to the Merger the Embassy Common Stock was quoted), the last
reported closing bid price of the Embassy Common Stock was $9.25.

On November 6, 1997 (the last day prior to the public announcement of the
execution of the Merger Agreement the Embassy Common Stock was quoted), the last
reported closing bid price was $8.00.

On March 25, 1998 (the last day prior to the date of this Proxy
Statement/Prospectus), the last reported closing bid price of the Embassy Common
Stock was $8.75. On that date, there were 46 record holders of Embassy Common
Stock, inclusive of those brokerage firms and/or clearing houses holding shares
of Embassy Common Stock for their clientele (with each such brokerage house
and/or clearing house being considered as one holder).

Embassy has not paid or declared any dividends upon its Common Stock since
its inception and, by reason of its present financial status and its
contemplated financial requirements, does not contemplate or anticipate paying
any dividends upon its Common Stock in the foreseeable future.

36
44

MANAGEMENT'S DISCUSSION AND ANALYSIS OR
PLAN OF OPERATION OF EMBASSY

Embassy Acquisition Corp. was formed in November 1995 to seek to effect a
merger, exchange of capital stock, asset acquisition or similar business
combination (a "Business Combination") with a business (an "Acquired Business").
In connection with its initial capitalization, Embassy issued 1,160,000 shares
of its Embassy Common Stock to its officers, directors and other shareholders
for an aggregate sum of $76,078. On April 2, 1996, Embassy's Registration
Statement on Form SB-2 (the "SB-2 Registration Statement") was declared
effective by the Commission. Pursuant to the SB-2 Registration Statement,
Embassy, in its initial public offering of securities, offered and sold
1,380,000 shares of Common Stock, par value $.0001 per share, at a purchase
price of $6.00 per share (the "Offering"). The Offering was a "blank check"
offering. In connection with the closing of the Offering, Embassy issued
1,380,000 shares of Common Stock and received gross proceeds of $8,280,000.

Embassy, as a result of the offering had net proceeds of approximately
$7,052,000 (the "Net Proceeds"). Approximately 90% of such proceeds ($6,346,800)
was placed in escrow (the "Escrow Fund") immediately following the Offering.

For the three and nine month periods ended September 30, 1997, Embassy
incurred $16,609 and $67,019, respectively, of operating expenses and derived
interest income of $91,140 and $258,793, respectively, as compared with the
three and nine month periods ended September 30, 1996 when Embassy incurred
$11,655 and $26,247, respectively, of operating expenses and derived interest
income of $58,517 and $116,100, respectively. For the period from inception
(November 30, 1995) through September 30, 1997, Embassy incurred $111,077 of
operating expenses and derived interest income of $502,536.

At December 31, 1996 and September 30, 1997, Embassy had cash and cash
equivalents of $763,965 and $655,033, respectively, restricted short-term
investments of $6,566,206 and $6,800,767, respectively, long-term assets of
$8,472 and $8,472, respectively, and liabilities of $79,963 and $77,748,
respectively.

[This Space Intentionally Left Blank]

37
45

MANAGEMENT'S DISCUSSION AND ANALYSIS OR
PLAN OF OPERATION OF ORTHODONTIX

The following discussion and analysis contains certain statements of a
forward-looking nature relating to future events or the future financial
performance of Orthodontix. Such statements are only predictions, and the actual
events or results may differ materially from the results discussed in the
forward-looking statements. Factors that could cause or contribute to such
differences include, but are not limited to, those discussed in "RISK FACTORS,"
as well as those discussed elsewhere in this Proxy Statement/Prospectus. The
historical results set forth in this discussion and analysis are not indicative
of trends with respect to any actual or projected future financial performance
of Orthodontix. The following should be read in conjunction with the financial
statements and related notes thereto appearing elsewhere in this Proxy
Statement/Prospectus.

OVERVIEW

Orthodontix has conducted no operations to date other than entering into
agreements to acquire the Founding Practices. Immediately subsequent to the
consummation of the Practice Acquisitions, Orthodontix will provide practice
management services to the Founding Practices pursuant to long-term
administrative services agreements (the "Administrative Services Agreements")
with separately organized PA Contractors. The PA Contractors directly employ
Affiliated Orthodontists or affiliate with other separately formed professional
associations owned by practicing orthodontists (the "Practitioner PAs") pursuant
to employment agreements (the "PA Contractor Employment Agreements") or service
agreements, as the case may be (the "Service Agreements") with terms ranging
from two to ten years. In those practices where the PA Contractors do not
directly employ the Affiliated Orthodontists, the Practitioner PAs directly
employ orthodontists pursuant to employment agreements (the "Practitioner PA
Employment Agreements") with substantially similar terms. In all cases
Orthodontix directly employs all non-orthodontic personnel and subject to
applicable law directly owns the tangible equipment and other assets utilized in
the practice.

ADMINISTRATIVE SERVICES AGREEMENTS

General. Pursuant to the Administrative Services Agreements, Orthodontix
provides and has control over all non-orthodontic functions of the PA
Contractors including all administrative, management, billing and support
functions, while the PA Contractors and the Affiliated Orthodontists they employ
or affiliate with, have control over all functions relating to the provision of
orthodontic services. Orthodontix receives a management fee for the services.
Subject to applicable state law the management fee (the "Management Fee") is
either equal to (i) 15% percent of the accrued revenue derived by the PA
Contractor and a percentage of the net income earned by the PA Contractor; or
(ii) a flat based fee, which is determined on an annual basis.

Services Provided by Orthodontix. Pursuant to the Administrative Services
Agreements, Orthodontix provides practice management services to the PA
Contractors, which include consultation and other activities regarding the
suitability of facilities and equipment, nonprofessional staffing, regulatory
compliance, productivity improvements, inventory and supplies management,
information systems management, marketing services, site selection and layout,
billing and financial services, malpractice insurance, and, subject to
applicable law, other services as Orthodontix deems necessary to meet the day to
day requirements of the PA Contractors. Under the Administrative Services
Agreements, Orthodontix has responsibility over billing of professional
services, claims for reimbursement or indemnification from third parties,
collection of accounts receivable, custody of checks, notes, and other forms of
payment and funds deposited.

Advisory Board. Orthodontix will establish an advisory board (the
"Advisory Board") consisting of licensed orthodontists designated by Orthodontix
and the PA Contractors who will meet to review, evaluate and make
recommendations concerning capital improvements and expenditures, ancillary
services, provider-payor relationships, strategic planning, fee-dispute
resolution, and other management issues. In addition, the members of the
Advisory Board who are licensed healthcare professionals shall have exclusive
authority to review and resolve issues regarding the type and levels of
healthcare services to be provided, fee schedules, any

38
46

orthodontic or dental related functions and any other decisions required by
applicable law to be made solely by dentists and orthodontists.

Term and Termination. The Administrative Services Agreements have initial
terms of 40 years, subject to prior termination by either party in the event the
other party (i) becomes subject to bankruptcy proceedings or (ii) materially
breaches the Administrative Services Agreement and such party fails to cure the
breach within 30 days. In addition, the Administrative Services Agreement may be
terminated by either party upon the occurrence of adverse legislative,
regulatory or administrative change.

SERVICE AGREEMENTS AND PA CONTRACTOR EMPLOYMENT AGREEMENTS

Under the Service Agreements and the PA Contractor Employment Agreements,
the PA Contractor owns and operates each Affiliated Practice and has the
exclusive right to bill and receive payment for orthodontic services rendered by
the Affiliated Orthodontist. In exchange, the PA Contractor pays to the
Practitioner PA in the case of a Service Agreement, or directly to the
Affiliated Orthodontist, in the case of a PA Contractor Employment Agreement, a
monthly base amount (the "Base Compensation") equal to a percentage (ranging
from a low of 15% to a high of 48% of the practice's Accrued Revenue. "Accrued
Revenue" is defined as: (i) 24% of the Initial Contract Amount; plus (ii) the
Monthly Contract Residual Amount; plus (iii) Additional Non-Contract Service
Charges. "Initial Contract Amount" for a given month is defined as the total
value of any contracts to provide orthodontic services between a patient or
third party payor on the one hand and the Affiliated Orthodontist, the
Practitioner PA, or the PA Contractor on the other, for the provision of
orthodontic services at a pre-determined fee-for service amount (whether or not
payable in cash) which contract was generated by the Affiliated Orthodontist
after the Effective Date (the "Contract"), entered into on or prior to the last
business day of each month. "Monthly Contract Residual Amount" is defined as
that amount equal to the amounts remaining to be paid by the patient or third
party payor under a Contract (the "Remaining Amounts Payable") divided by the
number of months remaining in the term of such Contract; except that the
Remaining Amounts Payable shall not be in excess of 76% (other than for a
Contract entered into prior to the Effective Date) of the total amounts payable
by the patient or third party payor under the Contract. "Additional Non-Contract
Service Charges" is defined as that amount charged for orthodontic services
which are not included in a patient contract. Such orthodontic services include,
but are not limited to, diagnosis charges, observation charges, retention
charges and office visit charges.

In addition to the Base Compensation, under certain conditions, a Service
Fee (the "Service Fee"), equal to 70% of the "Net Operating Income" generated
from the delivery of orthodontic services by the Affiliated Orthodontist is paid
to the Practitioner PA in the case of a Service Agreement and directly to the
Affiliated Orthodontist in the case of a PA Contractor Employment Agreement.
"Net Operating Income" is defined as that amount, if any, equivalent to the
percentage by which Practice Overhead declines as a percentage of Accrued
Revenue annually; multiplied by the annual Accrued Revenue. "Practice Overhead"
is generally defined as the sum of:

(i) an agreed upon allocable share of salaries, benefits, and other
direct costs of all employees other than licensed healthcare professional
at the practice location (the "Location");

(ii) an agreed upon allocable share of direct costs of all patient
care and office supplies purchased in connection with the operation of the
Location;

(iii) an agreed upon allocable share of personal property and real
property leasehold obligations entered into in connection with the
performance of orthodontic services at the Location;

(iv) an agreed upon allocable share of personal property and
intangible taxes assessed against the assets used in connection with the
operation of the orthodontic practice at the Location;

(v) an agreed upon allocable share of malpractice insurance expenses
and orthodontist recruitment expenses;

(vi) the annual Base Compensation; and

(vii) the Management Fee.
39
47

PRACTICE ACQUISITIONS

In accordance with SAB 48, the acquisition of the tangible and intangible
assets and assumption of certain liabilities of the Founding Practices from
certain promoters of the transactions (the orthodontists who own the Founding
Practices) pursuant to the Practice Acquisitions will be accounted for by
Orthodontix at the transferors' historical cost basis, with the shares of
Embassy Common Stock to be issued in connection with the acquisition of the
Founding Practices recorded at the historical net book value of net assets being
acquired, as reflected on the books of the Founding Practices. Future
acquisitions of certain of the assets and liabilities of Affiliated Practices
accounted for as purchases may result in substantial annual noncash amortization
charges for intangible assets in Orthodontix' statements of operations.

Subsequent to the Effective Date, Orthodontix intends to implement a growth
strategy focused on (i) affiliating with additional orthodontic practices that
have a high quality practice with strong financial performance; (ii) expanding
Affiliated Practices by providing capital, support and consultation for
satellite office expansion; (iii) assisting the Affiliated Practices with their
internal growth by increasing gross revenues through increased patient volume;
and (iv) enhancing profitability through operational efficiencies.

RESULTS OF OPERATIONS

Orthodontix has conducted no significant operations to date and will not
conduct significant operations until the Practice Acquisitions and the Merger
are consummated on the Effective Date. From inception through September 30,
1997, Orthodontix incurred general and administrative expenses of $515,700. See
Orthodontix' Financial Statements and the notes thereto.

LIQUIDITY AND CAPITAL RESOURCES

If the Practice Acquisitions and Merger had occurred on September 30, 1997,
Orthodontix would have had pro forma working capital of approximately $3.3
million, including the payment of $3.4 million in cash to the Founding
Practices.

Orthodontix anticipates the primary uses of capital will include
affiliation with orthodontic practices and funding working capital needs of
Orthodontix and the Affiliated Practices. Orthodontix anticipates that it will
incur approximately $535,000 of operating expenses for the year ending December
31, 1997, which does not include any expenses associated with the Merger or the
acquisition of the Founding Practices. As part of its growth strategy,
Orthodontix intends to enter into affiliations with additional orthodontic
practices that will involve the payment of cash and issuance of capital stock.

YEAR 2000 COMPUTER COMPLIANCE

The Commission has issued Staff Legal Bulletin No. 5 (CF/IM) stating that
public operating companies should consider whether they will suffer any
anticipated costs, problems or uncertainties as a result of the "Year 2000"
issue , which affects existing computer programs that use only two digits to
identify a year in the date field. Orthodontix anticipates that its business
operations will electronically interact with third parties very minimally, and
the issues raised by Staff Legal Bulletin No. 5 are not applicable in any
material way to its contemplated business or operations. Additionally,
Orthodontix intends that any computer systems that it will purchase or lease
will have already addressed the "Year 2000" issue.

40
48

BUSINESS OF ORTHODONTIX

GENERAL

Orthodontix was organized in August 1996 to provide practice management
services to orthodontic practices. Upon consummation of the Merger, Orthodontix
intends to manage the business aspects of the Affiliated Practices and may
provide capital for the development and growth of such practices. Orthodontix
will affiliate with Affiliated Practices and will generate revenues by providing
management, marketing and development services to Affiliated Practices.
Orthodontix presently intends to seek to expand its network of Affiliated
Practices by acquiring certain operating assets of and entering into long-term
management services agreements with additional orthodontic practices.
Orthodontix has no current plans, arrangements, understandings or agreements to
acquire any orthodontic practices other than the Founding Practices.

The Founding Practices and Their Affiliated Orthodontists. Orthodontix has
entered into definitive agreements, to be consummated concurrently with the
closing of the Merger, to acquire certain operating assets of the Founding
Practices, and enter into Service Agreements or PA Contractor Employment
Agreements with the Founding Practices or the Affiliated Orthodontists, as the
case may be, which include 28 orthodontists operating 41 offices located in 12
states. Management believes that the Founding Practices are leading practices in
their markets and the Founding Practices were selected based upon a variety of
factors, including size, profitability, historical growth and reputation for
high quality care, among local consumers of orthodontic services and within the
orthodontic services industry. Management intends to capitalize on the
reputations and relationships of the Founding Practices and their Affiliated
Orthodontists to assist Orthodontix in affiliating with additional orthodontic
practices. Management believes that Orthodontix' management, marketing,
recruiting and growth strategies, as applied to the Founding Practices, will
maximize Orthodontix' revenues.

Services of Orthodontix. Orthodontix will provide practice management
services to the Affiliated Practices. Orthodontix will not practice orthodontics
or dentistry, but generally will acquire certain tangible and intangible assets
of an orthodontic practice, employ the non-orthodontic employees, and cause the
PA Contractors to enter into Service Agreements or PA Contractor Employment
Agreements with the Affiliated Practices or the Affiliated Orthodontists, as the
case may be. Where state law allows and upon request by an Affiliated Practice,
Orthodontix may lease equipment or office space to the Affiliated Practices.
Each Affiliated Practice, in its sole discretion, determines the fees to be
charged for services provided to patients based upon market conditions in the
service area and other factors deemed appropriate by the Affiliated Practice.

Orthodontix will generate revenues by providing practice management
services to the Affiliated Practices, including billing and collections, cash
management, purchasing, inventory management, payroll processing, employee
benefits administration, advertising and marketing, financial reporting and
analysis, productivity reporting and analysis. Management believes, based on its
experience with the Founding Practices and data available to it, that
Orthodontix' emphasis on high quality patient care and its business, marketing,
technological and practice-growth support systems will appeal to orthodontists
inclined to affiliate with Orthodontix.

THE ORTHODONTIC INDUSTRY

Orthodontics historically has been one of the more profitable specialties
in dentistry. According to the JCO Study, in 1994, orthodontists in the United
States conducted examinations of nearly 2.5 million potential new patients and
initiated treatment for approximately 1.5 million patients. The typical
orthodontist initiated treatment for approximately 170 patients in 1994 and
maintained approximately 380 active cases.

The primary target market for orthodontic treatment is children ages 8 to
18. In 1994, approximately 80%, or 1.2 million, of all patients treated were
children. The U.S. Census Bureau estimates that as of July 1, 1996, there were
approximately 37.6 million children and adolescents between the ages of 10 and
19. Management believes that as many as 50% of these children and adolescents
could benefit from orthodontic treatment, presenting an attractive opportunity
for Orthodontix. In addition to the traditional juvenile market,
41
49

the adult market has been a rapidly growing market for orthodontic services.
Management believes the market for adults has grown rapidly over the last 15
years as a result of several factors. Adults today are more conscious about
their appearance, which may be improved by orthodontic treatment they may not
have received as children. Moreover, many adults today are more willing to
undergo orthodontic treatment in light of the development of new orthodontic
materials and techniques that allow the orthodontist largely to conceal the
bands and brackets used during treatment because they match the color of the
teeth. Based on statistics obtained from the JCO Study, management believes that
the adult market for orthodontic services remains untapped, as the number of
adults who need or want orthodontic treatment substantially exceeds the number
of patients currently seeking treatment. In 1994, standard case fees averaged
approximately $3,500 for children and $3,800 for adults. On an individual
practice basis, the 1997 Study reported median annual revenues of $518,800 and
median operating income of $224,000 in 1996. Median overhead as a percentage of
revenues was 55%. Median down payments were equal to approximately 25% of the
total treatment cost. Median case starts and active treatment cases, according
to the 1997 Study, were 180 and 400 per practice in 1996, respectively.

Currently, there are approximately 9,000 practicing orthodontists in the
United States. The industry is highly fragmented, with approximately 90% of the
practicing orthodontists acting as sole practitioners and the balance practicing
in multiple-doctor practices (generally two orthodontists) or in groups
affiliated with competitors of Orthodontix. The training and qualification of an
orthodontist is rigorous.

OPERATING STRATEGY

Management believes that Orthodontix' operating strategy will enable
Affiliated Practices to compete more effectively and realize significantly
greater profitability than other orthodontic practices, thereby providing an
inducement for additional orthodontists to affiliate with Orthodontix. Key
elements of Orthodontix' operating strategy are anticipated to include:

Emphasizing Quality Patient Care. Management believes that the services
and support it provides to Affiliated Orthodontists will positively impact the
level of patient care by increasing the Affiliated Orthodontists' time to
concentrate on patient care. Management believes that the primary hindrances to
consistent delivery of quality patient care are (i) the discrepancy in
qualifications among practicing orthodontists and (ii) the amount of time each
orthodontist spends on patient care. The qualifications of providers of
orthodontic services vary from general dentists who have taken certain courses
in orthodontics to graduates of accredited three-year programs.

Capitalizing on the Best Demonstrated Practices of Affiliated
Orthodontists. Orthodontix believes that it will be positioned to identify
practice-level strategies that have proven successful for individual Affiliated
Practices and share this information among other Affiliated Practices.
Management will routinely evaluate the policies and procedures of the Affiliated
Practices, including such critical areas as treatment quality, delivery of
patient care, practice-building, marketing, patient financing programs and
expense control. Orthodontix will provide Affiliated Orthodontists with
comparative operating and financial data that will enable Affiliated
Orthodontists to detect areas of their practices that could be improved.
Orthodontix will provide its own analysis of such operating and financial data
and recommend changes to improve performance. Orthodontix expects that a primary
means of identifying and implementing solutions to particular practice issues
will be to consult with Affiliated Practices that have had demonstrated success
in a certain area. Orthodontix generally will seek to facilitate communication
among Affiliated Practices through periodic conferences and meetings and,
ultimately, through an intranet system. In addition, Orthodontix will establish
an Advisory Board whose members are licensed orthodontists designated by
Orthodontix and the PA Contractors, which will meet to review, evaluate and make
recommendations concerning capital improvements and expenditures, ancillary
services, provider-payor relationships, strategic planning, fee-dispute
resolution, and other management issues. The Advisory Board shall have authority
to review and resolve issues regarding the type and levels of healthcare
services to be provided, fee schedules, any orthodontic or dental related
functions and any other decisions required by applicable law to be made solely
by dentists and orthodontists.

42
50

Achieving Operating Efficiencies and Economies of Scale. Orthodontix
intends to implement a variety of operating procedures and systems designed to
improve the productivity and profitability of each orthodontic practice which
becomes an Affiliated Practice and to achieve economies of scale. Orthodontix
intends to implement centralized payroll processing, inventory control and
national group purchasing contracts. Orthodontix plans to implement appropriate
credit and collection policies which will accommodate specific needs of the
target market of each Affiliated Practice. Management believes that patient flow
and work flow could be enhanced by physical improvements in designs to
facilities, which should result in an increase in the number of patients seen
and an increase in employee and orthodontist productivity. If such physical
improvement in design is supported by an adequate return on investment, the
Affiliated Practice and Orthodontix may undertake such design changes. Operating
efficiencies and economies will be instituted on a per market or per Affiliated
Practice need basis after thorough analysis, including review of work flow,
patient flow, aged accounts receivable history, facilities, employee work load
and productivity, and employee and patient satisfaction.

Increasing the Affordability of Orthodontic Care through Flexible Payment
Plans. Orthodontix will assist Affiliated Practices in developing and
implementing payment plans designed to make orthodontic services more affordable
to prospective patients, thereby making orthodontic services available to a
larger segment of the population in their respective markets. Many of the
Founding Practices have historically received a down payment of approximately
20% of the total cost of services, which is typical in the orthodontics industry
and is based on the costs incurred by an orthodontic practice at the time
treatment is initiated. Recognizing that orthodontic services are largely
discretionary and that a significant down payment is often a deterrent to
prospective patients, Orthodontix believes that flexible payment plans are an
effective means of increasing patient volume. Management believes that the
markets in which Affiliated Practices are located are different and payment
plans should be tailored to respond to the various market demands and
opportunities. Orthodontix will make general recommendations to all Affiliated
Practices with respect to instituting flexible payment plans and will develop
and implement market-tailored plans upon the request of individual Affiliated
Practices. In addition, Orthodontix will provide the working capital necessary
for the Affiliated Practices to implement flexible payment plans which may
result in the reduction or elimination of down payments.

Stimulating Demand in Local Markets Through Aggressive Marketing. In
consultation with and upon approval of the Affiliated Practices, Orthodontix may
develop and implement marketing plans to augment each Affiliated Practice's
referral and other marketing systems currently in place. Management believes
that the orthodontic industry has not taken advantage of the gains that can be
achieved through strategic direct marketing and intends to, upon request of an
Affiliated Practice, may implement direct marketing campaigns. Upon the request
of an Affiliated Practice and in appropriate markets, Orthodontix may attempt to
reach potential patients through print, local television and radio advertising.

GROWTH STRATEGY

Management believes the continued growth of the Founding Practices and the
affiliation of new Affiliated Practices are key components of the future success
of Orthodontix. To increase Orthodontix' revenues and profits and gain market
share, management intends to initiate a growth strategy designed to increase the
number of Affiliated Practices and Affiliated Orthodontists over time.
Management's expansion strategy includes:

Affiliations with Orthodontic Practices. Management believes that
Orthodontix' target market for affiliations includes approximately half of the
orthodontic practices in the United States (approximately 4,500 practices),
because these practices offer quality orthodontic services and opportunity for
revenue and earnings growth. Management believes that affiliation will be an
attractive option for many orthodontists because Orthodontix intends to (i)
identify and recruit qualified associate orthodontists for the Affiliated
Practices, (ii) offer business systems for each Affiliated Practice, (iii) with
the approval of the Affiliated Orthodontist, hire the necessary business and
non-orthodontic personnel for each new Affiliated Practice, (iv) help increase
each Affiliated Practice's market share and the number of new patients seen by
recommending successful

43
51

marketing and advertising strategies, and (vi) reduce the time Affiliated
Orthodontists spend on administrative and business related tasks, allowing them
to focus on delivering quality patient care.

Internal Growth through Improved Operating Efficiencies. An element of
management's growth strategy is internal Affiliated Practice growth through
improving each practice's operating efficiencies. Orthodontix plans to implement
payroll processing, employee benefits administration, financial reporting and
analysis, inventory management and national group purchasing discounted
contracts and intends to implement appropriate credit and collection policies
which accommodate specific needs of the general target markets of each
Affiliated Practice. Operating efficiencies and economies may be instituted on a
per market or per Affiliated Practice need basis after thorough analysis,
including review of work flow, patient flow, aged accounts receivable history,
facilities, employee work load and productivity, employee satisfaction and
patient satisfaction.

AFFILIATED PRACTICE OPERATIONS AND LOCATIONS

Payment Plan; Case Fees. At the initial orthodontic treatment, the patient
signs a contract outlining the terms of the treatment, including the anticipated
length of treatment and the total fees. Each Affiliated Orthodontist determines
the appropriate fee to charge for services to patients based upon market
conditions in the area served by that Affiliated Orthodontist. Generally, the
amount of fees charged by the Affiliated Orthodontists are independent of the
patient's source of payment. The number of required monthly payments is
estimated at the beginning of the case and generally corresponds to the
anticipated number of months of treatment. Depending on the patient's credit
history, the down payment will range from a substantial down payment to no down
payment. Patients are typically required to pay equal monthly installments
although each Affiliated Practice will offer a payment plan tailored to its
market and patients.

If the treatment period exceeds the period originally estimated by the
orthodontist, the patient and the Affiliated Orthodontist will determine whether
payment for additional treatment will be required. If the treatment is completed
prior to the scheduled completion date, the patient is required to pay the
remaining balance of the contract. If a patient terminates the treatment prior
to the completion of the treatment period, the patient is required to pay the
balance due for services rendered to date. Other payment plans with lower
monthly payments are available for patients who have insurance coverage for the
treatment. Payments for patients with insurance may be lower, depending upon the
amount of the fee paid on behalf of the patient by insurance policies. For
patients with insurance coverage, the portion of the fee not covered by
insurance is paid by the patient and is not generally waived or discounted by
the Affiliated Practice.

Information Systems ("IS"). Orthodontix plans to implement a comprehensive
IS strategy over the next several years. Orthodontix may implement a
communications and data transmission program utilizing an intranet system and
commercially available integration technology. Typically, an orthodontic
practice utilizes an accounting and general ledger system as well as a
production system. The accounting and general ledger system will be implemented
promptly upon the Affiliated Practice's affiliation with Orthodontix. The
production system, which provides patient and practice management functions,
will take more time to implement. While it is Orthodontix' stated objective to
protect the computer system and applications investment of each Affiliated
Practice, management intends to use a combination of integration and interface
technologies to tie together the disparate systems.

Purchasing. Orthodontix plans to coordinate quantity discounts of
equipment, office furniture, inventory and supplies for the Affiliated Practices
in order to reduce per unit costs. In addition, Orthodontix will negotiate
arrangements with other suppliers, such as casualty insurance carriers, that
should provide cost savings to the Affiliated Practices.

44
52

Locations. Upon consummation of the Practice Acquisitions, Orthodontix
will provide management services to the following locations:

NUMBER OF NUMBER OF NUMBER OF
STATE ORTHODONTISTS(1) OFFICES CITIES
- ----- ---------------- --------- ---------

California 1 1 1
Florida 14 21 19
Georgia 1 1 1
Illinois 4 6 5
Kentucky 1 2 2
Louisiana 1 1 1
Maryland 1 1 1
Massachusetts 1 2 2
Ohio 1 2 2
Pennsylvania 1 1 1
Texas 1 1 1
Virginia 1 2 2
-- -- --
Total 28 41 38

- ---------------

(1) The 27 Founding Practices include an aggregate of 28 Affiliated
Orthodontists, operating in 12 states.

AFFILIATED ORTHODONTIST, PA CONTRACTOR AND OTHER CONTRACTUAL RELATIONSHIPS

Orthodontix contracts with the PA Contractors who employ Affiliated
Orthodontists pursuant to PA Contractor Employment Agreements or affiliate with
Affiliated Orthodontists pursuant to Service Agreements to provide orthodontic
services. The PA Contractor Employment Agreements and Service Agreements
typically have terms ranging from two to ten years. The Affiliated Orthodontists
generally receive a percentage of the gross revenue generated at the Affiliated
Practice as well as a percentage of the Net Operating Income derived from the
Affiliated Practice. The Affiliated Orthodontists are required to hold a valid
license to practice orthodontics in the jurisdiction in which the Affiliated
Orthodontist practices. Orthodontix is responsible for billing patients and
third party payors for services rendered by the Affiliated Orthodontist. All of
the Affiliated Orthodontists have agreed, for a period of one to two years after
the termination of employment or affiliation, not to compete with Orthodontix or
the PA Contractor within a defined geographic area and not to solicit Affiliated
Orthodontists, other employees or patients of the Affiliated Practices.

Orthodontix has Administrative Services Agreements with the PA Contractors.
Under the Administrative Services Agreements, Orthodontix has control over all
non-orthodontic functions of the PA Contractors, including all administrative,
management, billing and support functions. The PA Contractors pay Orthodontix a
management fee for its services. In certain states, the fee is equal to a
percentage of the gross revenue generated by the underlying Affiliated Practices
contracting with the PA Contractors as well as a percentage of the Net Operating
Income of such underlying Affiliated Practices. In other states, the management
fee consists of a flat base fee, which is determined on an annual basis. Each of
the Administrative Services Agreements has a term of 40 years and is subject to
renegotiation at the end of such term.

GOVERNMENT REGULATION

General. The business of Orthodontix is subject to a variety of
governmental and regulatory requirements relating to healthcare matters as well
as laws and regulations which relate to business corporations in general. In
general, regulation of healthcare companies is increasing. Every state imposes
licensing requirements on individual orthodontists and on facilities operated by
and services rendered by orthodontists. In addition, federal and state laws
regulate health maintenance organizations and other managed care organizations
for which orthodontists may be providers. In connection with the entry into new
markets, Orthodontix, the Affiliated Practices and the Affiliated Orthodontists
may become subject to compliance with additional regulations.

45
53

The operations of the Affiliated Practices must meet federal, state and
local regulatory standards in the areas of safety and health. Historically,
compliance with those standards has not had any material adverse effect on the
operations of the Founding Practices. Based on its familiarity with the
historical operations of the Founding Practices and the activities of
Orthodontix' Affiliated Orthodontists, management believes that the Affiliated
Practices are in compliance in all material respects with all applicable
federal, state and local laws and regulations relating to safety and health.

State Legislation. The laws of several states prohibit orthodontists from
splitting fees with non-orthodontists. Furthermore, many states prohibit
non-orthodontic entities from practicing orthodontics, employing orthodontists,
or in some circumstances, employing orthodontic assistants. The laws of some
states prohibit advertising orthodontic services under a trade or corporate name
and require that all advertising be in the name of the orthodontist. A number of
states also regulate the content of advertisement of orthodontic services and
the use of promotional gift items. A number of states limit the ability of a
non-licensed dentist or non-orthodontist to own equipment or offices used in an
orthodontic practice. Some of these states allow leasing of equipment and office
space to an orthodontic practice, under a bona-fide lease, if the equipment and
office remain in the complete care and custody of the orthodontist. Management
believes, based on its familiarity with the historical operations of the
Founding Practices, the activities of Orthodontix' Affiliated Orthodontists and
applicable regulations, that Orthodontix' planned activities do not constitute
the prohibited practices contemplated by these statutes and regulations. There
can be no assurance, however, that future interpretations of such laws, or the
enactment of more stringent laws, will not require structural and organizational
modifications of Orthodontix' initial relationships with its Affiliated
Orthodontists or the operation of the Affiliated Practices. In addition,
statutes in some states could restrict expansion of Orthodontix operations in
those jurisdictions.

Regulatory Compliance. Orthodontix may be required to modify its
agreements, operations and marketing strategies from time to time in response to
changes in the business and regulatory environment. Orthodontix intends to
structure all of its agreements, operations and marketing in accordance with
applicable law, although there can be no assurance that its arrangements will
not be successfully challenged or that required changes may not materially
affect Orthodontix' business, financial condition and results of operations.

COMPETITION

Orthodontix anticipates facing substantial competition from other entities
as Orthodontix seeks to affiliate with additional orthodontic practices.
Orthodontix is aware of several practice management companies that are focused
in the area of orthodontics. Additional entities may enter this market and
compete with Orthodontix. Certain of these competitors have greater financial or
other resources than Orthodontix.

The business of providing orthodontic services is highly competitive in
each market in which the Affiliated Practices and other practices operate.
Founding Practices compete with orthodontists who maintain single offices or
operate a single satellite office, as well as with orthodontists that maintain
group practices or operate in multiple offices. Founding Practices also compete
with general dentists and pedodontists who provide certain orthodontic services,
some of whom have more established practices. The provision of orthodontic
services by such dentists and pedodontists has increased in recent years. There
can be no assurance that Orthodontix or the Affiliated Practices will be able to
compete effectively within their markets.

EMPLOYEES

Upon completion of the Practice Acquisitions and the Merger, Orthodontix
will employ an aggregate of approximately 220 employees. None of Orthodontix'
employees are represented by a collective bargaining agreement.

PROPERTIES

Orthodontix currently subleases, on a month to month basis, approximately
1,200 square feet of office space in Coral Gables, Florida from Guilford &
Associates, P.A., a firm wholly owned by F.W. Mort Guilford, the President and
Chief Operating Officer of Orthodontix, for a monthly rental amount of
approximately
46
54

$1,000. In addition to the monthly rental amount, Orthodontix is liable to pay
to Guilford & Associates, P.A. Orthodontix' pro-rata share of office expenses.
Upon consummation of the Merger, it is presently anticipated that Orthodontix
shall rent approximately 3,000 square feet of office space in the Miami-Dade
County, Florida area. In addition, upon consummation of the Practice
Acquisitions, Orthodontix will become obligated under 41 separate lease
agreements relating to the office space of the Founding Practices.

INTELLECTUAL PROPERTY

Orthodontix has not applied for or obtained any registrations of its
trademarks or service marks. Orthodontix is aware of one other orthodontic
practice management company in the United States that uses, in part the name
"Orthodontix." There can be no assurances that actions taken by Orthodontix will
be adequate to protect Orthodontix' intellectual property rights, if any.

LITIGATION AND INSURANCE

Orthodontix does not have any pending litigation. The Affiliated Practices
provide orthodontic services to the public and are exposed to the risk of
professional liability and other claims. Such claims, if successful, could
result in substantial damage awards to the claimants that may exceed the limits
of any applicable insurance coverage. Although Orthodontix does not control the
practice of orthodontics by the Affiliated Practices, it could be asserted that
Orthodontix should be held liable for malpractice of an Affiliated Orthodontist.

Orthodontix intends to maintain general liability insurance for itself and
on behalf of the Affiliated Practices and it is anticipated that, where
permitted by applicable law and insurers, Orthodontix will be named as an
additional insured under the policies of the Affiliated Practices. There can be
no assurance that any claims against Orthodontix or any of the Affiliated
Practices will not be successful, or if successful, will not exceed the limits
of available insurance coverage or that such coverage will continue to be
available at acceptable rates.

MANAGEMENT OF ORTHODONTIX

EXECUTIVE OFFICERS AND DIRECTORS

The current and contemplated position (subsequent to the consummation of
the Merger) of each executive officer and director of Orthodontix is listed
below.

CONTEMPLATED POSITION
NAME AGE CURRENT POSITION AFTER THE MERGER
- ---- --- ---------------- ---------------------

Stephen Grussmark, D.D.S., 57 Chief Executive Officer and Chief Chief Executive Officer and
M.S.D. Clinical Officer Chief Clinical Officer, Director of
Embassy (responsibilities include new
business development and liaison with
orthodontic practices)
F.W. Mort Guilford 70 President, Chief Operating Officer, President, Chief Operating Officer,
Director Director of Embassy, President of
Orthodontix
Richard L. Alfonso 34 Vice President-Operations, Vice President-Operations, Secretary
Secretary of Embassy, Secretary

Stephen Grussmark, D.D.S., M.S.D. has been Chief Executive Officer and
Chief Clinical Officer of Orthodontix since its inception. Since 1968, Dr.
Grussmark has been a practicing orthodontist in the Miami, Florida area. Since
1990, Dr. Grussmark has been an Assistant Clinical Professor of Graduate
Orthodontics at the University of Florida Dental School and has been a staff
member at Miami Children's Hospital since 1969. Since 1997, Dr. Grussmark has
been a Clinical Instructor at Nova University Dental School -- Graduate
Department of Orthodontics. Dr. Grussmark is a member of the Dade County Dental
Research Group, the American Dental Association, the American Association of
Orthodontists, the Southern Association of Orthodontists, and is Past President
of both the Florida Cleft Palate Association and the South Florida Academy of
Orthodontists.

47
55

F.W. Mort Guilford has been President, Chief Operating Officer and a
director of Orthodontix since its inception. Since 1956, Mr. Guilford has been
practicing business, real estate and land use law in the Miami, Florida area and
has been an investor in numerous business ventures, including real estate,
banking and food franchises. Mr. Guilford has served as Chairman of The Alma
Jennings Foundation, a charitable foundation, since 1984, and from 1989 through
1994 he served on the Florida Public Service Nominating Committee, which makes
recommendations to the Governor of Florida for appointees to the Florida Public
Service Commission. In addition, Mr. Guilford served on the State of Florida
Finance and Bond Council, was a member of the University of Miami Board of
Trustees, and was Chairman of the Economic Development Committee and Code
Enforcement Board for the City of Coral Gables, Florida. Since 1995, Mr.
Guilford has been a member of the Coral Gables Foundation.

Richard L. Alfonso has been Vice President -- Operations and Secretary of
Orthodontix since November 1996. From April 1996 through October 1996 and from
June 1994 through December 1995, Mr. Alfonso was Director of Mergers and
Acquisitions at Sterling Healthcare Group, Inc. ("Sterling"), a firm engaged in
providing practice management services to emergency room physicians. From
January 1996 through March 1996, Mr. Alfonso was Vice President -- Mergers and
Acquisitions at Lifeway, Inc., a firm engaged in providing practice management
services to physicians. From December 1993 through May 1994, Mr. Alfonso was
Director of Medical Staff Services at Sterling. From May 1990 through November
1993, Mr. Alfonso was employed by the Federal Reserve Bank of Atlanta, Miami
Branch, as a supervisor in the security services department.

COMPENSATION OF OFFICERS AND DIRECTORS

Other than Mr. Alfonso, who was paid $10,000 during the year ended December
31, 1996 and $60,000 during the year ended December 31, 1997, no executive
officer of Orthodontix has received any cash compensation from Orthodontix since
inception.

Directors of Orthodontix receive no compensation for their services as
directors, other than accountable reimbursement for any reasonable business
expenses incurred in connection with their activities on behalf of Orthodontix;
however, they will be entitled to receive stock options under the Stock Option
Plan. See "PROPOSAL 3: RATIFICATION AND APPROVAL OF THE 1997 EMBASSY ACQUISITION
CORP. STOCK OPTION PLAN."

ADVISORY BOARD

Upon consummation of the Merger, it is currently anticipated that
Orthodontix will establish an advisory board (the "Advisory Board") consisting
of the following licensed orthodontists:

Donald E. Adams, D.D.S. Brent W. Bernard, D.M.D.
John A. Benkovich, III, D.D.S., M.S. Steve A. Chapman, D.M.D.
Robert L. Edgerton, D.D.S. C. Lynn Hurst, D.D.S., M.S.
Alan W. Kaplin, D.D.S. E. Joseph LeCompte, D.D.S., M.S.
Clifford Marks, D.D.S. Ernest H. McDowell, D.M.D.
Stephen Paige, D.D.S. Bradley A. Taylor, D.M.D.
Jeffrey Thompson, D.M.D.

The Advisory Board will meet to review, evaluate and make recommendations
concerning capital improvements and expenditures, ancillary services,
provider-payor relationships, strategic planning, fee-dispute resolution, and
other management issues. In addition, the members of the Advisory Board shall
have exclusive authority to review and resolve issues regarding the type and
levels of healthcare services to be provided, fee schedules, any orthodontic or
dental related functions and any other decisions required by applicable law to
be made solely by dentists and orthodontists.

Each member of the Advisory Board shall be granted, on the Effective Date,
the option to acquire 7,500 shares of Embassy Common Stock at the Average Price
per share for a three year period commencing on the

48
56

date which is three years from the Effective Date, so long as such member
maintains continuous service on the Advisory Board.

ANTICIPATED EMPLOYMENT ARRANGEMENTS

Upon consummation of the Merger it is currently anticipated that Dr.
Grussmark, Mr. Guilford, and Mr. Alfonso will become Embassy's Chief Executive
Officer and Chief Clinical Officer; President and Chief Operating Officer; Chief
Financial Officer, Vice President -- Operations, Treasurer and Secretary,
respectively. Immediately following the Merger, it is contemplated that Dr.
Grussmark, an Affiliated Orthodontist, will not receive a salary in his capacity
as Chief Executive Officer but will be provided with health insurance benefits
for himself and his dependants. Further, Dr. Grussmark's responsibilities will
include business development and acting as a liaison between Embassy and the
orthodontic practices. It is not anticipated that Dr. Grussmark will be involved
in the day to day operations of Embassy following the Merger. Upon consummation
of the Merger, it is anticipated that Messrs. Guilford and Alfonso will receive
base annual salaries of $80,000 and $70,000, respectively, as well as be
provided with health insurance benefits for themselves and their dependents. It
is presently anticipated that Messrs. Guilford and Alfonso shall enter into
written employment agreements with Embassy subsequent to the Effective Date.
Orthodontix is currently in the process of interviewing several candidates to
replace Mr. Alfonso as Chief Financial Officer. Upon the retention of a Chief
Financial Officer, it is contemplated that Mr. Alfonso will retain his other
executive officer positions with Orthodontix but will resign from the Chief
Financial Officer position.

In addition, Mr. Guilford will be granted the option for a period of five
years from the Effective Date, to purchase at a per share purchase price equal
to the Average Price 150,000 shares. Richard L. Alfonso, Vice
President -- Operations of Orthodontix, will be granted on the Effective Date
the option to purchase at a per share purchase price equal to the Average Price
25,000 shares (the "Alfonso Options"), 20% of which shares may be purchased
commencing on the Effective Date through the date which is 60 months from the
Effective Date (the "60 Month Date"), an additional 20% of which may be
purchased commencing on the date which is 12 months from the Effective Date
through the 60 Month Date, an additional 20% of which may be purchased
commencing on the date which is 24 months from the Effective Date through the 60
Month Date, an additional 20% of which may be purchased commencing on the date
which is 36 months from the Effective Date through the 60 Month Date, and the
remainder of which may be purchased commencing on the date which is 48 months
from the Effective Date through the 60 Month Date. In the event Mr. Alfonso
resigns or is terminated for cause by Orthodontix from his employment with
Orthodontix, the Alfonso Options shall terminate.

CERTAIN TRANSACTIONS RELATING TO ORTHODONTIX

Orthodontix has met its cash requirements in its developmental stage from
bank financing and from personal loans made by F.W. Mort Guilford (the "Guilford
Loans"). In July 1997, Orthodontix obtained a credit facility from a bank which
enables Orthodontix to borrow up to $500,000 for working capital purposes (the
"Bank Credit Facility"). The repayment obligations of Orthodontix under the Bank
Credit Facility have been secured by the pledge of certain collateral by Dr.
Dresnick. The Guilford Loans and the borrowings under the Bank Credit Facility
bear interest at the prime rate plus 1%. As of March 20, 1998, the amounts
outstanding under the Guilford Loans and the Bank Credit Facility are
approximately $331,000 and $487,000, respectively. The amounts outstanding under
the Guilford Loans are contemplated to be satisfied in full upon the Effective
Date with the working capital of Embassy. In February 1998, Stephen Grussmark,
D.D.S., M.S.D., the Chief Executive Officer and Chief Clinical Officer of
Orthodontix, loaned to the Orthodontix $100,000 (the "Grussmark Loan"). The
Grussmark Loan bears interest at the prime rate plus 1%. The amounts outstanding
under the Grussmark Loan are contemplated to be satisfied in full upon the
Effective Date with the working capital of Embassy.

Concurrently with the closing of the Merger, Orthodontix will consummate
the Practice Acquisitions pursuant to which it will acquire certain operating
assets of 27 separate Founding Practices in exchange for cash and shares of
Embassy Common Stock and enter into long-term practice management services

49
57

agreements with the Founding Practices. The acquisition of each of the Founding
Practices was individually negotiated between Orthodontix and each Founding
Practice with respect to all material terms, including without limitation,
valuation. The aggregate consideration to be paid to the Founding Practices is
approximately $22.1 million, consisting of 2,187,940 shares of Embassy Common
Stock at a price of $8.5625 per share and $3.4 million in cash, all of which is
payable upon the closing of the Practice Acquisitions. The aggregate
consideration to be paid for the Founding Practices will not change; however,
the actual number of shares of Embassy Common Stock issued to the Founding
Practices will increase or decrease depending upon the average of the closing
bid and ask price, as reported on the OTC Bulletin Board, of Embassy Common
Stock for the 15 trading days immediately preceding the date of the closing of
the Practice Acquisitions (the "Average Price"). The exact number of shares will
be determined by dividing $18.7 million by the Average Price.

Dr. Grussmark, who will become an officer and a director of Embassy at the
closing of the Merger, will receive 102,774 shares of Embassy Common Stock and
$220,000 in cash as a result of the Practice Acquisitions. The analysis used to
determine the consideration to be paid to Dr. Grussmark in connection with the
sale of his orthodontic practice is consistent with the analysis used to
calculate the consideration to be paid in the other Practice Acquisitions.

Attorneys in the law firm of Berman Wolfe & Rennert, P.A., counsel to
Embassy, are shareholders of Embassy and Orthodontix. Berman Wolfe & Rennert,
P.A. has provided legal services in the past to Orthodontix. Upon closing of the
Merger, attorneys in Berman Wolfe & Rennert, P.A. shall own, in the aggregate,
104,567 shares of Common Stock of Embassy and options to acquire 50,000 shares
of Embassy Common Stock. Jack Greenman, advisor to Orthodontix, is a shareholder
of Embassy and Orthodontix and has provided services in the past to Orthodontix.
Upon closing of the Merger, Mr. Greenman shall own, in the aggregate, 69,712
shares of Common Stock of Embassy and options to acquire 50,000 shares of
Embassy Common Stock. "PROPOSAL 1 -- THE MERGER -- Interest of Certain Persons
in the Merger."

The following table provides certain information concerning each of the
Founding Practices and each person who has an ownership interest in a Founding
Practice, all of whom are deemed to be promoters of the transaction:

CONSIDERATION TO BE RECEIVED BY FOUNDING PRACTICES

ASSETS VALUE OF
FOUNDING PRACTICE SHAREHOLDER CONTRIBUTED(1)(2) CASH DISTRIBUTION SHARES(3)
- ----------------------------- ----------------- ---------- ------------ ---------

Adams, Donald E., D.D.S............. $ 66,035 $ 127,378 $ 849,184 84,299
Aguirre, Michael, D.D.S............. $ 40,470 $ 163,917 $ 1,092,779 108,480
Aylward, Gerry, D.D.S............... $ 16,647 $ 73,898 $ 492,653 48,906
Benkovich, John A., III, D.D.S.,
M.S............................... $ 80,539 $ 102,000 $ 510,000 47,650
Bernard, Brent, D.M.D............... $ 42,571 $ 123,000 $ 615,000 57,460
Chapman, Steve, D.M.D............... $ 91,126 $ 263,688 $ 1,318,440 123,183
Downs, Maurice, D.D.S............... $ 31,336 $ 93,120 $ 465,600 43,501
Edgerton, Robert, D.D.S............. $ 12,352 $ 126,000 $ 840,000 83,387
Gray, James, D.M.D.................. $ 40,608 $ 53,713 $ 537,127 56,457
Grosser, Scott, D.M.D............... $ 11,620 $ 114,614 $ 764,097 75,852
Grussmark, Stephen, D.D.S........... $ 58,835 $ 220,000 $ 1,100,000 102,774
Herzberg, Robert, D.D.S., M.D.S..... $ 15,960 $ 43,701 $ 218,504 20,415
Hurst, Lynn, C., D.M.D.............. $ 62,515 $ 190,926 $ 954,630 89,192
Kaplin, Alan, D.D.S................. $ 28,246 $ 235,200 $ 1,176,000 109,874
Kopf, Joseph, D.D.S................. $ 43,649 $ 33,328 $ 333,278 35,031
Krop, Michael, D.D.S................ $ 50,135 $ 99,000 $ 660,000 65,518
LeCompte, Joseph, E., D.D.S.,
M.S............................... $ 56,765 $ 240,000 $ 1,200,000 112,117
Marks, Clifford, D.D.S.............. $ 11,596 $ 58,213 $ 582,134 61,188
McAdams Gilbert, D.D.S.............. $ 10,242 $ 57,044 $ 380,291 37,751

50
58

ASSETS VALUE OF
FOUNDING PRACTICE SHAREHOLDER CONTRIBUTED(1)(2) CASH DISTRIBUTION SHARES(3)
- ----------------------------- ----------------- ---------- ------------ ---------

McDowell, Ernest H., D.M.D.......... $ 248,832 $ 179,204 $ 1,792,041 188,361
Paige, Stephen, D.D.S............... $ 139,362 $ 221,603 $ 1,108,016 103,523
Rosenstein, Sheldon W., D.D.S....... $ 30,526 $ 94,485 $ 472,427 44,139
Smith, James B., D.D.S.............. $ 104,351 $ 95,367 $ 635,777 63,114
Starr, Stanley, D.D.S............... $ 73,614 $ 169,442 $ 1,129,616 112,137
Taylor, Bradley A., D.M.D........... $ 71,632 $ 139,000 $ 1,390,000 146,102
Taylor, Ronald, D.M.D., M.S......... $ 53,427 $ 50,000 $ 500,000 52,555
& Taylor, Roger, D.M.D.
Thompson, Jeffrey, D.M.D............ $ 27,371 $ 18,000 $ 1,002,466 114,974
---------- ---------- ----------- ---------
TOTAL..................... $1,520,362 $3,385,841 $22,120,060 2,187,940

- ---------------

(1) Assets to be contributed reflect the historical book value of the
nonmonetary assets of each practice. These nonmonetary assets are reflected
at historical cost in accordance with SAB 48. All monetary assets, including
patient receivable balances, are recorded at fair value, which is
approximated by the historical costs recorded by the practices.
(2) In addition, in connection with the Practice Acquisitions, certain operating
lease obligations of the Founding Practices will be assumed.
(3) Based on the Average Price as of March 26, 1998 of $8.5625.

[This Space Intentionally Left Blank]

51
59

PRINCIPAL SHAREHOLDERS OF ORTHODONTIX

The following table sets forth information as of the date of this Proxy
Statement/Prospectus and as of such date, giving effect to the Merger, based on
information from the persons below with respect to the beneficial ownership of
shares of Orthodontix Common Stock, in the aggregate, and upon consummation of
the Merger, the number of shares of Embassy Common Stock expected to be held by
(i) each person known by Orthodontix to be the owner of more than 5% of the
outstanding shares of Orthodontix Common Stock; (ii) each current officer and
director of Orthodontix; and (iii) all executive officers and directors as a
group:

AMOUNT, NATURE
AND PERCENTAGE OF
BENEFICIAL AMOUNT, NATURE AND
OWNERSHIP OF PERCENTAGE OF
ORTHODONTIX BENEFICIAL OWNERSHIP
COMMON STOCK OF EMBASSY
NAME AND ADDRESS PRIOR TO THE COMMON STOCK AFTER
OF BENEFICIAL OWNER MERGER(1) THE MERGER(2)
- ------------------- ------------------ ---------------------

Stephen Grussmark, D.D.S., M.S.D.(3)............. 795,385 61.2% 898,159(3) 13.6%
2222 Ponce de Leon Blvd., 3(rd) Floor
Coral Gables, FL 33134

F.W. Mort Guilford............................... 347,980 26.8% 497,980(4) 7.6%
2222 Ponce de Leon Blvd., 3(rd) Floor
Coral Gables, FL 33134

Richard L. Alfonso............................... 24,856 1.9% 29,856(4) 0.5%
2222 Ponce de Leon Blvd., 3(rd) Floor
Coral Gables, FL 33134

All Officers and Directors....................... 1,168,221 89.9% 1,425,995 21.6%
as a Group (3 persons before Merger)

- ---------------

(1) As used herein, "beneficial ownership" means the sole or shared power to
vote, or direct the voting of, a security, or the sole or shared power to
dispose, or direct the disposition, of a security. Except as otherwise
indicated, all persons named herein and therein have (i) sole voting power
and investment power with respect to their shares of Orthodontix Common
Stock, except to the extent that authority is shared by spouses under
applicable law; and (ii) record and beneficial ownership with respect to
their shares of Orthodontix Common Stock. For purposes of this table,
beneficial ownership is computed pursuant to Rule 13d-3 under the Securities
Exchange Act of 1934, as amended, (the "Exchange Act"); the inclusion of
shares as beneficially owned should not be construed as an admission that
such shares are beneficially owned for purposes of the Exchange Act. Under
the rules of the Securities and Exchange Commission a person is deemed to be
a "beneficial owner" of a security if he or she has or shares the power to
vote or direct the voting of such security or the power to dispose of or
direct the disposition of such security. Accordingly, more than one person
may be deemed to be a beneficial owner of the same security. Shares of
Common Stock subject to options to be held by persons listed in the table
that are exercisable within 60 days of the closing of the Merger are deemed
beneficially owned by such person and outstanding for the purposes of
computing such person's beneficial ownership and to the extent held by
officers and directors listed in the table, the beneficial ownership of all
directors and executive officers beneficial ownership as a group. 1,300,000
shares of Common Stock of Orthodontix were outstanding as of the close of
business on the date of this Proxy Statement/Prospectus.
(2) Assumes the issuance of the Merger Stock on the Effective Date, includes
shares of Embassy Common Stock issuable upon exercise of the Underwriter
Warrants and includes shares of Embassy Common Stock issuable upon exercise
of the Closing Stock Options which will become exercisable upon the
Effective Date. See "PROPOSAL 1: THE MERGER" and "DESCRIPTION OF EMBASSY'S
SECURITIES."
(3) Represents (i) 795,385 shares of Embassy Common Stock to be issued in
connection with the closing of the Merger; and (ii) 102,774 shares issuable
in connection with the acquisition of Dr. Grussmark's practice, based on an
Average Price per share of $8.5625.

52
60

(4) Represents (i) shares of Common Stock to be issued to Mr. Guilford (347,980)
and Mr. Alfonso (24,856) in connection with the Merger; and (ii) shares of
Common Stock issuable upon the exercise by Mr. Guilford (150,000) and Mr.
Alfonso (5,000) of stock options to be granted in connection with the
Merger, which options will be currently exercisable as of the Effective
Date.

DESCRIPTION OF ORTHODONTIX' SECURITIES

Orthodontix is authorized to issue 100,000,000 shares of Orthodontix Common
Stock, $.0001 par value per share, of which 1,300,000 shares are issued and
outstanding as of the date of this Proxy Statement/ Prospectus, excluding the
2,187,940 shares of Orthodontix Stock issuable in connection with the Practice
Acquisitions, and 1,000,000 shares of Preferred Stock, par value $.0001 per
share, none of which are issued or outstanding. The holders of Orthodontix
Common Stock are entitled to one vote per share. There is no established public
trading market for Orthodontix Common Stock.

BUSINESS OF EMBASSY

Embassy was formed in November 1995 to serve as a vehicle to effect a
merger, exchange of capital stock, asset acquisition or other similar business
combination (a "Business Combination") with an operating business (an "Acquired
Business"). Embassy's business objective has been to seek a Business Combination
with an Acquired Business which Embassy believes has growth potential. In April
1996, Embassy successfully consummated an initial public offering of its equity
securities ("IPO") from which it derived net proceeds of approximately
$7,052,000 (the "Net Proceeds"). Approximately 90% of the Net Proceeds
(inclusive of interest earned thereon, less operating expenses to date) is
presently held in escrow pending the consummation of a Business Combination and
will be released to Embassy upon consummation of the Merger. The balance of the
Net Proceeds is currently held by Embassy, less operating expenses to date.
Embassy's executive offices are located at 1428 Brickell Avenue, Suite 105,
Miami, Florida 33131; its telephone number is (305)374-6700.

Embassy is not presently a party to any material litigation nor to the
knowledge of management of Embassy is any such litigation presently threatened.

MANAGEMENT OF EMBASSY

EXECUTIVE OFFICERS AND DIRECTORS

The current executive officers and directors of Embassy are as follows:

NAME AGE POSITION
- ---- --- ------------------------------------

Glenn L. Halpryn.............................. 36 President, Director
Craig A. Brumfield(1)......................... 46 Vice President, Treasurer, Director
Ronald M. Stein(1)............................ 36 Vice President, Secretary, Director
Stephen J. Dresnick, M.D.(2).................. 47 Director
Andrew H. Marshak(1).......................... 29 Director
William Thompson, D.D.S....................... 65 (3)
Mel Gottlieb.................................. 52 (3)
Gary Gerson, CPA.............................. 64 (3)

- ---------------

(1) These persons shall resign their positions as officers and directors of
Embassy upon the closing of the Merger.
(2) Dr. Dresnick will become the Chairman of the Board of Directors upon the
closing of the Merger.
(3) These persons shall become directors of Embassy upon the closing of the
Merger.

Glenn L. Halpryn has been the President and a member of the Embassy Board
since Embassy's inception. Since 1985, Mr. Halpryn has been engaged in real
estate investment and development activities,

53
61

including the management, finance and leasing of commercial real estate. Since
April 1988, Mr. Halpryn has been Vice Chairman of Central Bank, a Florida
state-chartered bank. Since June 1987, Mr. Halpryn has been the President of and
beneficial holder of stock of United Security Corporation, a broker-dealer
registered with the NASD. From June 1992 through May 1994, Mr. Halpryn served as
the Vice President, Secretary -- Treasurer of Frost Hanna Halpryn Capital Group,
Inc., a "blank check" company whose business combination was effected in May
1994 with Sterling Healthcare Group, Inc. From June 1995 through October 1996,
Mr. Halpryn served as a member of the Board of Directors of Sterling Healthcare
Group, Inc.

Craig A. Brumfield has been the Vice President, Treasurer and a member of
the Embassy Board since Embassy's inception. Since April 1995, Mr. Brumfield has
been President and Chief Executive Officer of Pinecrest Capital, Inc., a private
investment firm that initiates structures and negotiates acquisitions and
provides advisory and consulting services to middle market companies in diverse
industries. From October 1984 through March 1995, Mr. Brumfield was an executive
officer of Trivest, Inc. ("Trivest"), a sponsor of middle market corporate
acquisitions. Mr. Brumfield has served as a member of the Board of Directors of
three public companies; Atlantis Plastics, Inc. (May 1991 through March 1995),
Loewenstein Furniture Group, Inc. (December 1990 through December 1994) and
WinsLoew Furniture, Inc. (December 1994 through March 1995). Prior to joining
Trivest, Mr. Brumfield was a Senior Manager with KPMG Peat Marwick.

Ronald M. Stein has been the Vice President, Secretary and a member of the
Embassy Board since Embassy's inception. Since October 1992, Mr. Stein has been
a vice president and account executive with First Equity Corporation of Florida,
a broker-dealer registered with the NASD. From April 1988 through October 1992,
Mr. Stein was an associate vice president and accountant executive with
Prudential Securities, a broker-dealer registered with the NASD.

Stephen J. Dresnick, M.D. has been a member of the Embassy Board since
Embassy's inception. Dr. Dresnick has served as President, Chief Executive
Officer and Chairman of the Board of Directors of Sterling Healthcare Group,
Inc. and its predecessor corporations since 1987. Dr. Dresnick currently serves
as the Vice Chairman of the Board of Directors of FPA Medical Management, Inc.,
the parent corporation of Sterling Healthcare Group, Inc. Dr. Dresnick is a
Diplomat of the National Board of Medical Examiners and is certified by the
American Board of Emergency Medicine. Dr. Dresnick is licensed to practice
medicine in 12 states. Dr. Dresnick currently holds an appointment as Assistant
Professor at University if Miami, School of Nursing; is on the Dean's Advisory
Committee at University of Miami, School of Business; is an Advisory Board
Member at the Center for the Advancement of Service Management, University of
Florida, College of Business Administration; is a Clinical Associate Professor
for the Department of Surgery, University of Florida, School of Medicine; and is
a member of the Board of Trustees of Florida International University.

Andrew H. Marshak has been a member of the Embassy Board since Embassy's
inception. Since November 1997, Mr. Marshak has been a Managing Director of
First Dominion Capital, L.L.P., a merchant banking and asset management firm.
From June 1994 through October 1997, Mr. Marshak was a Vice President of
Indosuez Capital, the North American merchant banking arm of Credit Agricales
Indosuez, a Paris-based banking institution. From July 1992 through June 1994,
Mr. Marshak was an associate with Indosuez Capital. From July 1990 through June
1992, Mr. Marshak was a Financial Analyst with Donaldson, Lufkin and Jenrette,
an investment bank.

William Thompson, D.D.S. has agreed to become a director of Embassy upon
consummation of the Merger. Dr. Thompson has been a consultant to Orthodontix
since its inception. Since 1960, Dr. Thompson has been a practicing orthodontist
in the Bradenton, Florida area. He is currently the Chairman of the Council on
Orthodontic Education of the American Association of Orthodontics. From 1985
through 1992, Dr. Thompson was a Director and from 1991 through 1992 was the
President of the American Board of Orthodontics. Dr. Thompson has received
numerous professional appointments as well as published numerous articles
concerning orthodontics. Dr. Thompson has been a member of the Board of
Directors of the First National Bank of Manatee since 1989.

Mel Gottlieb has agreed to become a director of Embassy upon consummation
of the Merger. Since August, 1995, Mr. Gottlieb has been the President and sole
shareholder of Gottlieb & Associates, a firm
54
62

engaged in providing investment management services. From November 1995 through
October 1996, Mr. Gottlieb served as a director and a member of the Audit
Committee of Sterling Healthcare Group, Inc. From 1978 through August 1995, he
was Chief Executive Officer of Gottlieb's Financial Services, Inc. ("GAS"),
which was acquired by Metaphase Corporation in September 1993 and provides
billing and accounts receivable management services to emergency physicians and
physician practice management companies.

Gary Gerson, CPA has agreed to become a director of Embassy upon
consummation of the Merger. Mr. Gerson is a founding partner, shareholder of and
practicing accountant with Gerson Preston & Co., an accounting firm located in
Miami Beach, Florida since 1958, with offices in Boca Raton and Tampa. Mr.
Gerson was former President and Chairman of the Board of Mount Sinai Medical
Center in Miami Beach, Florida, General Chairman of the Israel Bonds
Organization for Florida, Member of the Board of Directors of the Greater Miami
Jewish Federation, University of Florida Foundation and the Concert Association
of Florida. Mr. Gerson was the recipient of an Honorary Doctorate of Laws Degree
from St. Thomas University, the Distinguished Alumnus Award from the University
of Florida and the 1996 Man of the Year award from the City of Miami Beach
Chamber of Commerce.

COMPENSATION OF OFFICERS AND DIRECTORS

No executive officer or director has received any cash compensation from
Embassy since inception for services rendered. Embassy's officers and directors
receive no compensation, including salaries, for their services other than
accountable reimbursement for any reasonable business expenses incurred in
connection with their activities on behalf of Embassy.

There are no agreements, agreements in principle or understandings with
regard to compensation to be paid by Embassy to any officer or director of
Embassy other than the Dresnick Options. The Escrow Fund (including any interest
earned thereon) shall not be used to reimburse Embassy's officers and directors
for expenses incurred by such persons on behalf of Embassy. No funds (including
any interest earned thereon) will be disbursed from the Escrow Fund for
reimbursement of expenses. Other than the foregoing, there is no limit on the
amount of such reimbursable expenses, and there will be no review of the
reasonableness of such expenses by anyone other than the Board of Directors,
three of five members of which are officers. None of Embassy's executive
officers or directors or their respective affiliates will receive any consulting
or finder's fees in connection with a Business Combination. Furthermore, none of
such persons will receive any other payments or assets, tangible or intangible,
unless received by all other shareholders on a proportionate basis.

CERTAIN TRANSACTIONS RELATING TO EMBASSY

Embassy currently maintains a $1,000,000 "key man" policy insuring the life
of Mr. Halpryn. There can be no assurances that such "key man" insurance will be
maintained at reasonable rates, if at all. Upon the closing of the Merger, the
"key man" policy is presently intended to be terminated.

Embassy currently maintains, at no cost to Embassy, its executive offices
in approximately 500 square feet of office space located at 1428 Brickell
Avenue, Suite 105, Miami, Florida 33131. This office space is leased by Embassy
from Ivenco, Inc., a firm of which Ernest Halpryn, the father of Glenn L.
Halpryn, is an officer. Embassy considers this space adequate for its current
operations. Upon consummation of the Merger, Embassy will no longer occupy this
space.

Upon consummation of the Merger, the Embassy Board will consist of seven
persons, namely, Dr. Dresnick as Chairman, Mr. Halpryn, Mr. Guilford, Dr.
Grussmark, Dr. Thompson, Mr. Gottlieb and Mr. Gerson. Furthermore, upon
consummation of the Merger, it is presently contemplated that Messrs. Gottlieb
and Gerson shall serve on the Audit Committee of the Embassy Board, Dr.
Dresnick, Messrs. Gottlieb and Gerson shall serve on the Compensation and Stock
Option Committee of the Embassy Board and Mr. Halpryn, Mr. Guilford and Dr.
Grussmark will serve on the nominating committee of the Embassy Board.

55
63

PRINCIPAL SHAREHOLDERS OF EMBASSY

The following table sets forth information as of the date of this Proxy
Statement/Prospectus, and as of such date, giving effect to the Merger, based on
information obtained from the persons named below, with respect to the
beneficial ownership of shares of Embassy Common Stock by (i) each person known
by Embassy to be the owner of more than 5% of its outstanding shares of Common
Stock, (ii) each officer and director prior to and subsequent to the Merger and
(iii) all executive officers and directors as a group prior to and subsequent to
the Merger:

AMOUNT, NATURE
AND PERCENTAGE OF AMOUNT, NATURE AND
BENEFICIAL PERCENTAGE OF BENEFICIAL
NAME AND ADDRESS OWNERSHIP PRIOR TO OWNERSHIP AFTER THE
OF BENEFICIAL OWNER THE MERGER(1) MERGER(1)
------------------- ------------------- ------------------------

Glenn L. Halpryn(2).......................... 330,000 13.0% 330,000 5.5%
1428 Brickell Avenue, Suite 105
Miami, FL 33131

Ronald M. Stein.............................. 170,000 6.7% 170,000 2.8%
1428 Brickell Avenue, Suite 105
Miami, Florida 33131

Stephen J. Dresnick, M.D.(3)................. 160,000 6.3% 360,000 5.8%
5835 Blue Lagoon Drive, 4th Floor
Miami, Florida 33126

Andrew H. Marshak............................ 60,000 2.4% 60,000 1.0%
1428 Brickell Avenue, Suite 105
Miami, Florida 33131

Craig A. Brumfield........................... 60,000 2.4% 60,000 1.0%
1428 Brickell Avenue, Suite 105
Miami, Florida 33131

Stephen Grussmark, D.D.S., M.S.D............. 0 0.0% 898,159(4) 14.9%
2222 Ponce de Leon Blvd., 3rd Floor
Coral Gables, FL 33134

F.W. Mort Guilford........................... 0 0.0% 497,980(5) 8.1%
2222 Ponce de Leon Blvd., 3rd Floor
Coral Gables, FL 33134

Richard L. Alfonso........................... 0 0.0% 29,856(5) 0.5%
2222 Ponce de Leon Blvd., 3rd Floor
Coral Gables, FL 33134

William Thompson, D.D.S...................... 0 0.0% 47,500(6) 0.8%
2222 Ponce de Leon Blvd., 3rd Floor
Coral Gables, FL 33134

Mel Gottlieb................................. 0 0.0% 0 0.0%
2222 Ponce de Leon Blvd., 3rd Floor
Coral Gables, FL 33134

56
64

Gary Gerson.................................. 0 0.0% 0 0.0%
2222 Ponce de Leon Blvd., 3rd Floor
Coral Gables, FL 33134
All Officers and Directors as a Group (5
persons before the Merger, 9 persons after
the Merger).................................. 780,000 30.7% 2,453,495 38.2%

- ---------------

(1) As used herein, "beneficial ownership" means the sole or shared power to
vote, or direct the voting of, a security, or the sole or shared power to
dispose, or direct the disposition, of a security. Except as otherwise
indicated, all persons named herein and therein have (i) sole voting power
and investment power with respect to their shares of Embassy Common Stock,
except to the extent that authority is shared by spouses under applicable
law; and (ii) record and beneficial ownership with respect to their shares
of Embassy Common Stock. For purposes of this table, beneficial ownership is
computed pursuant to Rule 13d-3 under the Securities Exchange Act of 1934,
as amended, (the "Exchange Act"); the inclusion of shares as beneficially
owned should not be construed as an admission that such shares are
beneficially owned for purposes of the Exchange Act. Under the rules of the
Securities and Exchange Commission a person is deemed to be a "beneficial
owner" of a security if he or she has or shares the power to vote or direct
the voting of such security or the power to dispose of or direct the
disposition of such security. Accordingly, more than one person may be
deemed to be a beneficial owner of the same security. Shares of Common Stock
subject to options to be held by persons listed in the table that are
exercisable within 60 days of the closing of the Merger are deemed
beneficially owned by such person and outstanding for the purposes of
computing such person's beneficial ownership and to the extent held by
officers and directors listed in the table, the beneficial ownership of all
directors and executive officers beneficial ownership as a group. 2,540,000
shares of Common Stock of Embassy were outstanding as of the close of
business on the date of this Proxy Statement/Prospectus. Does not include
any shares issuable upon the exercise of the Underwriter Warrants.
(2) Does not include shares of Common Stock owned by Ernest Halpryn, Glenn L.
Halpryn's father, of which Glenn L. Halpryn disclaims beneficial ownership.
(3) Represents 160,000 shares held by Kinserd Limited Partnership ("KLP"). Dr.
Dresnick is the sole limited partner of KLP and the sole shareholder, sole
director and an officer of Kinserd, Inc., the general partner of KLP. With
respect to beneficial ownership subsequent to the Merger, includes 200,000
shares of Embassy Common Stock underlying certain stock options to be
granted to Dr. Dresnick in connection with the Merger.
(4) Represents (i) 795,385 shares of Embassy Common Stock to be issued in
connection with the closing of the Merger; and (ii) 102,774 shares issuable
in connection with the acquisition of Dr. Grussmark's practice, based on an
Average Price per share of $8.5625.
(5) Represents (i) shares of Common Stock to be issued to Mr. Guilford (347,980)
and Mr. Alfonso (24,856) in connection with the Merger; and (ii) shares of
Common Stock issuable upon the exercise by Mr. Guilford (150,000) and Mr.
Alfonso (5,000) of stock options to be granted in connection with the
Merger, which options will be currently exercisable as of the Effective
Date.
(6) Represents (i) 7,500 shares of Common Stock to be issued in connection with
the Merger, and (ii) 40,000 shares of Common Stock issuable upon the
exercise of stock options to be granted in connection with the Merger. Does
not included shares held by Jeffrey Thompson, D.M.D., William Thompson's
adult son, over which William Thompson disclaims beneficial ownership.

DESCRIPTION OF EMBASSY'S SECURITIES

GENERAL

Embassy is authorized to issue 100,000,000 shares of Common Stock, par
value $.0001 per share. As of
57
65

the date hereof, 2,540,000 shares of Embassy Common Stock are outstanding, held
of record by 46 persons. If approved by the Embassy Shareholders, Embassy will
be authorized to issue 100,000,000 shares of Preferred Stock, par value $.0001
per share.

COMMON STOCK

The holders of Embassy Common Stock are entitled to one vote for each share
held of record on all matters to be voted on by shareholders. There is no
cumulative voting with respect to the election of Directors, with the result
that the holders of more than 50% of the shares voted for the election of
Directors can elect all of the Directors. The holders of Embassy Common Stock
are entitled to receive dividends when, as and if declared by the Board of
Directors out of funds legally available therefor. In the event of liquidation,
dissolution or winding up of Embassy, the holders of Embassy Common Stock
(except for the existing shareholders who have agreed to waive their rights to
share in any distribution relating to a liquidation of Embassy due to the
failure of Embassy to effect the Merger by October 1, 1998), are entitled to
share ratably in all assets remaining available for distribution to them after
payment of liabilities and after provision has been made for each class of
stock, if any, having preference over the Embassy Common Stock. Holders of
shares of Embassy Common Stock, as such, have no conversion, preemptive or other
subscription rights, and there are no redemption provisions applicable to the
Embassy Common Stock. All of the outstanding shares of Embassy Common Stock are,
and the shares of Embassy Common Stock issuable in the Merger, when delivered in
accordance with the terms of the Merger Agreement, will be, fully paid and
nonassessable.

PREFERRED STOCK

Embassy's proposed Restated Articles authorizes the issuance of 100,000,000
shares of preferred stock (the "Preferred Stock") with such designation, rights
and preferences as may be determined from time to time by the Embassy Board.
Accordingly, the Embassy Board is empowered, without shareholder approval, to
issue Preferred Stock with dividend, liquidation, conversion, voting or other
rights which could adversely affect the voting power or other rights of the
holders of Embassy Common Stock. The Preferred Stock could be utilized, under
certain circumstances, as a method of discouraging, delaying or preventing a
change in control of Embassy subsequent to the Effective Date of the Merger.
Although Embassy does not currently intend to issue any shares of Preferred
Stock, there can be no assurance that Embassy will not do so subsequent to the
consummation of the Merger.

Embassy does not presently intend to pay any cash dividends for the
foreseeable future as all available cash will be utilized to further the growth
of Embassy business subsequent to the Effective Date of the Merger for the
proximate future thereafter. The payment of any subsequent cash dividends will
be in the discretion of the Embassy Board and will be dependent upon Embassy's
results of operations, financial condition, contractual restrictions and other
factors deemed relevant by the Embassy Board.

TRANSFER AGENT

The transfer agent for the Embassy Common Stock is American Stock Transfer
& Trust Company, 40 Wall Street, New York, New York 10005.

UNDERWRITER WARRANTS

In connection with Embassy's IPO, Embassy sold to Barron Chase Securities,
Inc., for nominal consideration, warrants to purchase up to 120,000 shares of
Common Stock, par value $.0001 per share of Embassy (the "Underwriter
Warrants"). The Underwriter Warrants are exercisable at $7.80 per share (the
"Exercise Price") for a period of five years commencing on April 2, 1996. The
Underwriter Warrants contain anti-dilution provisions providing for adjustment
of the Exercise Price upon the occurrence of certain events including the
issuance of shares of Embassy Common Stock or other securities convertible into
or exercisable for shares of Embassy Common Stock at a price per share less than
the Exercise Price, or in the event of any recapitalization, reclassification,
stock dividend, stock split, stock combination or similar transaction.

58
66

Embassy also agreed at the time of the issuance of the Underwriter Warrants
to use its best efforts to maintain an effective registration statement with
respect to the Underwriter Warrants and the underlying Embassy Common Stock. In
addition, the Underwriter Warrants granted to the holders thereof certain
"piggyback" and "demand" rights with respect to the registration under the
Securities Act of the securities issuable upon exercise of the Underwriter
Warrants.

COMPARISON OF RIGHTS OF EMBASSY SHAREHOLDERS
AND ORTHODONTIX SHAREHOLDERS

On the Effective Date, Orthodontix Shareholders will automatically become
Embassy Shareholders, and their rights as shareholders will be governed by
applicable Florida law, the Embassy Articles of Incorporation and Embassy
Bylaws. Holders of Embassy Common Stock immediately prior to the Effective Date
will continue as Embassy Shareholders subsequent to the Effective Date, and
although their ownership in Embassy will suffer significant dilution, their
rights as Embassy Shareholders will remain substantially unchanged and will
continue to be governed by applicable Florida law, the Embassy Articles of
Incorporation, as amended, and the Embassy Bylaws from and after the Effective
Date. As both Embassy and Orthodontix are incorporated under the laws of the
State of Florida, each of Embassy and Orthodontix are governed by Florida law.
The following sets forth the rights of an Embassy Shareholder under Embassy's
Articles of Incorporation.

Embassy's Articles of Incorporation provide, among other things, that (i)
officers and directors of Embassy will be indemnified to the fullest extent
permitted under Florida law; and (ii) Embassy has elected not to be governed by
Sections 607.0901 and 607.0902 of the Florida Business Corporation Act and other
laws relating thereto (the "Anti-Takeover Sections").

LEGAL MATTERS

The validity of the Embassy Common Stock offered hereby will be passed upon
on behalf of Embassy by Berman Wolfe & Rennert, P.A., Miami, Florida. Berman
Wolfe & Rennert, P.A. has provided legal services in the past to Orthodontix.
Upon closing of the Merger, attorneys in Berman Wolfe & Rennert, P.A. shall own,
in the aggregate, 104,567 shares of Common Stock of Embassy and options to
acquire 50,000 shares of Embassy Common Stock.

EXPERTS

The balance sheets of Embassy as of December 31, 1996 and 1995 and the
statements of income, retained earnings and cash flows for the year ended
December 31, 1996 and the period November 30, 1995 (date of inception) to
December 31, 1995 included in this Prospectus, have been incorporated herein in
reliance on the report of Coopers & Lybrand L.L.P., independent accountants,
given on the authority of said firm as experts in accounting and auditing.
59
67

The balance sheet of Orthodontix as of December 31, 1996 and the statement
of income, retained earnings and cash flows for the period August 14, 1996 (date
of inception) to December 31, 1996 included in this Prospectus, have been
incorporated herein in reliance on the report of Coopers & Lybrand L.L.P.,
independent accountants, given on the authority of said firm as experts in
accounting and auditing.

It is expected that representatives of Coopers & Lybrand L.L.P. will be
present at the Special Meeting and will be available to respond to questions.
They will be given an opportunity to make a statement at the Special Meeting if
they so desire.

[This Space Intentionally Left Blank]

60
68

INDEX TO FINANCIAL STATEMENTS

PAGES
-----

Orthodontix, Inc. Unaudited Pro Forma Balance Sheet
Unaudited Pro Forma Balance Sheet as of September 30,
1997.................................................. F-2
Notes to Unaudited Pro Forma Balance Sheet............. F-4
Embassy Acquisition Corp. Financial Statements
Report of Independent Accountants...................... F-5
Balance Sheets as of December 31, 1995 and 1996 and
September 30, 1997 (unaudited)........................ F-6
Statement of Operations for the year ended December 31,
1996, the three and nine months ended September 30,
1997 and 1996 (unaudited), and the period from
November 30, 1995 (date of inception) to September 30,
1997 (unaudited)...................................... F-7
Statement of Changes in Stockholders' Equity for the
period from November 30, 1995 (date of inception) to
December 31, 1995, the year ended December 31, 1996,
and the nine months ended September 30, 1997
(unaudited)........................................... F-8
Statements of Cash Flows for the period from November
30, 1995 (date of inception) to December 31, 1995, for
the year ended December 31, 1996, the nine months
ended September 30, 1997 and 1996 (unaudited), and the
period from November 30, 1995 (date of inception) to
September 30, 1997 (unaudited)........................ F-9
Notes to Financial Statements.......................... F-10
Orthodontix, Inc. Financial Statements
Report of Independent Accountants...................... F-15
Balance Sheets as of December 31, 1996 and September
30, 1997 (unaudited).................................. F-16
Statements of Operations for the period from August 14,
1996 (date of inception) to December 31, 1996, the
nine months ended September 30, 1997 (unaudited), and
the period from August 14, 1996 (date of inception) to
September 30, 1997 (unaudited)........................ F-17
Statement of Changes in Stockholders' Deficit for the
period from August 14, 1996 (date of inception) to
December 31, 1996 and the nine months ended September
30, 1997 (unaudited).................................. F-18
Statements of Cash Flows for the period from August 14,
1996 (date of inception) to December 31, 1996, the
nine months ended September 30, 1997 (unaudited), and
the period from August 14, 1996 (date of inception) to
September 30, 1997 (unaudited)........................ F-19
Notes to Financial Statements.......................... F-20

F-1
69

UNAUDITED PRO FORMA BALANCE SHEET

The unaudited pro forma balance sheet dated September 30, 1997 of
Orthodontix, Inc. (the "Company") has been prepared as if (a) the acquisition by
the Company of certain assets and assumption of certain liabilities of 27
orthodontic practices (the "Founding Practices") for consideration consisting of
a combination of cash and shares of its common stock, par value $.0001 per share
(the "Common Stock"), and the execution of agreements to provide management
services to the Founding Practices (collectively, the "Acquisitions") and (b)
the merger and recapitalization of the Company with and into Embassy Acquisition
Corp. ("Embassy") in exchange for Embassy common stock (the "Merger
Transaction") all had been completed and those transactions had occurred on
September 30, 1997. The Acquisition and the Merger Transaction are each
contingent on the occurrence of the other.

The Company will not employ orthodontic professionals or control the
practice of orthodontics by the orthodontists. As the Company will not be
acquiring the future patient revenues to be earned by the Founding Practices,
the Acquisitions are not deemed to be business combinations. In accordance with
the Securities and Exchange Commission's Staff Accounting Bulletin No. 48,
"Transfers of Nonmonetary Assets by Promoters or Shareholders," the Acquisitions
will be accounted for at their historical cost basis with the shares of Common
Stock to be issued in the Acquisitions being valued at the historical net book
value of the nonmonetary assets acquired, net of liabilities assumed.

The Merger Transaction will be treated as a capital transaction equivalent
to the issuance of stock by the Company for the net monetary assets of Embassy
accompanied by a recapitalization.

The unaudited pro forma balance sheet has been prepared by the Company
based on the unaudited historical financial statements of the Company and
Embassy included elsewhere in this Prospectus, including the unaudited combined
financial information of the Founding Practices included in the notes to the
Company's financial statements, and assumptions deemed appropriate by the
Company.

F-2
70

ORTHODONTIX, INC.
UNAUDITED PRO FORMA BALANCE SHEET
SEPTEMBER 30, 1997

EMBASSY
ACQUISITION ORTHODONTIX, PRO FORMA PRO FORMA
CORP. INC. ADJUSTMENTS AS ADJUSTED
----------- ------------ ----------- -----------
(UNAUDITED) (UNAUDITED)

ASSETS
Current assets:
Cash and cash equivalents................ $ 655,033 $ 9,320 $ 6,800,767(b) $3,767,339
(3,385,841)(c)
(311,940)(f)
Restricted cash and cash equivalents..... 6,800,767 -- (6,800,767)(b) --
Accounts receivable, net................. -- -- 593,947(c) 593,947
Accrued interest and other receivables... -- 130 -- 130
---------- --------- ----------- ----------
Total current assets............. 7,455,800 9,450 (3,103,834) 4,361,416
---------- --------- ----------- ----------
Property, plant and equipment:
Property, plant and equipment, net....... -- -- 764,185(c) 764,185
---------- --------- ----------- ----------
Total property, plant and
equipment...................... -- -- 764,185 764,185
---------- --------- ----------- ----------
Other assets:
Other assets............................. 8,472 932 162,230(c) 171,634
---------- --------- ----------- ----------
Total other assets............... 8,472 932 162,230 171,634
---------- --------- ----------- ----------
Total assets $7,464,272 $ 10,382 $(2,177,419) $5,297,235
========== ========= =========== ==========

LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accrued expenses and other payables...... $ -- $ 31,701 $ 660,000(d) $ 691,701
Income taxes payable..................... 77,748 -- 59,395(e) 137,143
Bank line of credit...................... -- 186,283 -- 186,283
---------- --------- ----------- ----------
Total current liabilities........ 77,748 217,984 719,395 1,015,127
---------- --------- ----------- ----------
Long-term liabilities:
Other long-term liabilities.............. -- -- 178,184(e) 178,184
Due to shareholder....................... -- 311,940 (311,940)(f) --
---------- --------- ----------- ----------
Total long-term liabilities...... -- 311,940 (133,756) 178,184
---------- --------- ----------- ----------
Total liabilities................ 77,748 529,924 585,639 1,193,311
---------- --------- ----------- ----------
Common stock subject to redemption......... 7,386,524 (7,386,524)(a) --
Commitments and contingencies
Stockholders' equity:
Common stock............................. -- 130 254(a) 603
219(c)
Paid-in-capital.......................... -- -- 7,386,270(a) 4,622,993
(1,865,698)(c)
(660,000)(d)
(237,579)(e)
Accumulated deficit...................... (519,672) -- (519,672)
---------- --------- ----------- ----------
Total stockholders' (deficit)
equity......................... -- (519,542) 4,623,466 4,103,924
---------- --------- ----------- ----------
Total liabilities and
stockholders' equity........... $7,464,272 $ 10,382 $(2,177,419) $5,297,235
========== ========= =========== ==========

See accompanying notes to unaudited pro forma balance sheet.

F-3
71

ORTHODONTIX, INC.

NOTES TO UNAUDITED PRO FORMA BALANCE SHEET
SEPTEMBER 30, 1997

UNAUDITED PRO FORMA BALANCE SHEET ADJUSTMENTS

The accompanying unaudited pro forma balance sheet as of September 30, 1997
gives effect to the Acquisitions and the Merger Transaction, as if those
transactions had occurred on September 30, 1997. The unaudited pro forma balance
sheet does not represent the historical or future financial position of the
Company.

(a) To record the issuance of 1,300,000 shares of Embassy common stock for
1,300,000 shares of the Company in connection with the Merger Transaction which
for financial reporting purposes is treated as a capital transaction of the
Company for the net monetary assets of Embassy.

(b) To reclassify the restricted cash and cash equivalents which are no
longer subject to restrictions as a result of the Merger Transaction.

(c) Reflects completion of the Acquisitions, which will involve the
issuance of 2,187,940 shares of common stock (based upon the average closing bid
and asked price of Embassy for the 15 trading days prior to March 26, 1998),
valued at the historical net book value of the assets transferred from the
Founding Practices, and cash distributions to be treated as dividends
aggregating $3,385,841. The historical net book value of the assets transferred
from the Founding Practices are as follows:

Accounts receivable, net of allowance for doubtful
accounts.................................................. $593,947
Property and equipment transferred.......................... 764,185
Other assets................................................ 162,230

(d) Reflects the estimated expenses to be incurred with completion of the
Acquisitions and Merger Transaction.

(e) Reflects the recording of a current liability in the amount of $59,395
and a long-term liability in the amount of $178,184 for income taxes as a result
of the acquisition of certain accounts receivable which were previously taxed on
a cash basis for the Founding Practices. As a result of the Acquisitions and
Merger Transaction, the tax on such amounts will be paid by the Company over a
four year period.

(f) Reflects the repayment of the amounts due to stockholder with the
proceeds of the Merger Transaction.

F-4
72

REPORT OF INDEPENDENT ACCOUNTANTS

To the Board of Directors of
Embassy Acquisition Corp.

We have audited the accompanying balance sheets of Embassy Acquisition
Corp. (a Florida Corporation in the development stage) as of December 31, 1996
and 1995, and the related statements of operations, changes in stockholders'
equity and cash flows for the year ended December 31, 1996 and the related
statements of changes in stockholders' equity and cash flows for the period from
November 30, 1995 (date of inception) to December 31, 1995. These financial
statements are the responsibility of the Company's management. Our
responsibility is to express an opinion on these financial statements based on
our audits.

We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly,
in all material respects, the financial position of Embassy Acquisition Corp. as
of December 31, 1996 and 1995, and the results of its operations and its cash
flows for the year ended December 31, 1996 and the period from November 30, 1995
(date of inception) to December 31, 1995, in conformity with generally accepted
accounting principles.

COOPERS & LYBRAND L.L.P.

Miami, Florida
March 19, 1997

F-5
73

EMBASSY ACQUISITION CORP.
(A DEVELOPMENT STAGE CORPORATION)

BALANCE SHEETS

DECEMBER 31, DECEMBER 31, SEPTEMBER 30,
1995 1996 1997
------------ ------------ -------------
(UNAUDITED)

ASSETS
Current assets:
Cash and cash equivalents............................ $ 76,078 $ 763,965 $ 655,033
Restricted cash and cash equivalents................. -- 6,566,206 6,800,767
Accrued interest receivable.......................... -- 1,342 --
-------- ---------- ----------
Total current assets......................... 76,078 7,331,513 7,455,800
-------- ---------- ----------
Other assets:
Deferred registration costs.......................... 28,144 -- --
Deferred tax assets.................................. -- 8,472 8,472
-------- ---------- ----------
Total other assets........................... 28,144 8,472 8,472
-------- ---------- ----------
Total assets................................. $104,222 $7,339,985 $7,464,272
======== ========== ==========

LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accrued expenses..................................... $ 28,144 $ 3,487 $ --
Income taxes payable................................. -- 76,476 77,748
-------- ---------- ----------
Total liabilities............................ 28,144 79,963 77,748
-------- ---------- ----------
Common stock subject to redemption..................... -- 7,260,022 7,386,524
Commitments and contingencies
Stockholders' equity:
Common stock, $.0001 par value, 100,000,000 shares
authorized, 1,160,000, 2,540,000 and 2,540,000
issued and outstanding at December 31, 1995,
December 31, 1996 and September 30, 1997,
respectively...................................... 116 -- --
Additional paid-in-capital........................... 75,962 -- --
Retained earnings accumulated during the development
stage............................................. -- -- --
-------- ---------- ----------
Total stockholders' equity................... 76,078 -- --
-------- ---------- ----------
Total liabilities and stockholders' equity... $104,222 $7,339,985 $7,464,272
======== ========== ==========

The accompanying notes are an integral part of these financial statements.

F-6
74

EMBASSY ACQUISITION CORP.
(A DEVELOPMENT STAGE CORPORATION)

STATEMENT OF OPERATIONS

FOR THE PERIOD
FROM
FOR THE YEAR FOR THE THREE MONTHS FOR THE NINE MONTHS NOVEMBER 30, 1995
ENDED ENDED SEPTEMBER 30, ENDED SEPTEMBER 30, (DATE OF INCEPTION)
DECEMBER 31, --------------------- --------------------- TO
1996 1997 1996 1997 1996 SEPTEMBER 30, 1997
------------ --------- --------- --------- --------- -------------------
(UNAUDITED) (UNAUDITED) (UNAUDITED)

Operating revenues................ $ -- $ -- $ -- $ -- $ -- $ --
--------- --------- --------- --------- --------- --------
Operating expenses:
General and administrative...... 44,058 16,609 11,655 67,019 26,247 111,077
--------- --------- --------- --------- --------- --------
Total operating
expenses............... 44,058 16,609 11,655 67,019 26,247 111,077
--------- --------- --------- --------- --------- --------
Loss from operations..... (44,058) (16,609) (11,655) (67,019) (26,247) (111,077)
--------- --------- --------- --------- --------- --------
Other income:
Interest income................. 243,743 91,140 58,517 258,793 116,100 502,536
--------- --------- --------- --------- --------- --------
Other income.................. 243,743 91,140 58,517 258,793 116,100 502,536
--------- --------- --------- --------- --------- --------
Income before income tax
provision....................... 199,685 74,531 46,862 191,774 89,853 391,459
Income tax provision.............. 68,004 25,340 17,620 65,271 33,798 133,275
--------- --------- --------- --------- --------- --------
Net income............... $ 131,681 $ 49,191 $ 29,242 $ 126,503 $ 56,055 $258,184
========= ========= ========= ========= ========= ========
Net income per share..... $ 0.06 $ 0.02 $ 0.01 $ 0.05 $ 0.03
========= ========= ========= ========= =========
Weighted average common and common
stock equivalent shares
outstanding..................... 2,164,670 2,540,000 2,540,000 2,540,000 2,039,560
========= ========= ========= ========= =========

The accompanying notes are an integral part of these financial statements.

F-7
75

EMBASSY ACQUISITION CORP.
(A DEVELOPMENT STAGE CORPORATION)

STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY
FOR THE PERIOD FROM NOVEMBER 30, 1995 (DATE OF INCEPTION) TO DECEMBER 31, 1995,
FOR THE YEAR ENDED DECEMBER 31, 1996, AND FOR THE NINE MONTHS ENDED
SEPTEMBER 30, 1997

COMMON STOCK ADDITIONAL
------------------ PAID-IN RETAINED
SHARES AMOUNT CAPITAL EARNINGS TOTAL
--------- ------ ---------- --------- --------

Issuance of stock to original stockholders... 1,160,000 $ 116 $ 75,962 $ -- $ 76,078
--------- ----- -------- --------- --------
Balance, December 31, 1995................... 1,160,000 116 75,962 -- 76,078
Issuance of stock to Public Stockholders in
connection with initial public offering.... 1,380,000 -- -- -- --
Net income for the year ended December 31,
1996....................................... -- -- -- 131,681 131,681
Amounts accruing to the benefit of Public
Stockholders............................... -- (116) (75,962) (131,681) (207,759)
--------- ----- -------- --------- --------
Balance, December 31, 1996................... 2,540,000 -- -- -- --
Net income for the nine months ended
September 30, 1997 (unaudited)............. -- -- -- 126,503 126,503
Amounts accruing to the benefit of Public
Stockholders (unaudited)................... -- -- -- (126,503) (126,503)
--------- ----- -------- --------- --------
Balance, September 30, 1997 (unaudited)...... 2,540,000 $ -- $ -- $ -- $ --
========= ===== ======== ========= ========

The accompanying notes are an integral part of these financial statements.

F-8
76

EMBASSY ACQUISITION CORP.
(A DEVELOPMENT STAGE CORPORATION)

STATEMENTS OF CASH FLOWS

FOR THE PERIOD
FROM FOR THE PERIOD
NOVEMBER 30, FROM
1995 (DATE OF FOR THE YEAR FOR THE NINE MONTHS NOVEMBER 30, 1995
INCEPTION) TO ENDED ENDED SEPTEMBER 30, (DATE OF INCEPTION)
DECEMBER 31, DECEMBER 31, ------------------------- TO
1995 1996 1997 1996 SEPTEMBER 30, 1997
-------------- ------------ ----------- ----------- -------------------
(UNAUDITED) (UNAUDITED) (UNAUDITED)

Cash flows from operating activities:
Net income......................... $ -- $ 131,681 $ 126,503 $ 56,055 $ 258,184
Adjustment to reconcile net income
to net cash used in operating
activities:
Deferred income taxes............ -- (8,472) -- -- (8,472)
Net interest on restricted cash
and cash equivalents........... -- (243,743) (258,794) (116,100) (502,537)
Changes in certain assets and
liabilities:
Accrued interest receivable.... -- -- 1,342 (1,461) 1,342
Accrued expenses............... -- 3,487 (3,487) 246 --
Income taxes payable........... -- 76,476 1,272 33,798 77,748
------- ----------- --------- ----------- -----------
Net cash used in operating
activities................ -- (40,571) (133,164) (27,462) (173,735)
------- ----------- --------- ----------- -----------
Cash flows from investing activities:
(Decrease) increase in restricted
cash and cash equivalents........ -- (6,323,805) 24,232 (6,331,602) (6,299,573)
------- ----------- --------- ----------- -----------
Net cash (used in) provided
by investing activities... -- (6,323,805) 24,232 (6,331,602) (6,299,573)
------- ----------- --------- ----------- -----------
Cash flows from financing activities:
Net proceeds from issue of common
stock............................ 76,078 7,052,263 -- 7,052,263 7,128,341
------- ----------- --------- ----------- -----------
Net cash provided by
financing activities...... 76,078 7,052,263 -- 7,052,263 7,128,341
------- ----------- --------- ----------- -----------
Net increase (decrease) in cash and
cash equivalents................... 76,078 687,887 (108,932) 693,199 655,033
Cash and cash equivalents at
beginning of period................ -- 76,078 763,965 76,078 --
------- ----------- --------- ----------- -----------
Cash and cash equivalents at end of
period............................. $76,078 $ 763,965 $ 655,033 $ 769,277 $ 655,033
======= =========== ========= =========== ===========

The accompanying notes are an integral part of these financial statements.

F-9
77

EMBASSY ACQUISITION CORP.
(A DEVELOPMENT STAGE CORPORATION)

NOTES TO FINANCIAL STATEMENTS
DECEMBER 31, 1996
(INFORMATION AS OF SEPTEMBER 30, 1997 AND FOR THE NINE MONTHS ENDED SEPTEMBER
30, 1997 IS UNAUDITED)

1. ORGANIZATION

Embassy Acquisition Corp. (the "Company") was incorporated in the State of
Florida on November 30, 1995 for the purpose of raising capital and to seek to
effect a merger, exchange of capital stock, asset acquisition or other similar
business combination (a "Business Combination") with an operating business,
which the Company believes has significant growth potential. The Company had no
operations from November 30, 1995, date of inception, to December 31, 1995. The
Company is currently in the development stage. On April 2, 1996, the Company's
Registration Statement (the "Registration Statement") on Form SB-2 was declared
effective by the U.S. Securities and Exchange Commission. Pursuant to the
Registration Statement the Company, in its initial public offering of
securities, offered and sold 1,380,000 shares of its common stock, $.0001 par
value, at a purchase price of $6 per share (the "Offering"). Proceeds totaled
$7,052,263, which was net of $1,227,737 in underwriting and other expenses (the
"Net Proceeds").

In connection with the Offering, the Company sold to the managing
underwriter (the "Underwriter") and its designees, for total consideration of
$10, stock purchase options ("the "Underwriter Options") to purchase up to
120,000 shares of the Company's common stock at an exercise price of $7.80 per
share. The Underwriter Options will be exercisable for a period of five years
from the effective date of the Company's Registration Statement. The Company has
also agreed to certain registration rights with respect to the shares underlying
the Underwriter Options.

The Offering can be considered a "blind pool/blank check" offering which is
characterized by an absence of substantive disclosures related to the use of the
Net Proceeds of the Offering. Consequently, although substantially all of the
Net Proceeds of the Offering are intended to be utilized to effect a Business
Combination, the Net Proceeds are not being designated for a specific Business
Combination at this time.

In accordance with the Offering, 90% of the Net Proceeds therefrom were
placed in an interest bearing escrow account (the "Escrow Fund") subject to the
earlier of (i) written notification by the Company of its need for all or
substantially all of the Escrow Fund for the purpose of implementing a Business
Combination, (ii) the exercise by certain shareholders of the Redemption Offer,
as hereinafter defined, or (iii) the expiration of no more than 30 months from
the date of the Offering.

Amounts in the Escrow Fund, including interest earned thereon, are
prohibited from being used for any purpose other than a Business Combination.
Such amounts are included in restricted cash at December 31, 1996.

The Company, prior to the consummation of any Business Combination, will
submit such transaction to the Company's stockholders for their approval. In the
event, however, that the holders of 30% or more of the shares sold in the
Offering which are outstanding (the "Public Stockholders") vote against approval
on any Business Combination, the Company will not consummate such Business
Combination. All of the officers and directors of the Company, who own in
aggregate 30.7% of the common stock outstanding, have agreed to vote their
respective shares of common stock in accordance with the vote of the Public
Stockholders with respect to any such Business Combination.

At the time the Company seeks stockholder approval of any potential
Business Combination, the Company will offer (the "Redemption Offer") to each of
the Public Stockholders the right, for a specified period of time of not less
than 20 days, to redeem all, but not a portion of, their shares of common stock
at a per share price equal to the Company's liquidation value on the record date
for determination of stockholders entitled to vote upon the proposal to approve
such Business Combination (the "Record Date") divided by the number of shares
held by all of the Public Stockholders. The Company's liquidation value will be
equal to the Company's book value, as determined by the Company (the "Company's
Liquidation Value"), calculated as
F-10
78
EMBASSY ACQUISITION CORP.
(A DEVELOPMENT STAGE CORPORATION)

NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)

of the Record Date. In no event, however, will the Company's Liquidation Value
be less than the Escrow Fund, inclusive of any net income thereon. If holders of
less than 30% of the shares held by the Public Stockholders elect to have their
shares redeemed, the Company may, but will not be required to, proceed with such
Business Combination. If the Company elects to so proceed, it will redeem
shares, based upon the Company's Liquidation Value, from those Public
Stockholders who affirmatively requested such redemption and who voted against
the Business Combination. If the holders of 30% or more of the shares held by
the Public Stockholders vote against approval of any potential Business
Combination, the Company will not proceed with such Business Combination and
will not redeem such shares. The Escrow Fund will be released to stockholders
voting against a Business Combination only if such proposed Business Combination
is consummated.

As a result of its limited resources, the Company will, in all likelihood,
have the ability to effect only a single Business Combination. Accordingly, the
prospects for the Company's success will be entirely dependent upon the future
performance of a single business.

The Company has not and will not receive any revenues, other than interest
income, until, at the earliest, the consummation of a Business Combination.
Although the Company believes that the Net Proceeds will be sufficient to effect
a Business Combination, the Company has not yet identified any prospective
business candidates. Accordingly, the Company cannot ascertain with any degree
of certainty the capital requirements for any particular transaction. In the
event that the Net Proceeds prove to be insufficient for purposes of effecting a
Businesses Combination, the Company will be required to seek additional
financing. In the event no Business Combination is identified, negotiations are
incomplete or no Business Combination has been consummated, and all of the Net
Proceeds other than the Escrow Fund have been expended, the Company currently
has no plans or arrangements with respect to the possible acquisition of
additional financing which may be required to continue the operations of the
Company.

Furthermore, there is no assurance that the Company will be able to
successfully effect a Business Combination. In the event that the Company does
not effect a Business Combination within 24 months (or in certain circumstances
30 months) from the date of the consummation of the Offering, the Company will
submit to the stockholders a proposal to liquidate the Company. If the proposal
is approved by a majority of the Public Stockholders, the Company will
distribute to the Public Stockholders, in proportion to their respective equity
interest in the Company, an aggregate sum equal to the Company's Liquidation
Value.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Cash and Cash Equivalents. Cash and cash equivalents are defined as all
highly liquid financial instruments with maturities of 90 days or less at the
date of purchase. The Company maintains its cash and cash equivalents which
consist principally of demand deposits and repurchase agreements with one
financial institution.

Restricted Cash and Cash Equivalents. Ninety percent of the Net Proceeds
were placed in the Escrow Fund, as described above. As of December 31, 1996,
there was $6,566,206 in the Escrow Fund which was invested in United States
government-backed securities with maturities of 90 days or less at the date of
purchase.

Common Stock Subject to Redemption. In the event that the Company does not
successfully effect a Business Combination within 24 months (or in certain
circumstances 30 months) from the date of consummation of the Offering, the
Company will submit a proposal to liquidate the Company. If such proposal is
approved, the Company will distribute the Company's Liquidation Value to the
Public Stockholders. Since the Company may be required to refund all available
equity to the Public Stockholders, such

F-11
79
EMBASSY ACQUISITION CORP.
(A DEVELOPMENT STAGE CORPORATION)

NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)

amounts have been classified in the accompanying balance sheet as common stock
subject to redemption. Periodic changes in the Liquidation Value are reflected
as adjustments to stockholders' equity.

Fair Value of Financial Instruments. The carrying amount of cash and cash
equivalents, restricted cash and cash equivalents and accrued expenses
approximate fair value due to the short maturities of these items.

Use of Estimates. The preparation of financial statements in conformity
with generally accepted accounting principles requires management to make
estimates and assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at the date of
the financial statements and the reported amounts of income and expenses during
the reporting period. Actual results could differ from those estimates.

Net Income Per Share. Net income per share is calculated by dividing net
income by the weighted average number of common and common equivalent shares
outstanding during the period. Common stock subject to redemption is treated as
common shares for purposes of calculating net income per share. Common
equivalent shares consist of the Underwriter Options which are not considered in
the calculation of net income per share since the impact of such is
antidilutive.

Recent Accounting Pronouncements. In February 1997, Statement of Financial
Accounting Standards ("SFAS") No. 128, "Earnings Per Share" was issued. SFAS No.
128 establishes new standards for computing and presenting earnings per share
("EPS"). This statement replaces the presentation of primary EPS and will
require a dual presentation of basic and diluted EPS. SFAS No. 128 is effective
for financial statements issued for periods ended after December 15, 1997 and
requires restatement of all prior-period EPS data presented. The Company does
not believe the adoption of SFAS No. 128 will have a material impact on the
Company's financial statements when adopted.

3. COMMON STOCK

The Company's Articles of Incorporation authorize the issuance of
100,000,000 shares of common stock. The Company's Board of Directors has the
power to issue any or all of the authorized but unissued common stock without
stockholder approval. The Company currently has no commitments to issue any
shares of common stock; however, the Company will, in all likelihood, issue a
substantial number of additional shares in connection with a Business
Combination. To the extent that additional shares of common stock are issued,
dilution of the interests of the Public Stockholders may occur.

4. RELATED PARTIES

None of the Net Proceeds have been nor will be used to pay any compensation
to the Company's officers or directors. In addition, no funds, including
interest earned thereon, have been nor will be disbursed from the Escrow Fund
for the reimbursement of expenses incurred on the Company's behalf by the
Company's officers and directors.

Currently, the officers and directors and the other non-public stockholders
own 30.7% and 15.0%, respectively, of the issued and outstanding shares of the
Company's common stock.

5. INCOME TAXES

The Company is a C Corporation under the provisions of the Internal Revenue
Code and related state income tax statutes.

F-12
80
EMBASSY ACQUISITION CORP.
(A DEVELOPMENT STAGE CORPORATION)

NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)

The components of the provision for income taxes for the year ended
December 31, 1996 are as follows:

Current provision:
Federal................................................... $64,507
State..................................................... 11,969
-------
76,476
-------
Deferred provision:
Federal................................................... (7,616)
State..................................................... (856)
-------
(8,472)
-------
Total............................................. $68,004
=======

The following reconciles the federal statutory rate with the effective rate
for the year ended December 31, 1996:

Federal statutory rate...................................... 34.0%
State taxes, net of federal effect.......................... 3.7
Benefit of graduated tax rates.............................. (3.6)
----
Effective tax rate.......................................... 34.1%
====

At December 31, 1996, the Company had a deferred tax asset relating to
amortization of organizational and start-up costs.

6. INTERIM FINANCIAL INFORMATION

Interim Unaudited Financial Statements. The financial statements as of
September 30, 1997 and for the three and nine months ended September 30, 1997
and 1996 are unaudited; however, in the opinion of management, all adjustments
(consisting of normal recurring adjustments) necessary for a fair presentation
of the unaudited financial statements for this interim period have been
included. The results of interim periods are not necessarily indicative of the
results of operations to be obtained for the full year.

On May 6, 1997, the Company entered into a letter of intent with
Orthodontix, Inc., a Florida corporation ("Orthodontix"), regarding a business
combination of the Company or a newly formed wholly-owned subsidiary and
Orthodontix (the "Transaction"). The intended principal business activity of
Orthodontix is providing practice management services to orthodontic practices.
Orthodontix has conducted no operations to date other than in connection with
its agreements to acquire certain assets, assume certain liabilities, and
provide long-term management services to certain orthodontic practices (the
"Practices") in exchange for cash and shares of common stock (the "Practice
Acquisitions").

On August 29, 1997, the Company and Orthodontix amended the terms of the
Letter of Intent to provide that either party can terminate the Letter of Intent
if a definitive agreement had not been executed by October 30, 1997. The Letter
of Intent had previously provided that either party could terminate the Letter
of Intent if a definitive agreement regarding the Transaction had not been
executed by August 30, 1997. As of October 30, 1997, the Company and Orthodontix
entered into an Agreement and Plan of Merger and Reorganization (the
"Agreement") regarding the Transaction. Pursuant to the Agreement, the parties
shall engage in the Transaction, which at the closing of the Transaction (the
"Closing") will result in Orthodontix becoming a wholly owned subsidiary
corporation of the Company in exchange for that number of shares of Common Stock
of the Company (the "Merger Stock") representing approximately 56% of the
Company's outstanding shares of Common Stock after giving effect to the
Transaction but without giving effect to any

F-13
81
EMBASSY ACQUISITION CORP.
(A DEVELOPMENT STAGE CORPORATION)

NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)

options or warrants to acquire shares of Common Stock which are contemplated to
be outstanding at the Closing. The actual number of shares to be issued in
connection with the Transaction is subject, in part, to the average of the
closing bid and ask price, as reported on the OTC Electronic Bulletin Board or
similar quotation board of the Company's shares of Common Stock for the 15
trading days immediately preceding the date of the Closing (the "Share Value").

Pursuant to the terms of the Agreement, the recipients of 1,300,000 shares
of the Merger Stock (approximately 23% of the Company's outstanding shares of
Common Stock after giving effect to the Transaction, assuming an Embassy Share
Value of $8.00 per share) and the shares of Merger Stock to be issued in
connection with the Practice Acquisitions (approximately 33% of Embassy's
outstanding shares of Common Stock after giving effect to the Transaction
assuming an Embassy Share Value of $8.00 per share), respectively, have agreed,
for a period of 15 months and six months, respectively, from the date of the
Closing, not to make any offer, sale or disposition of any of the Merger Stock
to be issued to them in connection with the Transaction. The Transaction is
contemplated to be tax-free to the Company and its shareholders.

Based on information received from Orthodontix, at the Closing, Orthodontix
shall provide practice management services to approximately 24 orthodontic
practices, which practices generate gross revenue of approximately $16 million
annually.

The Closing is subject to, among other conditions, the closing of the
Transaction by April 1, 1998 (unless that date is extended by mutual agreement
of the parties), approval of the Transaction by the shareholders of the Company
and Orthodontix, certain regulatory and third party approvals and consents, and
the closing of the Practice Acquisitions. There can be no assurance that the
proposed Transaction will be consummated on these or any other terms.

Based upon the price per share of the common stock of the Company as of
October 30, 1997, at the closing of the Practice Acquisitions (assuming the
Practice Acquisitions represent orthodontic practices totaling $16 million of
revenue) and the Transaction, the Company would be obligated to issue
approximately 3.3 million shares of Common Stock and expend up to approximately
$3.0 million in consideration for the Transaction. The Company currently has
outstanding 2,540,000 shares of Common Stock and warrants entitling the holder
to purchase an additional 120,000 shares of Common Stock. Upon effectiveness of
the Transaction, the Company will change its name to "Orthodontix, Inc.,"
Stephen J. Dresnick, M.D., a member of the Company's Board of Directors,
President and Chief Executive Officer of Sterling Healthcare Group, Inc. and
Vice Chairman of the Board of FPA Medical Management, Inc. and Glenn Halpryn,
Chairman of the Company would continue to be members of the Board of Directors
of the Company with Dr. Dresnick assuming the role of Chairman of the Company.
There can be no assurance that the proposed Transaction will be consummated on
these or any other terms.

F-14
82

REPORT OF INDEPENDENT ACCOUNTANTS

To the Board of Directors and Stockholders of
Orthodontix, Inc.

We have audited the accompanying balance sheet of Orthodontix, Inc. (a
Florida corporation in the development stage) as of December 31, 1996, and the
related statements of operations, changes in stockholders' equity, and cash
flows for the period from August 14, 1996 (date of inception) to December 31,
1996. These financial statements are the responsibility of the Company's
management. Our responsibility is to express an opinion on these financial
statements based on our audit.

We conducted our audit in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audit provides a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly,
in all material respects, the financial position of Orthodontix, Inc. as of
December 31, 1996, and the results of its operations and its cash flows for the
period from August 14, 1996 (date of inception) to December 31, 1996, in
conformity with generally accepted accounting principles.

COOPERS & LYBRAND L.L.P.

Miami, Florida
December 19, 1997

F-15
83

ORTHODONTIX, INC.
(A DEVELOPMENT STAGE CORPORATION)

BALANCE SHEETS

DECEMBER 31, SEPTEMBER 30,
1996 1997
------------ -------------
(UNAUDITED)

ASSETS
CURRENT ASSETS:
Cash...................................................... $ 2,682 $ 9,320
Due from shareholder...................................... 130 130
-------- ---------
Total current assets.............................. 2,812 9,450
Other assets................................................ -- 932
-------- ---------
Total assets...................................... $ 2,812 $ 10,382
======== =========

LIABILITIES AND STOCKHOLDERS' DEFICIT
CURRENT LIABILITIES:
Accounts payable.......................................... $ 28,259 $ 26,628
Accrued expenses and other payables....................... -- 5,073
Bank line of credit....................................... -- 186,283
-------- ---------
Total current liabilities......................... 28,259 217,984
-------- ---------
LONG-TERM LIABILITIES:
Due to shareholder........................................ 48,598 311,940
-------- ---------
Total long-term liabilities............................ 48,598 311,940
-------- ---------
Total liabilities...................................... 76,857 529,924
-------- ---------
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' DEFICIT:
Preferred stock, $.0001 par value, 1,000,000 shares
authorized, none issued and outstanding at December 31,
1996 and at September 30, 1997......................... -- --
Common stock, $.0001 par value, 100,000,000 shares
authorized, 1,300,000 issued and outstanding at
December 31, 1996 and September 30, 1997............... 130 130
Deficit accumulated during the development stage.......... (74,175) (519,672)
-------- ---------
Total stockholders' deficit....................... (74,045) (519,542)
-------- ---------
Total liabilities and stockholders' deficit....... $ 2,812 $ 10,382
======== =========

The accompanying notes are an integral part of these financial statements.

F-16
84

ORTHODONTIX, INC.
(A DEVELOPMENT STAGE CORPORATION)

STATEMENTS OF OPERATIONS

FOR THE PERIOD FOR THE PERIOD
FROM FROM
AUGUST 14, 1996 FOR THE NINE AUGUST 14, 1996
(DATE OF INCEPTION) MONTHS (DATE OF INCEPTION)
TO ENDED TO
DECEMBER 31, SEPTEMBER 30, SEPTEMBER 30,
1996 1997 1997
------------------- ------------- -------------------
(UNAUDITED) (UNAUDITED)

OPERATING REVENUES................................ $ -- $ -- $ --
--------- --------- ---------
OPERATING EXPENSES:
General and administrative...................... 74,175 441,525 515,700
--------- --------- ---------
Total operating expenses................ 74,175 441,525 515,700
--------- --------- ---------
Loss from operations.................... (74,175) (441,525) (515,700)
--------- --------- ---------
Other income (expense):
Interest income................................. -- 29 29
Interest expense................................ -- (4,001) (4,001)
--------- --------- ---------
Other income............................ -- (3,972) (3,972)
--------- --------- ---------
Net loss................................ $ (74,175) $(445,497) $(519,672)
========= ========= =========
Net loss per share...................... $ (0.06) $ (0.34) $ (0.40)
========= ========= =========
Common stock outstanding.......................... 1,300,000 1,300,000 1,300,000
========= ========= =========

The accompanying notes are an integral part of these financial statements.

F-17
85
'
ORTHODONTIX, INC.
(A DEVELOPMENT STAGE CORPORATION)

STATEMENT OF CHANGES IN STOCKHOLDERS' DEFICIT
FOR THE PERIOD FROM AUGUST 14, 1996 (DATE OF INCEPTION) TO DECEMBER 31, 1996
AND FOR THE NINE MONTH ENDED SEPTEMBER 30, 1997

DEFICIT
ACCUMULATED
COMMON STOCK ADDITIONAL DURING
------------------ PAID-IN DEVELOPMENT
SHARES AMOUNT CAPITAL STAGE TOTAL
--------- ------ ---------- ----------- ---------

Issuance of stock to original stockholders... 1,300,000 $130 $ -- $ -- $ 130
Net loss for the period from August 14, 1996
(date of inception) to December 31, 1996... -- -- -- (74,175) (74,175)
--------- ---- -- --------- ---------
Balance, December 31, 1996................... 1,300,000 130 -- (74,175) (74,045)
Net loss for the nine months ended September
30, 1997 (unaudited)....................... -- -- -- (445,497) (445,497)
--------- ---- -- --------- ---------
Balance, September 30, 1997 (unaudited)...... 1,300,000 $130 $0 $(519,672) $(519,542)
========= ==== == ========= =========

The accompanying notes are an integral part of these financial statements.

F-18
86

ORTHODONTIX, INC.
(A DEVELOPMENT STAGE CORPORATION)

STATEMENTS OF CASH FLOWS

FOR THE PERIOD FOR THE PERIOD
FROM FROM
AUGUST 14, 1996 FOR THE NINE AUGUST 14, 1996
(DATE OF INCEPTION) MONTHS ENDED (DATE OF INCEPTION)
TO DECEMBER 31, SEPTEMBER 30, TO SEPTEMBER 30,
1996 1997 1997
------------------- ------------- -------------------
(UNAUDITED) (UNAUDITED)

Cash flows from operating activities:
Net loss...................................... $(74,175) $(445,497) $(519,672)
Adjustments to reconcile net loss to net cash
used in operating activities:
Changes in assets and liabilities
Other assets............................... -- (932) (932)
Accounts payable, accrued expenses and
other payables........................... 28,259 3,442 31,701
-------- --------- ---------
Net cash used in operating
activities.......................... (45,916) (442,987) (488,903)
-------- --------- ---------
Cash flows from financing activities:
Proceeds from bank line of credit............. -- 186,283 186,283
Advances from shareholder..................... 48,598 263,342 311,940
-------- --------- ---------
Net cash provided by financing
activities.......................... 48,598 449,625 498,223
-------- --------- ---------
Net increase in cash.................. 2,682 6,638 9,320
Cash at beginning of period..................... -- 2,682 --
-------- --------- ---------
Cash at end of period........................... $ 2,682 $ 9,320 $ 9,320
======== ========= =========

The accompanying notes are an integral part of these financial statements.

F-19
87

ORTHODONTIX, INC.
(A DEVELOPMENT STAGE CORPORATION)

NOTES TO FINANCIAL STATEMENTS
DECEMBER 31, 1996
(INFORMATION AS OF SEPTEMBER 30, 1997 AND FOR THE NINE MONTHS
ENDED SEPTEMBER 30, 1997 IS UNAUDITED)

1. BUSINESS AND ORGANIZATION

Orthodontix, Inc. (the "Company") was incorporated in the State of Florida
on August 14, 1996 for the purpose of creating a practice management services
company to manage orthodontic practices in the United States. The Company has
had no operations to date except seeking affiliations with orthodontic
practices, negotiating to acquire the tangible assets of those practices, and
negotiating agreements to provide management services to those practices. (See
Notes 3 and 6).

The financial statements have been prepared on the basis that the proposed
transactions will occur, although no assurance can be made that the proposed
transactions described in Notes 3 and 6 will be completed or that the Company
will be successful in completing future acquisitions. The Company intends to
expand through the acquisition of management rights to practices throughout the
United States. In order to expand, the Company will need further acquisition
financing in the form of debt or equity financing. There can be no assurance
that such financing will be available.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Income Taxes. The Company utilizes the liability method of accounting for
income taxes. Under this method, deferred taxes are determined based on
differences between the financial reporting and tax bases of assets and
liabilities and are measured using the enacted marginal tax rates currently in
effect when the differences reverse.

As reflected in the accompanying statement of operations, the Company
incurred a net loss of $74,175 during the period from its inception, August 14,
1996 through December 31, 1996. The Company has recognized no tax benefit from
this loss. Due to the limited operations of the Company since its inception, a
valuation allowance has been established to offset the deferred tax asset
related to these losses that have been capitalized for tax purposes. There is no
other significant difference in the tax and book bases of the Company's assets
or liabilities that would give rise to deferred tax balances.

Advertising. Costs incurred for advertising are expensed when incurred.

Net Loss Per Share. Net loss per share is calculated by dividing net loss
for the period by the weighted average number of common shares outstanding
during the period.

Recent Pronouncements. In February 1997, Statement of Financial Accounting
Standards ("SFAS") No. 128, "Earnings Per Share" was issued. SFAS No. 128
establishes new standards for the computation, presentation and disclosure
requirements of earnings per share ("EPS") and replaces Accounting Principles
Board Opinion No. 15, "Earnings per Share." This statement replaces the
presentation of primary EPS and will require a dual presentation of basic and
diluted EPS. Basic EPS excludes the impact of common stock equivalents. Diluted
EPS utilizes the average market price per share as opposed to the greater of the
average market price or ending market price per share when applying the treasury
stock method in determining common stock equivalents. SFAS No. 128 is effective
for both interim and annual periods ending after December 15, 1997.

F-20
88
ORTHODONTIX, INC.
(A DEVELOPMENT STAGE CORPORATION)

NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)

Fair Value of Financial Instruments. The carrying value of cash, accounts
payable, accrued expenses and amounts due to shareholder approximates fair
values principally because of the short-term maturities of these instruments.

Recent Pronouncements. In November 1997, the Emerging Issues Task Force of
the FASB (the "EITF") reached a consensus relating to the conditions under which
a physician practice management company would consolidate the accounts of an
affiliated physician practice. The Company believes that its accounting policies
conform to the EITF consensus.

Interim Unaudited Financial Statements. The financial statements as of
September 30, 1997 and for the nine months ended September 30, 1997 are
unaudited; however, in the opinion of management, all adjustments (consisting of
normal recurring adjustments) necessary for a fair presentation of the unaudited
financial statements for this interim period have been included. The results of
interim periods are not necessarily indicative of the results of operations to
be obtained for the full year.

3. PLANNED TRANSACTIONS

The Company plans to complete, through a series of mergers and asset
transfers, the acquisition of certain assets and assumption of certain
liabilities of 27 orthodontic practices (the "Founding Practices") (collectively
the "Affiliations Acquisitions"). Owners of the Founding Practices (the
"Promoters") will receive shares of common stock and cash as consideration in
the Affiliations Acquisitions. In connection with the Affiliations Acquisitions,
the Promoters selling orthodontists and their professional corporations or other
entities (collectively, the "PCs") will enter into long-term service agreements
with the Company. Additionally, those Promoters orthodontists will enter into
employment and noncompete agreements with the PCs.

The Company will not employ orthodontists or control the practice of
orthodontics by the orthodontists employed by the PCs. The Company will be
executing management service agreements and will not hold any equity ownership
interest in the PCs, therefore, the Affiliations Acquisitions are deemed not to
be business combinations. Because each of the owners of the Founding Practices
is a Promoter of the transaction, Securities and Exchange Commission's Staff
Accounting Bulletin ("SAB") No. 48, "Transfers of Nonmonetary Assets by
Promoters or Shareholders" each Founding Practice will be deemed a promoter of
the Merger. Pursuant to SAB No. 48, requires the transferred nonmonetary assets
and assumed liabilities will be accounted for at the historical cost basis of
the Founding Practices and any monetary assets assumed and any monetary
liabilities included in the Affiliations Acquisitions will be recorded at fair
value, and cash consideration paid in excess of net assets transferred, to be
reflected as a dividend paid by the Company.

The information set forth below assumes all the Founding Practices will
participate in the Affiliations Acquisitions. Although management expects that
all the practices will participate, there is no assurance that will be the case.

The net assets to be transferred and the liabilities to be assumed from the
Founding Practices are summarized, on a combined basis, in the following table:

DECEMBER 31, SEPTEMBER 30,
1996 1997
------------ -------------
(UNAUDITED) (UNAUDITED)

Patient receivables, net of allowance....................... $ 611,166 $ 593,947
Property, equipment and improvements, net................... 753,653 764,185
Other assets................................................ 123,355 162,230
---------- ----------
Assets transferred.......................................... $1,488,174 $1,520,362
========== ==========

F-21
89
ORTHODONTIX, INC.
(A DEVELOPMENT STAGE CORPORATION)

NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)

Upon consummation of the Affiliations Acquisitions, the Company will enter
into a service agreement with each Founding Practice under which the Company
will provide management services which include consultation and other activities
regarding the suitability of facilities and equipment, nonprofessional staffing,
regulatory compliance, productivity improvements, inventory and supplies
management, information systems management, marketing services, site selection
and layout, billing and financial services, malpractice insurance, and, subject
to applicable law, other services as the Company deems necessary to meet the day
to day requirements of the Founding Practices.

In general, the resulting fee will be based primarily on the practice's
accrued revenue (the "Standard Contract"). In those instances where the Standard
Contract may not be permitted by applicable law, an alternative form of
agreement (the "Alternative Contract") will be used.

Founding Practices are summarized, on a combined basis, in the following
tables for the year ended December 31, 1996 and the nine months ended September
30, 1997:

YEAR ENDED
DECEMBER 31, 1996
-------------------------
PATIENT OPERATING
REVENUE EXPENSES
----------- -----------
(UNAUDITED)

Practices participating under the Standard Contract......... $14,267,596 $ 9,467,699
Practices participating under the Alternative Contract...... 877,375 626,794
----------- -----------
Totals for Founding Practices..................... $15,144,971 $10,094,493
=========== ===========

NINE MONTHS ENDED
SEPTEMBER 30, 1997
------------------------
PATIENT OPERATING
REVENUE EXPENSES
----------- ----------
(UNAUDITED)

Practices participating under the Standard Contract......... $11,304,128 $7,144,675
Practices participating under the Alternative Contract...... 749,816 456,076
----------- ----------
Totals for Founding Practices..................... $12,053,944 $7,600,751
=========== ==========

Subsequent to the Affiliations Acquisitions, the operating expenses of the
Founding Practices will be the responsibility of the Company. The Company will
have the discretion to control the level of those expenses in conjunction with
providing the related expenses to the PCs. The historical operating expenses of
the Founding Practices for the year ended December 31, 1996 and the nine months
ended September 30, 1997 that will assumed by the Company in the future are
summarized, on a combined basis, excluding those employment

F-22
90
ORTHODONTIX, INC.
(A DEVELOPMENT STAGE CORPORATION)

NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)

expenses for the orthodontist or other employee that the Company is prohibited
from employing by law, in the following table:

YEAR ENDED NINE MONTHS ENDED
DECEMBER 31, SEPTEMBER 30,
1996 1997
------------ -----------------
(UNAUDITED) (UNAUDITED)

Salaries, wages and benefits of non-orthodontic
personnel............................................. $ 3,455,894 $2,608,538
Orthodontic supplies.................................... 1,353,786 860,973
Rent.................................................... 1,006,589 786,797
Advertising and marketing expenses...................... 203,502 171,588
General and administrative expenses..................... 3,731,018 2,940,004
----------- ----------
Total operating expenses...................... 9,750,789 7,367,900
Depreciation and amortization........................... 343,704 232,851
----------- ----------
Total expenses................................ $10,094,493 $7,600,751
=========== ==========

The combined historical financial information of the Founding Practices
presented herein is not related to the financial position or results of
operations of the Company. This information is presented solely for the purpose
of providing disclosures regarding the group of entities with which the Company
will be contracting to provide future services. The Founding Practices were not
operated under common control or management during the fiscal year ended
December 31, 1996 or the nine months ended September 30, 1997.

UNAUDITED PRO FORMA MANAGEMENT SERVICES FEES

The unaudited pro forma management service fee pursuant to the service
agreements for the Founding Practices, based on the historical patient revenues
set forth above is summarized in the following table for the year ended December
31, 1996 and the nine months ended September 30, 1997:

NINE MONTHS
YEAR ENDED ENDED
DECEMBER 31, SEPTEMBER 30,
1996 1997
------------ -------------
(UNAUDITED) (UNAUDITED)

Practices participating under the Standard Contract......... $2,140,139 $1,695,619
Practices participating under the Alternative Contract...... 155,500 116,625
---------- ----------
Total pro forma service agreement revenues........ $2,295,639 $1,812,244
========== ==========

Management has concluded that the changes in the orthodontists' incentive
structure are unlikely to affect the conduct of the orthodontists' practices.

4. RELATED PARTY TRANSACTIONS

The Company currently shares office space and several support employees
with one of its shareholders. The shareholder has advanced the pro rata share of
these costs to the Company. Such amounts which are $8,598 and $48,642 for the
period August 14, 1996, date of inception, to December 31, 1996 and for the nine
month period ending September 30, 1997, respectively, have been reflected in
general and administrative expenses in the accompanying statement of operations.
The Company believes that the consideration being paid to this related party
reflects the fair market value of the services being provided to the Company.

One of the Company's shareholders has funded expenses of the Company from
the date of inception to date. Such amounts are classified as a long-term
liability in the accompanying balance sheets as the

F-23
91
ORTHODONTIX, INC.
(A DEVELOPMENT STAGE CORPORATION)

NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)

shareholder has agreed not to demand repayment of such amounts until the Company
completes the Transaction as described in Note 6.

5. CONTINGENCIES

The Company will be subject to certain government regulation at the federal
and state levels. In compliance with certain regulatory requirements, the
Company will not control the practice of orthodontics. Long-term service
agreements may be challenged by certain states as to their legality. There can
also be no assurance that the laws and regulations of the states in which the
Company will maintain operations will not change or be interpreted in the future
to restrict the Company's relationships with orthodontists.

Although the Company will not employ orthodontists or control the practice
of orthodontists, the Company intends to acquire certain liability insurance for
itself since the orthodontists may be subject to legal liability suits while
under service agreement with the Company.

6. SUBSEQUENT EVENT

On May 6, 1997, the Company entered into a letter of intent with Embassy
Acquisition Corp., a Florida corporation ("Embassy"), regarding a business
combination of the Company and Embassy (the "Transaction").

Embassy was formed in November 1995 to serve as a vehicle to effect a
merger, exchange of capital stock, asset acquisition or other similar business
combination with an operating company. In April 1996, Embassy consummated an
initial public offering of its equity securities from which it derived net
proceeds of approximately $7.1 million of which $6.8 million was held in escrow
at September 30, 1997 pending the consummation of a business combination.
Embassy has conducted no operations to date other than in connection with its
efforts to effect a business combination.

As of October 30, 1997, the Company and Embassy entered into an Agreement
and Plan of Merger and Reorganization (the "Agreement") regarding the
Transaction. Pursuant to the Agreement, the parties shall engage in the
Transaction, which at closing will result in the Company becoming a wholly owned
subsidiary corporation of Embassy. The Transaction will be treated as a capital
transaction equivalent to the issuance of stock by the Company for the net
monetary assets of Embassy accompanied by a recapitalization.

Concurrently with the consummation of the Merger, the Company will exchange
cash and shares of Embassy common stock for certain assets and liabilities of
the Founding Practices as discussed in Note 3.

In July 1997, the Company entered into a loan agreement with a bank for a
$500,000 line of credit to fund the Company's permanent working capital. The
Company may borrow, repay and reborrow from time to time as long as the total
indebtedness does not exceed the principal amount. All amounts outstanding are
due and payable on demand. The line of credit will accrue interest, payable
monthly, on the unpaid balance at the LIBOR market index rate plus 2% (7.6250%
at September 30, 1997). As of September 30, 1997, the Company had approximately
$314,000 available under the line of credit. A limited partnership, the sole
limited partner of which is Stephen J. Dresnick, M.D., who, upon consummation of
the Merger is contemplated to be the Chairman of the Company, collateralized the
Company's repayment obligation under the line of credit.

F-24
92

APPENDIX A

AGREEMENT AND PLAN OF MERGER AND REORGANIZATION dated as of October 30,
1997 (the "Agreement") by and among Embassy Acquisition Corp., a Florida
corporation ("Embassy") and Orthodontix, Inc., a Florida corporation
("Orthodontix").

R E C I T A L S

The respective Boards of Directors of Embassy and Orthodontix deem it
desirable and in the best interests of their respective corporations, and of
their respective shareholders, that prior to the Closing (as defined in Section
6.1), Embassy form a wholly owned subsidiary corporation, namely, Orthodontix
Acquisition Corp., a Florida corporation ("Acquisition") and that at the
Closing, subject to, among other things, the approval of the shareholders of
Embassy and Orthodontix, Acquisition merge with and into Orthodontix; as a
result of which Orthodontix will become a wholly owned subsidiary corporation of
Embassy, and the holders of shares of capital stock of Orthodontix will, in the
aggregate, receive the consideration hereinafter set forth (collectively, the
"Merger"). Upon the terms and subject to the conditions of this Agreement, at
the Effective Date (as defined in Section 2.3 of this Agreement) in accordance
with the Florida Business Corporation Act ("BCA"), Acquisition shall be merged
with and into Orthodontix and the separate existence of Acquisition shall
thereupon cease. Orthodontix shall be the surviving corporation in the Merger
and is hereinafter sometimes referred to as the "Surviving Corporation." As a
result of the Merger, among other things, Orthodontix will become a wholly owned
subsidiary corporation of Embassy.

NOW, THEREFORE, in consideration of the terms, conditions, agreements and
covenants contained herein, and in reliance upon the representations and
warranties contained in this Agreement, the parties hereto agree as follows:

I. RECITALS; TRUE AND CORRECT

The above stated recitals are true and correct and are incorporated into
this Agreement.

II. MERGER

2.1 Merger. In the manner and subject to the terms and conditions set
forth herein, Embassy shall cause Acquisition to merge with and into
Orthodontix, and Orthodontix shall be the surviving corporation after the Merger
and shall continue to exist as a corporation created and governed by the laws of
Florida.

2.2 Name Change. Upon the Closing of the Merger, Embassy shall change its
name to Orthodontix, Inc. and Orthodontix, Inc. shall change its name to
Orthodontix Subsidiary, Inc. (the "Name Change").

2.3 Effective Date. If all of the conditions precedent to the obligations
of each of the parties hereto as hereinafter set forth shall have been satisfied
or shall have been waived, the Merger shall become effective on the date (the
"Effective Date") the Articles of Merger, together with Plans of Merger
reflecting the Merger, shall be accepted for filing by the Secretary of State of
Florida.

2.4 Securities of the Corporations. The authorized capital stock of
Orthodontix is comprised of 100,000,000 shares of Common Stock, par value $.0001
per share (the "Orthodontix Stock"), of which 1,300,000 shares are issued and
outstanding, excluding the approximately 2,000,000 shares of Orthodontix Stock,
assuming an Embassy share value of $8.00 per share, issuable in connection with
the Practice Acquisitions (as defined in Section 2.7 of this Agreement). The
authorized capital stock of Embassy is comprised of 100,000,000 shares of Common
Stock, par value $.0001 per share (the "Embassy Stock"), of which 2,540,000
shares are issued and outstanding. In addition, Embassy has issued and
outstanding, warrants to purchase 120,000 shares of Embassy Stock for a period
of five years at any time and from time to time commencing April 2, 1996 at a
purchase price of $7.80 per share (the "Embassy Warrants").

A-1
93

2.5 Shares of the Constituent and Surviving Corporations. The manner and
basis of converting the shares of Orthodontix Stock into shares of Embassy Stock
shall be as follows:

Consideration. At the Effective Date, by virtue of the Merger and
without any action on the part of any holder of any capital stock of either
Embassy or Orthodontix, each share of Orthodontix Stock issued and
outstanding shall be converted into the right to receive one share of
Embassy Stock (the "Exchange Ratio"). In connection with the consummation
of the Practice Acquisitions, Embassy shall issue shares of Embassy Stock
as required under the agreements regarding the Practice Acquisitions.

2.6 Effect of the Merger. As of the Effective Date, all of the following
shall occur:

(a) The separate existence and corporate organization of Acquisition
shall cease (except insofar as it may be continued by statute), and
Orthodontix shall continue to exist as the surviving corporation, a wholly
owned subsidiary corporation of Embassy, which shall also continue to exist
as a surviving corporation.

(b) Except as otherwise specifically set forth herein, the corporate
identity, existence, purposes, powers, franchises, rights and immunities of
Orthodontix shall continue unaffected and unimpaired by the Merger, and the
corporate identity, existence, purposes, powers, franchises and immunities
of Acquisition shall be merged with and into Orthodontix as the surviving
corporation, shall be fully vested therewith.

(c) Neither the rights of creditors nor any liens upon or security
interests in the property of any of Acquisition or Orthodontix shall be
impaired by the Merger.

(d) All corporate acts, plans, policies, agreements approvals and
authorizations of the shareholders and Board of Directors of Acquisition
and of its respective officers, directors and agents, which were valid and
effective immediately prior to the Effective Date, shall be the acts,
plans, policies, agreements, approvals and authorizations of Orthodontix
and shall be as effective and binding on Orthodontix as the same were on
Acquisition.

(e) Orthodontix shall be liable for all of the obligations and
liabilities of Acquisition.

(f) The rights, privileges, goodwill, inchoate rights, franchises and
property, real, personal and mixed, and debts due on whatever account and
all other things in action belonging to Acquisition, shall be, and they
hereby are, bargained, conveyed, granted, confirmed, transferred, assigned
and set over to and vested in Orthodontix, without further act or deed.

(g) No claim pending at the Effective Date by or against any of
Acquisition or Orthodontix, or any stockholder, officer or director
thereof, shall abate or be discontinued by the Merger, but may be enforced,
prosecuted, settled or compromised as if the Merger had not occurred.

(h) All rights of employees and creditors and all liens upon the
property of each of Acquisition and Orthodontix shall be preserved
unimpaired, limited in lien to the property affected by such liens at the
Effective Date, and all the debts, liabilities and duties of each of
Acquisition shall attach to Orthodontix and shall be enforceable against
Orthodontix, respectively, to the same extent as if all such debts,
liabilities and duties had been incurred or contracted by Orthodontix.

(i) The Articles of Incorporation of Embassy, as in effect on the
Effective Date, shall continue to be the Articles of Incorporation of
Embassy without change or amendment, except (i) to change the name of
Embassy to "Orthodontix, Inc."; and (ii) to authorize the issuance of
100,000,000 shares of Preferred Stock, par value $.0001 per share (the
"Preferred Stock"), with rights, preferences and designations to be
determined by the Board of Directors of Embassy until such time, if ever,
as it is amended thereafter in accordance with the provisions thereof and
applicable laws. The Articles of Incorporation of Orthodontix, as in effect
on the Effective Date, shall continue to be the Articles of Incorporation
of Orthodontix without change or amendment, except to change the name of
Orthodontix to "Orthodontix Subsidiary, Inc."

A-2
94

(j) The Bylaws of Embassy, as in effect on the Effective Date, shall
continue to be the Bylaws of Embassy without change or amendment until such
time, if ever, as it is amended thereafter in accordance with the
provisions thereof and applicable laws.

(k) Upon the Effective Date, the Board of Directors of Embassy shall
consist of four designees of Orthodontix, Stephen J. Dresnick ("Dresnick"),
Glenn L. Halpryn ("Halpryn"), and one designee of Embassy to be specified
in the Proxy Statement hereinafter referred to, and the officers of Embassy
shall be the officers specified by Orthodontix to hold such offices, as set
forth in the Proxy Statement hereinafter defined. Subsequent to the
Effective Date, the management of Embassy shall be conducted in accordance
with that certain Agreement attached hereto as Schedule 2.6(k).

2.7 Disclosure Schedules. Prior to the execution of this Agreement, (a)
Orthodontix delivered to Embassy a schedule relating to Orthodontix and the
several pending acquisitions of orthodontic practices (the "Practices")
contemplated to be consummated on or prior to the Effective Date (the "Practice
Acquisitions") as well as other due diligence information (collectively, the
"Orthodontix Disclosure Schedule") incorporated by reference hereby; and (b)
Embassy delivered to Orthodontix, Embassy's (i) Annual Report on Form 10-KSB for
the fiscal year ended December 31, 1996; (ii) Quarterly Report on Form 10-QSB
for the quarters ended June 30, 1997, March 31, 1997, June 30, 1996 and
September 30, 1996; and (iii) Prospectus dated April 2, 1996 (collectively, the
"Embassy Disclosure Schedule" and together with the Orthodontix Disclosure
Schedule (the "Disclosure Schedules", referred to as Exhibit "A") setting forth
the matters required to be set forth in the Disclosure Schedules as described
elsewhere in this Agreement. The Disclosure Schedules shall be deemed to be a
part of this Agreement.

2.8 Practice Acquisitions. On the Effective Date, the Practice
Acquisitions shall be consummated, which practices had generated, gross cash
collections, in the aggregate, no less than $15 million for the twelve month
period ended December 31, 1996 (unaudited). Pursuant to the terms of the various
agreements regarding the Practice Acquisitions, in connection with the Practice
Acquisitions, at the Closing, Embassy shall (i) provide to Orthodontix
sufficient cash (the "Cash Consideration") for the purpose of consummating the
Practice Acquisitions; and (ii) issue that aggregate number of shares of Embassy
Stock equal to the quotient of (x) the difference between the aggregate purchase
price of the Practices less the Cash Consideration divided by (y) the Share
Value. The term Share Value shall mean the average of the closing bid and ask
price, as reported on the OTC Electronic Bulletin Board or similar quotation
board of Embassy Stock for the 15 trading days immediately preceding the date of
the Closing.

III. CONDUCT OF BUSINESS PENDING CLOSING; STOCKHOLDER APPROVAL

Orthodontix and Embassy covenant that between the date hereof and the date
of the Closing:

3.1 Access to Orthodontix. Orthodontix shall (a) give to Embassy and to
Embassy's counsel, accountants and other representatives reasonable access,
during normal business hours, throughout the period prior to the Closing Date
(as defined in Section 6.1), to all of the books, contracts, commitments and
other records of Orthodontix and shall furnish Embassy during such period with
all information concerning Orthodontix that Embassy may reasonably request; and
(b) afford to Embassy and to Embassy's representatives, agents, employees and
independent contractors reasonable access, during normal business hours, to the
properties of Orthodontix, in order to conduct inspections at Embassy's expense
to determine that Orthodontix is operating in compliance with all applicable
federal, state, local and foreign statutes, rules and regulations, and all
material building, fire and zoning laws or regulations and that the assets of
Orthodontix, including any assets to be acquired in connection with the Practice
Acquisitions, are substantially in the condition and of the capacities
represented and warranted in this Agreement; provided, however, that in every
instance described in (a) and (b), Embassy shall make arrangements with
Orthodontix reasonably in advance and shall use its best efforts to avoid
interruption and to minimize interference with the normal business and
operations of Orthodontix. Any such investigation or inspection by Embassy shall
not be deemed a waiver of, or otherwise limit, the representations, warranties
or covenants of Orthodontix contained herein.

A-3
95

3.2 Conduct of Business. During the period from the date hereof to the
Closing Date, Orthodontix shall and shall use reasonable efforts, to the extent
such efforts are within Orthodontix's control, to cause the practices to be
acquired in connection with the Practice Acquisitions (the "Practices") to be
operated in the usual and ordinary course of business and in material compliance
with the terms of this Agreement. Without limiting the generality of the
foregoing:

(a) Orthodontix shall and shall use reasonable efforts, to the extent
such efforts are within Orthodontix's control, to cause the Practices to
use reasonable efforts consistent with past practices to preserve the
respective businesses and organizations of Orthodontix and the Practices,
respectively, including using reasonable efforts to cause the Practice
Acquisitions to close, so as to (i) keep available the services of their
present employees and agents; (ii) complete or maintain all of the
Orthodontix Contracts (as hereinafter defined) in full force and effect in
accordance with their existing terms, materially unimpaired by litigation;
(iii) maintain the integrity of all confidential information; (iv) maintain
in full force and effect the existing insurance policies (or policies
providing substantially the same coverage, copies of which shall be made
available to Embassy) insuring the business and properties of Orthodontix
and the Practices, respectively; and (v) preserve the goodwill of, and
business and contractual relationships with, suppliers, customers and
others having business relationships with Orthodontix and the Practices
respectively; except for such changes which, in the aggregate, would not
have a material adverse effect on the business, prospects or financial
condition of Orthodontix and the Practices, respectively, taken as a whole;
and

(b) Orthodontix shall not and shall use reasonable efforts, to the
extent such efforts are within Orthodontix's control, to cause the
Practices not to (i) sell or transfer any of their material assets or
property except (A) as set forth in the Orthodontix Disclosure Schedule, or
(B) in the usual and ordinary course of business; or, (ii) except for cash
applied in payment of liabilities or credits given in the usual and
ordinary course of business, make any distribution, whether by dividend or
otherwise, to any of its shareholders or employees except for (A)
compensation to employees in the usual and ordinary course of business; (B)
payments on the Orthodontix Indebtedness (as hereinafter defined). Without
limiting the generality of the foregoing, Orthodontix shall: (i) comply in
all material respects with all laws applicable to it; and (ii) except as
provided above or otherwise in this Agreement, not declare any dividend or
other distribution, redeem or otherwise acquire any shares of its capital
stock or other securities, sell or issue any shares of its capital stock or
other securities or agree to do any of the foregoing.

3.3 Exclusivity to Embassy. Neither Orthodontix nor its respective
officers, directors, representatives or agents, as appropriate, from the date
hereof until the Closing or the earlier termination of this Agreement, shall
solicit any inquiries, proposals or offers to purchase the business of
Orthodontix or the shares of capital stock of Orthodontix, from any person other
than Embassy. Any person inquiring as to the availability of the business or
shares of capital stock of Orthodontix or making an offer therefor shall be told
that Orthodontix is bound by the provisions of this Agreement. Orthodontix as
well as its officers, directors, representatives or agents further agree to
advise Embassy promptly of any such inquiry or offer.

3.4 Access to Embassy. Embassy shall (a) give to Orthodontix and to
Orthodontix's counsel, accountants and other representatives reasonable access,
during normal business hours, throughout the period prior to the Closing Date,
to all of the books, contracts, commitments and other records of Embassy and
shall furnish Orthodontix during such period with all information concerning
Embassy that Orthodontix may reasonably request; and (b) afford to Orthodontix
and to Orthodontix's representatives, agents, employees and independent
contractors reasonable access, during normal business hours, to the properties
of Embassy in order to conduct inspections at Orthodontix's expense to determine
that Embassy is operating in compliance with all applicable federal, state,
local and foreign statutes, rules and regulations, and all material building,
fire and zoning laws or regulations and that the assets of Embassy are
substantially in the condition and of the capacities represented and warranted
in this Agreement; provided, however, that in every instance described in (a)
and (b), Orthodontix shall make arrangements with Embassy reasonably in advance
and shall use its best efforts to avoid interruption and to minimize
interference with the normal business and operations of Embassy. Any such
investigation or inspection by Orthodontix shall not be deemed a waiver of, or
otherwise limit, the representations, warranties or covenants of Embassy
contained herein.
A-4
96

3.5 Conduct of Business. During the period from the date hereof to the
Closing Date, the business of Embassy shall be operated by Embassy in the usual
and ordinary course of such business and in material compliance with the terms
of this Agreement. Without limiting the generality of the foregoing:

(a) Embassy shall (i) comply in all material respects with all laws
applicable to it; (ii) not declare any dividend or other distribution,
redeem or otherwise acquire any shares of its capital stock or other
securities, sell or issue any shares of its capital stock or other
securities other than with respect to the Embassy Warrants, or agree to do
any of the foregoing; (iii) not make any payments to any of its employees
other than reimbursement of accountable expenses in the ordinary course of
business in accordance with past practices; (iv) not make any payments,
loans or other distribution to any officer, director, employee or agent or
prepay any obligations due to any of the foregoing; and (v) not expend nor
incur any liabilities or indebtedness, direct or indirect, or enter into
any agreements or commitments with respect to same, aggregating more than
$30,000 during the period between the date hereof and the Closing Date
exclusive of (i) costs and expenses relating to the consummation of the
transactions contemplated by this Agreement; (ii) any understandings
relating to funding the purchase of shares of Embassy Stock offered for
redemption to Embassy by its non-affiliated shareholders in the manner
contemplated by the Proxy Statement; and (iii) liabilities based on
applications for directors' and officers' liability insurance; and

(b) Embassy shall timely file all reports required to be filed by it
with the Securities and Exchange Commission (the "SEC").

3.6 Exclusivity to Orthodontix. Embassy and its officers, directors,
representatives or agents, as appropriate, shall not, from the date hereof until
the Closing or the earlier termination of this Agreement, solicit any inquiries,
proposals or offers to purchase the business of Embassy or the shares of capital
stock of Embassy from any person other than Orthodontix. Any person inquiring as
to the availability of the business or shares of capital stock of Embassy or
making an offer therefor shall be told that Embassy is bound by the provisions
of this Agreement. Each of Embassy and its officers, directors, representatives
or agents further agree to advise Orthodontix promptly of any such inquiry or
offer.

3.7 Stockholder Approval. (a) As promptly as reasonably practicable
following the date of this Agreement, Embassy shall take all action reasonably
necessary in accordance with the Securities Exchange Act of 1934, as amended
(the "Exchange Act"), the laws of the State of Florida and its Articles of
Incorporation and Bylaws to call, give notice of and convene a meeting (the
"Meeting") of its shareholders to consider and vote upon the approval and
adoption of (i) the Merger; (ii) the amendment to Embassy's Articles of
Incorporation effectuating the Name Change and the authorization to issue the
Preferred Stock; (iii) the 1997 Embassy Acquisition Corp. Stock Option Plan (the
"Stock Option Plan"); and (iv) such other matters as shall properly come before
the Meeting in connection with this Agreement. The approval and adoption of this
Agreement and the Merger by the Board of Directors and the shareholders of
Orthodontix in accordance with the laws of the State of Florida, Articles of
Incorporation and Bylaws and the receipt of the approvals and consents referred
to in Section 7.9 is a condition precedent to the undertaking and obligation of
Embassy to mail its definitive Proxy Statement (as hereinafter defined) subject
to, among other things, approval by the shareholders of Embassy to its
shareholders and to hold the Meeting. The Board of Directors of Embassy shall
unanimously recommend that Embassy's shareholders vote to approve and adopt the
Merger, this Agreement and any other matters to be submitted to Embassy's
shareholders in connection therewith. Embassy shall, subject as aforesaid, use
its best efforts to solicit and secure from shareholders of Embassy such
approval and adoption.

(b) Certain shareholders of Embassy, as evidenced by their signature on the
signature page of this Agreement, agree that if a majority of the non-affiliated
shareholders of Embassy approve and adopt the Merger and this Agreement, they
will each vote all of their respective shares of Embassy Stock for the approval
and adoption of the Merger and this Agreement.

(c) As promptly as reasonably practicable following the date of this
Agreement, Embassy shall prepare and file with the SEC under the Securities Act
of 1933, as amended (the "Securities Act"), and the rules and regulations
promulgated by the SEC thereunder: a registration statement on Form S-4 (or
other form of
A-5
97

registration statement as agreed by the parties) covering (i) all shares of
Embassy Stock issuable as a consequence of the Merger, including the shares
issuable in connection with the Practice Acquisitions (the "Initial Registration
Statement"). Prior to such filing, Orthodontix shall supply to Embassy, for
inclusion in the Initial Registration Statement, the Financial Statements (as
hereinafter defined). Concurrent with the filing of the Initial Registration
Statement, Embassy shall also prepare and file with the SEC under the Securities
Act and the rules and regulations promulgated by the SEC thereunder, a
preliminary proxy statement (the "Proxy Statement"; the Proxy Statement and the
Initial Registration Statement are collectively referred to as the "Registration
Statement") pertaining to the Merger. Orthodontix shall cooperate fully with
Embassy in the preparation and filing of the Registration Statement and any
amendments and supplements thereto, including, without limitation, the
furnishing to Embassy of such information regarding Orthodontix as shall be
required by each of the Securities Act and the Exchange Act and the respective
rules and regulations promulgated by the SEC thereunder. The Registration
Statement shall not be filed, and no amendment or supplement thereto shall be
made by Embassy, without prior consultation with and the consent of Orthodontix,
which consent shall not be unreasonably withheld or delayed. As promptly as
reasonably practicable following the date of this Agreement, Embassy shall cause
to be mailed a definitive Proxy Statement to its shareholders entitled to vote
at the Meeting promptly following completion of any review by, or in the absence
of such review, the termination of any applicable waiting period of, the SEC and
the SEC's declaration of effectiveness of the Registration Statement under the
Securities Act.

(d) As promptly as practicable but in no event later than the Effective
Date, Embassy shall prepare and file with the NASDAQ Small Cap Market
("Nasdaq"), an application to have the Embassy Stock listed for trading on
Nasdaq.

(e) As promptly as practicable, Embassy shall prepare and file with the SEC
under the Securities Act and the rules and regulations promulgated by the SEC
thereunder, a Registration Statement on Form S-8 covering the Embassy Stock
issuable upon the exercise of certain stock options to be granted under the
Stock Option Plan (the "S-8 Registration Statement").

3.8 Formation and Acts of Acquisition. No later than the date of the
Meeting, Embassy shall cause Acquisition to be incorporated under the laws of
Florida. Prior to the Closing Date, Embassy shall cause Acquisition to engage in
no activity other than activity in anticipation of the Merger. At the Closing,
following satisfaction of the conditions precedent set forth in this Agreement,
Embassy shall cause Acquisition to execute Articles of Merger referred to in
Section 2.1.

IV. REPRESENTATIONS AND WARRANTIES OF ORTHODONTIX

Orthodontix represents and warrants to Embassy as follows, with the
knowledge and understanding that Embassy is relying materially upon such
representations and warranties:

4.1 Organization and Standing. Orthodontix is a corporation duly
organized, validly existing and in good standing under the laws of the state of
Florida. Orthodontix has all requisite corporate power to carry on its business
as it is now being conducted and is duly qualified to do business as a foreign
corporation and is in good standing in each jurisdiction where such
qualification is necessary under applicable law, except where the failure to
qualify (individually or in the aggregate) does not have any material adverse
effect on the assets, business or financial condition of Orthodontix, and all
states in which each is qualified to do business as of the date hereof, are
listed in the Orthodontix Disclosure Schedule. The copies of the Articles of
Incorporation and Bylaws of Orthodontix, as amended to date, delivered to
Embassy, are true and complete copies of these documents as now in effect.
Except as otherwise set forth in the Orthodontix Disclosure Schedule,
Orthodontix does not own any interest in any other corporation, business trust
or similar entity. The minute book of Orthodontix contains accurate records of
all meetings of its respective Board of Directors and shareholders since its
incorporation.

4.2 Capitalization. The authorized capital stock of Orthodontix, the
number of shares of capital stock which are issued and outstanding and par value
thereof are as set forth in the Orthodontix Disclosure Schedule. All of such
shares of capital stock are duly authorized, validly issued and outstanding,
fully paid and

A-6
98

nonassessable, and were not issued in violation of the preemptive rights of any
person. There are no subscriptions, options, warrants, rights or calls or other
commitments or agreements to which Orthodontix is a party or by which it is
bound, calling for any issuance, transfer, sale or other disposition of any
class of securities of Orthodontix. There are no outstanding securities
convertible or exchangeable, actually or contingently, into shares of common
stock or any other securities of Orthodontix. Orthodontix has no subsidiaries.

4.3 Authority. This Agreement constitutes, and all other agreements
contemplated hereby will constitute, when executed and delivered by Orthodontix
in accordance therewith (and assuming due execution and delivery by the other
parties hereto), the valid and binding obligation of Orthodontix, enforceable in
accordance with their respective terms, subject to general principles of equity
and bankruptcy or other laws relating to or affecting the rights of creditors
generally.

4.4 Properties. Except as set forth on the Orthodontix Disclosure
Schedule, Orthodontix has good title to all of the assets and properties which
it purports to own as reflected on the balance sheet included in the Financial
Statements (as hereinafter defined), or thereafter acquired. Orthodontix has a
valid leasehold interest in all material property of which it is the lessee and
each such lease is valid, binding and enforceable against Orthodontix, as the
case may be, and, to the knowledge of Orthodontix, the other parties thereto in
accordance with its terms. Neither Orthodontix nor the other parties thereto are
in material default in the performance of any material provisions thereunder.
Neither the whole nor any material portion of the assets of Orthodontix is
subject to any governmental decree or order to be sold or is being condemned,
expropriated or otherwise taken by any public authority with or without payment
of compensation therefor, nor, to the knowledge of Orthodontix, any such
condemnation, expropriation or taking been proposed. None of the assets of
Orthodontix is subject to any restriction which would prevent continuation of
the use currently made thereof or materially adversely affect the value thereof.

4.5 Contracts Listed; No Default. All contracts, agreements, licenses,
leases, easements, permits, rights of way, commitments, and understandings,
written or oral, connected with or relating in any respect to present or
proposed future operations of Orthodontix (except employment or other agreements
terminable at will and other agreements which, in the aggregate, are not
material to the business, properties or prospects of Orthodontix and except
governmental licenses, permits, authorizations, approvals and other matters
referred to in Section 4.17), which would be required to be listed as exhibits
to a Registration Statement on Form S-4 or an Annual Report on Form 10-K if
Orthodontix were subject to the reporting requirements of the Exchange Act
(individually, the "Orthodontix Contract" and collectively, the "Orthodontix
Contracts"), are listed and described in the Orthodontix Disclosure Schedule.
Orthodontix is the holder of, or party to, all of the Orthodontix Contracts. To
the knowledge of Orthodontix, the Orthodontix Contracts are valid, binding and
enforceable by the signatory thereto against the other parties thereto in
accordance with their terms. Neither Orthodontix nor any signatory thereto is in
default or breach of any material provision of the Orthodontix Contracts.
Orthodontix's operation of its business has been, is, and will, between the date
hereof and the Closing Date, continue to be, consistent with the material terms
and conditions of the Orthodontix Contracts. Attached hereto as Schedule 4.5 is
a list of those Orthodontix Contracts regarding the Practice Acquisitions which
contain termination dates earlier than the Termination Date (as defined in
Section 10.1 of this Agreement).

4.6 Litigation. Except as disclosed in the Orthodontix Disclosure
Schedule, there is no claim, action, proceeding or investigation pending or, to
the knowledge of Orthodontix, threatened against or affecting Orthodontix before
or by any court, arbitrator or governmental agency or authority which, in the
reasonable judgment of Orthodontix, could have any materially adverse effect on
Orthodontix. There are no decrees, injunctions or orders of any court,
governmental department, agency or arbitration outstanding against Orthodontix.

4.7 Taxes. For purposes of this Agreement, (A) "Tax" (and, with
correlative meaning, "Taxes") shall mean any federal, state, local or foreign
income, alternative or add-on minimum, business, employment, franchise,
occupancy, payroll, property, sales, transfer, use, value added, withholding or
other tax, levy, impost, fee, imposition, assessment or similar charge, together
with any related addition to tax, interest, penalty or fine

A-7
99

thereon; and (B) "Returns" shall mean all returns (including, without
limitation, information returns and other material information), reports and
forms relating to Taxes or to any benefit plans.

Orthodontix has duly filed all Returns required by any law or regulation to
be filed by it, except for extensions duly obtained. All such Returns were, when
filed, and to the knowledge of Orthodontix are, accurate and complete in all
material respects and were prepared in conformity with applicable laws and
regulations in all material respects. Orthodontix has paid or will pay in full
or has adequately reserved against all Taxes otherwise assessed against it
through the Closing Date, and the assessment of any material amount of
additional Taxes in excess of those paid and reported is not reasonably
expected.

Orthodontix is not a party to any pending action or proceeding by any
governmental authority for the assessment of any Tax, and no claim for
assessment or collection of any Tax has been asserted against Orthodontix that
has not been paid. There are no Tax liens upon the assets (other than the lien
of property taxes not yet due and payable) of Orthodontix. There is no valid
basis, to the knowledge of Orthodontix, except as set forth in the Orthodontix
Disclosure Schedule, for any assessment, deficiency, notice, 30-day letter or
similar intention to assess any Tax to be issued to Orthodontix by any
governmental authority.

4.8 Compliance with Laws and Regulations. To its knowledge, Orthodontix is
in compliance, in all material respects, with all laws, rules, regulations,
orders and requirements (federal, state and local) applicable to it in all
jurisdictions where the business of Orthodontix is currently conducted or to
which Orthodontix is currently subject which has a material impact on
Orthodontix, including, without limitation, all applicable civil rights and
equal opportunity employment laws and regulations, and all state and federal
antitrust and fair trade practice laws and the Federal Occupational Health and
Safety Act. Orthodontix knows of no assertion by any party that Orthodontix is
in violation of any such laws, rules, regulations, orders, restrictions or
requirements with respect to its current operations, and no notice in that
regard has been received by Orthodontix. To the knowledge of Orthodontix, there
is not presently pending any proceeding, hearing or investigation with respect
to the adoption of amendments or modifications to existing laws, rules,
regulations, orders, restrictions or requirements which, if adopted, would
materially adversely affect the current operations of Orthodontix.

4.9 Compliance with Laws. (a) To its knowledge, the business, operations,
property and assets of Orthodontix and the Practices (and, to the knowledge of
Orthodontix, the business of any sub-tenant or licensee which is occupying or
has occupied any space on any premises of Orthodontix and the activities of
which could result in any material adverse liability to Orthodontix) (i) conform
with and are in compliance in all material respects with all, and are not in
material violation of any applicable federal, state and local laws, rules and
regulations, including, but not limited to, the Comprehensive Environmental
Response Compensation and Liability Act of 1980, as amended (including the 1986
Amendments thereto and the Superfund Amendments and Reauthorization Act)
("CERCLA"), and the Resource Conservation and Recovery Act ("RCRA"), as well as
any other laws, rules or regulations relating to tax, product liability,
controlled substances, product registration, environmental protection, hazardous
or toxic waste, employment, or occupational safety matters; and (ii) have been
conducted and operated in a manner such that, to Orthodontix's knowledge,
Orthodontix has foreseeable potential liabilities for environmental clean-up
under CERCLA, RCRA or under any other law, rule, regulation or common or civil
law doctrine.

(b) To its knowledge, no predecessor-in-title to any real property now or
previously owned or operated by Orthodontix, nor any predecessor operator
thereof conducted its business or operated such property in violation of CERCLA
and RCRA or any other applicable federal, state and local laws, rules and
regulations relating to environmental protection or hazardous or toxic waste
matters.

(c) Except as disclosed in the Orthodontix Disclosure Schedule, no suit,
action, claim, proceeding, nor investigation, review or inquiry by any court or
federal, state, county, municipal or local governmental department, commission,
board, bureau, agency or instrumentality, including, without limitation, any
state or local health department (all of the foregoing collectively referred to
as "Governmental Entity") concerning any such possible violations by Orthodontix
is pending or, to the knowledge of Orthodontix, threatened, including, but not
limited to, matters relating to diagnostic tests and products and product
liability, environmental protection, hazardous or toxic waste, controlled
substances, employment, occupational safety or
A-8
100

tax matters. Orthodontix does not know of any reasonable basis or ground for any
such suit, claim, investigation, inquiry or proceeding. For purposes of this
Section 4.9, the term "inquiry" includes, without limitation, all pending
regulatory issues (whether before federal, state, local or inter-governmental
regulatory authorities) concerning any regulated product, including, without
limitation, any diagnostic drugs and products.

4.10 Reserved.

4.11 Condition of Assets. The equipment, fixtures and other personal
property of Orthodontix, including the assets to be acquired in connection with
the Practice Acquisitions, taken as a whole, is in good operating condition and
repair (ordinary wear and tear excepted) for the conduct of the business of
Orthodontix as is contemplated to be conducted.

4.12 No Breaches. To its knowledge, the making and performance of this
Agreement and the other agreements contemplated hereby by Orthodontix will not
(i) conflict with or violate the Articles of Incorporation or the Bylaws of
Orthodontix; (ii) violate any material laws, ordinances, rules or regulations,
or any order, writ, injunction or decree to which Orthodontix is a party or by
which Orthodontix or any of its respective assets, businesses, or operations may
be bound or affected; or (iii) result in any breach or termination of, or
constitute a default under, or constitute an event which, with notice or lapse
of time, or both, would become a default under, or result in the creation of any
encumbrance upon any asset of Orthodontix under, or create any rights of
termination, cancellation or acceleration in any person under, any Orthodontix
Contract.

4.13 Employees. Except as set forth in the Orthodontix Disclosure
Schedule, none of the employees of Orthodontix is represented by any labor union
or collective bargaining unit and, to the knowledge of Orthodontix, no
discussions are taking place with respect to such representation.

4.14 Financial Statements. To its knowledge, the Orthodontix Disclosure
Schedule contains, as to Orthodontix, an unaudited balance sheet as of December
31, 1996 and related statements of operations, statements of cash flows and
statements of shareholders' equity of Orthodontix for the one-year period ended
December 31, 1996 and an unaudited balance sheet as of September 30, 1997 and
related statements of operations, statements of cash flows and statement of
shareholders' equity for the nine-month period ended September 30, 1997
(collectively, the "Financial Statements"). The Financial Statements present
fairly, in all respects, the consolidated financial position and results of
operations of Orthodontix as of the dates and periods indicated, prepared in
accordance with generally accepted accounting principles consistently applied
("GAAP"). The Financial Statements, when submitted to Embassy for inclusion in
the Registration Statement, will have been prepared in accordance with
Regulation S-X of the SEC and, in particular, Rules 1-02 and 3-05 promulgated
thereunder. Without limiting the generality of the foregoing, (i) there is no
basis for any assertion against Orthodontix as of the date of the Financial
Statements of any debt, liability or obligation of any nature not fully
reflected or reserved against in the Financial Statements; and (ii) there are no
assets of Orthodontix as of the date of the Financial Statements, the value of
which is overstated in the Financial Statements. Except as disclosed in the
Financial Statements, Orthodontix has no known contingent liabilities (including
liabilities for Taxes), forward or long-term commitments or unrealized or
anticipated losses from unfavorable commitments other than in the ordinary
course of business. Orthodontix is not a party to any contract or agreement for
the forward purchase or sale of any foreign currency that is material to
Orthodontix taken as a whole.

4.15 Absence of Certain Changes or Events. Except as set forth in the
Orthodontix Disclosure Schedule, since December 31, 1996, there has not been:

(a) any material adverse change in the financial condition,
properties, assets, liabilities or business of Orthodontix;

(b) any material damage, destruction or loss of any material
properties of Orthodontix, whether or not covered by insurance;

A-9
101

(d) any material change in the treatment and protection of trade
secrets or other confidential information of Orthodontix;

(e) any material change in the business or contractual relationship of
Orthodontix with any customer or supplier which might reasonably be
expected to materially and adversely affect the business or prospects of
Orthodontix;

(f) any agreement by Orthodontix, whether written or oral, to do any
of the foregoing; and

(g) any occurrence not included in paragraphs (a) through (f) of this
Section 4.16 which has resulted, or which Orthodontix has reason to
believe, in its reasonable judgment, might be expected to result, in a
material adverse change in the business or prospects of Orthodontix.

4.16 Governmental Licenses, Permits, Etc. To its knowledge, Orthodontix
and the Practices each have all governmental licenses, permits, authorizations
and approvals necessary for the conduct of its business as currently conducted
("Licenses and Permits"). The Orthodontix Disclosure Schedule includes a list of
all Licenses and Permits. All Licenses and Permits are in full force and effect,
and no proceedings for the suspension or cancellation of any thereof is pending
or threatened.

4.17 Employee Agreements. (a) For purposes of this Agreement, the
following definitions apply:

(1) "ERISA" means the Employee Retirement Income Security Act of 1974,
as amended, and any regulations promulgated thereunder.

(2) "Multi-employer Plan" means a plan, as defined in ERISA Section
3(37), to which Orthodontix contributes or is required to contribute.

(3) "Employee Plan" means any pension, retirement, profit sharing,
deferred compensation, vacation, bonus, incentive, medical, vision, dental,
disability, life insurance or any other employee benefit plan as defined in
Section 3(3) of ERISA other than a Multi-employer Plan to which Orthodontix
contributes, sponsors, maintains or otherwise is bound to with regard to
any benefits on behalf of the employees of Orthodontix.

(4) "Employee Pension Plan" means any Employee Plan for the provision
of retirement income to employees or which results in the deferral of
income by employees extending to the termination of covered employment or
beyond as defined in Section 3(2) of ERISA.

(5) "Employee Welfare Plan" means any Employee Plan other than an
Employee Pension Plan.

(6) "Compensation Arrangement" means any plan or compensation
arrangement other than an Employee Plan, whether written or unwritten,
which provides to employees of Orthodontix, former employees, officers,
directors or shareholders of Orthodontix any compensation or other
benefits, whether deferred or not, in excess of base salary or wages,
including, but not limited to, any bonus or incentive plan, stock rights
plan, deferred compensation arrangement, life insurance, stock purchase
plan, severance pay plan and any other employee fringe benefit plan.

(b) The Orthodontix Disclosure Schedule hereto lists, all (1) employment
agreements and collective bargaining agreements to which Orthodontix is a party;
(2) Compensation Arrangements of Orthodontix; (3) Employee Welfare Plans; (4)
Employee Pension Plans; and (5) consulting agreements under which Orthodontix
has or may have any monetary obligations to employees or consultants of
Orthodontix or their beneficiaries or legal representatives or under which any
such persons may have any rights. Orthodontix has previously made available to
Embassy true and complete copies of all of the foregoing employment contracts,
collective bargaining agreements, Employee Plans and Compensation Arrangements,
including descriptions of any unwritten contracts, agreements, Compensation
Arrangements or Employee Plans, as amended to date. In addition, with respect to
any Employee Plan which continues after the Closing Date, Orthodontix has
previously delivered or made available to Embassy (1) any related trust
agreements, master trust agreements, annuity contracts or insurance contracts;
(2) certified copies of all Board of Directors' resolutions adopting such plans
and trust documents and amendments thereto; (3) current investment management
agreements; (4) custodial agreements; (5) fiduciary liability insurance
policies; (6) indemnification agreements; (7) the
A-10
102

most recent determination letter (and underlying application thereof and
correspondence and supplemental material related thereto) issued by the Internal
Revenue Service with respect to the qualification of each Employee Plan under
the provisions of Section 401(a) of the Code; (8) copies of all "advisory
opinion letters," "private letter rulings," "no action letters," and any similar
correspondence (and the underlying applications therefor and correspondence and
supplemental material related thereto) that was issued by any governmental or
quasigovernmental agency with respect to the last plan year; (9) Annual Reports
(Form 5500 Series) and Schedules A and B thereto for the last plan year; (10)
all actuarial reports prepared for the last plan year; (11) all certified
Financial Statements for the last plan year; and (12) all current Summary Plan
Descriptions, Summaries of Material Modifications and Summary Annual Reports.
All documents delivered by Orthodontix to Embassy as photocopies faithfully
reproduce the originals thereof, such originals are authentic and were, to the
extent execution was required, duly executed.

(1) It is not a party to and has, in effect or to become effective
after the date of this Agreement, any bonus, cash or deferred compensation,
severance, medical, health or hospitalization, pension, profit sharing or
thrift, retirement, stock option, employee stock ownership, life or group
insurance, death benefit, welfare, incentive, vacation, sick leave,
cafeteria, so-called "golden parachute" payment, disability or trust
agreement or arrangement.

4.18 Brokers. Orthodontix has not made any agreement or taken any action
with any person or taken any action which would cause any person to be entitled
to any agent's, broker's or finder's fee or commission in connection with the
transactions contemplated by this Agreement.

4.19 Business Locations. Orthodontix does not nor shall it in connection
with the Practice Acquisitions own or lease any real or personal property in any
state except as set forth on the Orthodontix Disclosure Schedule. Orthodontix
does not have a place of business (including, without limitation, Orthodontic's
executive offices or place where Orthodontic's books and records are kept)
except as otherwise set forth on the Orthodontix Disclosure Schedule.

4.20 Intellectual Property. The Orthodontix Disclosure Schedule lists all
of the Intellectual Property (as hereinafter defined) used by Orthodontix which
constitutes a material patent, trade name, trademark, service mark or
application for any of the foregoing. "Intellectual Property" means all of
Orthodontix's right, title and interest in and to all patents, trade names,
assumed names, trademarks, service marks, and proprietary names, copyrights
(including any registration and pending applications for any such registration
for any of them), together with all the goodwill relating thereto and all other
intellectual property of Orthodontix. Other than as disclosed in the Orthodontix
Disclosure Schedule, Orthodontix does not have any licenses granted by or to it
or other agreements to which it is a party, relating in whole or in part to any
Intellectual Property, whether owned by Orthodontix or otherwise. All of the
patents, trademark registrations and copyrights listed in the Orthodontix
Disclosure Schedule that are owned by Orthodontix are valid and in full force
and effect. To the knowledge of Orthodontix, it is not infringing upon, or
otherwise violating, the rights of any third party with respect to any
Intellectual Property. No proceedings have been instituted against or claims
received by Orthodontix, nor to its knowledge are any proceedings threatened
alleging any such violation, nor does Orthodontix know of any valid basis for
any such proceeding or claim. To the knowledge of Orthodontix, there is no
infringement or other adverse claims against any of the Intellectual Property
owned or used by Orthodontix. To the knowledge of Orthodontix, its use of
software does not violate or otherwise infringe the rights of any third party.

4.21 Warranties. The Orthodontix Disclosure Schedule sets forth a true and
complete list of the forms of all express warranties and guaranties made by
Orthodontix to third parties with respect to any services rendered by
Orthodontix.

4.22 Suppliers. Except as set forth in the Orthodontix Disclosure
Schedule, Orthodontix knows and has no reason to believe that, either as a
result of the transactions contemplated hereby or for any other reason
(exclusive of expiration of a contract upon the passage of time), any present
material supplier of Orthodontix

A-11
103

or the Practices will not continue to conduct business with Orthodontix or the
Practices, as the case may be as applicable, after the Closing Date in
substantially the same manner as it has conducted business prior thereto.

4.23 Accounts Receivable. The accounts receivable reflected on the balance
sheets included in the Financial Statements, or thereafter acquired by
Orthodontix, consists, in the aggregate in all material respects, of items which
are collectible in the ordinary and usual course of business.

4.24 Governmental Approvals. To its knowledge, other than as set forth
herein, no authorization, license, permit, franchise, approval, order or consent
of, and no registration, declaration or filing by Orthodontix with, any
governmental authority, federal, state or local, is required in connection with
Orthodontix's execution, delivery and performance of this Agreement.

4.25 No Omissions or Untrue Statements. None of the information relating
to Orthodontix supplied or to be supplied in writing by it specifically for
inclusion in the Registration Statement, at the respective times that the
Registration Statement becomes effective (or any registration statement included
therein), the Proxy Statement is first mailed to Embassy's shareholders and the
meeting of Embassy's shareholders takes place, as the case may be, contains or
will contain any untrue statement of a material fact or omits or will omit to
state a material fact required to be stated therein or necessary in order to
make the statements therein, in light of the circumstances under which they were
made, not misleading. Embassy shall give notice to Orthodontix in advance of the
dates of such effectiveness, mailing and meeting sufficient to permit
Orthodontix to fulfill its obligations under the second sentence of this
Section.

4.26 Orthodontix Disclosure Schedule Complete. Orthodontix shall promptly
supplement the Orthodontix Disclosure Schedule if events occur prior to the
Closing Date that would have been required to be disclosed had they existed at
the time of executing this Agreement. The Orthodontix Disclosure Schedule, as
supplemented prior to the Closing Date, will contain a true, correct and
complete list and description of all items required to be set forth therein. The
Orthodontix Disclosure Schedule, as supplemented prior to the Closing Date, is
expressly incorporated herein by reference. Notwithstanding the foregoing, any
such supplement to the Orthodontix Disclosure Schedule following the date hereof
shall not in any way affect Embassy's right not to consummate the transactions
contemplated hereby as set forth in Section 8.2 hereof.

V. REPRESENTATIONS AND WARRANTIES OF EMBASSY

Embassy represents and warrants to Orthodontix as follows, with the
knowledge and understanding that Orthodontix is relying materially on such
representations and warranties:

5.1 Organization and Standing of Embassy. Embassy is a corporation duly
organized, validly existing and in good standing under the laws of the State of
Florida, and has the corporate power to carry on its business as now conducted
and to own its assets and it not required to qualify to transact business as a
foreign corporation in any state or other jurisdiction. The copies of the
Articles of Incorporation and Bylaws of Embassy, delivered to Orthodontix, are
true and complete copies of those documents as now in effect. Embassy does not
own any capital stock in any other corporation, business trust or similar
entity, and is not engaged in a partnership, joint venture or similar
arrangement with any person or entity. The minute books of Embassy contain
accurate records of all meetings of its incorporator, shareholders and Board of
Directors since its date of incorporation.

5.2 Acquisition. Acquisition when formed by Embassy for the purposes
hereinabove set forth, will be a corporation duly organized, validly existing
and in good standing under the laws of Florida, respectively, and will have the
corporate power to carry on its business as herein contemplated and to own its
assets. True and correct copies of the Articles of Incorporation and Bylaws of
Acquisition will be delivered to Orthodontix prior to the Closing. The
authorized capital stock of Acquisition will consist of 1,000 shares of Common
Stock, par value $.0001 per share of which 100 shares of Acquisition will be
issued and outstanding on the Closing Date and owned of record and beneficially
by Embassy. Other than as stated in this section, on the Closing Date there will
be no outstanding securities convertible or exchangeable, actually or
contingently, into shares of Common Stock or other stock of Acquisition. Prior
to the Merger Acquisition will not engage in any business

A-12
104

other than to serve as a vehicle to implement the Merger, and will have no
assets, operations or liabilities of any kind.

5.3 Embassy's Authority. Embassy's Board of Directors has approved and
adopted this Agreement and the Merger and has resolved to recommend approval and
adoption of this Agreement and the Merger by Embassy's shareholders. This
Agreement constitutes, and all other agreements contemplated hereby will
constitute, when executed and delivered by Embassy in accordance herewith (and
assuming due execution and delivery by the other parties hereto), the valid and
binding obligations of Embassy, enforceable in accordance with their respective
terms, subject to general principles of equity and bankruptcy or other laws
relating to or affecting the rights of creditors generally.

5.4 No Breaches. To its knowledge, the making and performance of this
Agreement (including, without limitation, the issuance of the Embassy Stock) by
Embassy will not (i) conflict with the Articles of Incorporation or the Bylaws
of Embassy; (ii) violate any order, writ, injunction, or decree applicable to
Embassy; or (iii) result in any breach or termination of, or constitute a
default under, or constitute an event which, with notice or lapse of time, or
both, would become a default under, or result in the creation of any encumbrance
upon any asset of Embassy under, or create any rights of termination,
cancellation or acceleration in any person under, any agreement, arrangement or
commitment, or violate any provisions of any laws, ordinances, rules or
regulations or any order, writ, injunction or decree to which Embassy is a party
or by which Embassy or any of its assets may be bound.

5.5 Capitalization. The Embassy Stock consists of 100,000,000 shares of
common stock, par value $.0001 per share, of which 2,540,000 shares are issued
and outstanding; and Embassy Warrants to purchase 120,000 shares of Embassy
Stock for a period of five years at any time and from time to time commencing
April 2, 1996 at a purchase price of $7.80 per share. All of the outstanding
Embassy Stock is duly authorized, validly issued, fully paid and nonassessable,
and was not issued in violation of the preemptive rights of any person. The
Embassy Stock to be issued upon effectiveness of the Merger, when issued in
accordance with the terms of this Agreement, as well as the Embassy Stock to be
issued upon the exercise of Embassy's outstanding Embassy Warrants, when issued
in accordance with the terms of the agreements governing each issuance, shall be
duly authorized, validly issued, fully paid and nonassessable. Other than as
stated in this Section 5.5, there are no outstanding subscriptions, options,
warrants, calls or rights of any kind issued or granted by, or binding upon,
Embassy, to purchase or otherwise acquire any shares of capital stock of
Embassy, or other equity securities or equity interests of Embassy or any debt
securities of Embassy. There are no outstanding securities convertible or
exchangeable, actually or contingently, into shares of Embassy Stock or other
stock of Embassy, and as to the Embassy Warrants, there are no additional shares
of Embassy Stock issuable upon exercise thereof as a result of Embassy's
issuance of its shares delivered in connection with the Merger. Notwithstanding
the foregoing, the parties acknowledge that the Options granted hereunder
contain certain anti-dilution provisions.

5.6 Business. Embassy, since its formation, has engaged in no business
other than to seek to serve as a vehicle for the acquisition of an operating
business, and, except for this Agreement, is not a party to any contract or
agreement for the acquisition of an operating business.

5.7 Governmental Approval; Consents. To its knowledge, except for the
reports required to be filed in the future by Embassy, as a reporting company,
under the Exchange Act, and under the Securities Act with respect to the shares
of Embassy Stock issuable upon exercise of the Embassy Warrants, the filing of
the Registration Statement under the Securities Act, the Proxy Statement under
the Exchange Act for the purpose of seeking stockholder approval of the Merger
referred to in Section 2.1 and the issuance of the Embassy Stock pursuant to the
Merger and the filing of the S-4 Registration Statement (or other form of
registration statement as agreed by the parties), no authorization, license,
permit, franchise, approval, order or consent of, and no registration,
declaration or filing by Embassy with, any governmental authority, federal,
state or local, is required in connection with Embassy's execution, delivery and
performance of this Agreement. No consents of any other parties are required to
be received by or on the part of Embassy to enable Embassy to enter into and
carry out this Agreement.

A-13
105

5.8 Financial Statements. To its knowledge, the financial statements of
Embassy included in Embassy's SEC Reports, as hereinafter defined (collectively,
the "Embassy Financial Statements") present fairly, in all material respects,
the financial position of Embassy as of the respective dates and the results of
its operations for the periods covered in accordance with GAAP. Without limiting
the generality of the foregoing, (i) except as set forth in the Embassy
Disclosure Schedule, there is no basis for any assertion against Embassy as of
the date of said balance sheets of any material debt, liability or obligation of
any nature not fully reflected or reserved against in such balance sheets or in
the notes thereto; and (ii) there are no assets of Embassy, the value of which
(in the reasonable judgment of Embassy) is materially overstated in said balance
sheets. Except as disclosed therein, Embassy has no known material contingent
liabilities (including liabilities for taxes), unusual forward or long-term
commitments or unrealized or anticipated losses from unfavorable commitments.
Embassy is not a party to any contract or agreement for the forward purchase or
sale of any foreign currency.

5.9 Adverse Developments. Except as expressly provided or set forth in, or
required by, this Agreement, or as set forth in the Embassy Financial
Statements, since December 31, 1995, there have been no materially adverse
changes in the assets, liabilities, properties, operations or financial
condition of Embassy, and no event has occurred other than in the ordinary and
usual course of business or as set forth in Embassy's SEC Reports or in the
Embassy Financial Statements which could be reasonably expected to have a
materially adverse effect upon Embassy, and Embassy does not know of any
development or threatened development of a nature that will, or which could be
reasonably expected to, have a materially adverse effect upon Embassy's
operations or future prospects.

5.10 Embassy's U.S. Securities and Exchange Commission Reports. The
Embassy Stock was registered under Section 12 of the Exchange Act on Form 8-A.
Since its inception, Embassy and each of its officers and directors has filed
all reports, registrations and other documents, together with any amendments
thereto, required to be filed under the Securities Act and the Exchange Act,
including, but not limited to, proxy statements and reports on Form 10-KSB, Form
10-QSB and Form 8-K, and Embassy and each of its officers and directors will
file all such reports, registrations and other documents required to be filed by
it from the date of this Agreement to the Closing Date (all such reports,
registrations and documents, including registrations and documents voluntarily
filed or to be filed with the SEC, with the exception of the Registration
Statement and the Proxy Statement, are collectively referred to as "Embassy's
SEC Reports"). As of their respective dates, Embassy's SEC Reports complied or
will comply in all material respects with all rules and regulations promulgated
by the SEC and did not or will not contain any untrue statement of a material
fact or omit to state a material fact required to be stated therein or necessary
in order to make the statements therein, in light of the circumstances under
which they were made, not misleading. As part of the Embassy Disclosure
Schedule, Embassy has provided to Orthodontix a true and complete copy of all of
Embassy's SEC Reports filed on or prior to the date hereof, and will promptly
provide to Orthodontix a true and complete copy of any such reports filed after
the date hereof and on or prior to the Closing Date.

5.11 Contracts Listed; No Default. All material contracts, agreements,
licenses, leases, easements, permits, rights of way, commitments, and
understandings, written or oral, connected with or relating in any respect to
the present operations of Embassy are, with the exception of this Agreement,
described in Embassy's SEC Reports. All of such contracts, agreements, leases,
commitments and understandings, written or oral, and any other contract,
agreement, lease, commitment or understanding, written or oral, binding upon
Embassy, are listed in the Embassy Disclosure Schedule (the "Embassy
Contracts"). To the knowledge of Embassy, the Embassy Contracts are valid,
binding and enforceable by Embassy against the other parties thereto in
accordance with their terms. Neither Embassy nor, to the knowledge of Embassy,
any of the other parties thereto is in default or breach of any material
provision of the Embassy Contracts. Embassy has furnished Orthodontix with a
true and complete copy of each Embassy Contract, as amended.

5.12 Taxes. Embassy has duly filed all Returns required by any law or
regulation to be filed by it except for extensions duly obtained. All such
Returns were, when filed, and to the best of Embassy's knowledge are, accurate
and complete in all material respects and were prepared in conformity with
applicable laws and regulations. Embassy has paid or will pay in full or has
adequately reserved against all Taxes otherwise

A-14
106

assessed against it through the Closing Date, and the assessment of any material
amount of additional Taxes in excess of those paid and reported is not
reasonably expected.

Embassy is not a party to any pending action or proceeding by any
governmental authority for the assessment of any Tax, and no claim for
assessment or collection of any Tax has been asserted against Embassy that has
not been paid. There are no Tax liens upon the assets of Embassy (other than the
lien of personal property taxes not yet due and payable). There is no valid
basis, to the best of Embassy's knowledge, except as set forth in the Embassy
Disclosure Schedule, for any assessment, deficiency, notice, 30-day letter or
similar intention to assess any Tax to be issued to Embassy by any governmental
authority.

5.13 Litigation. Except as disclosed in the Embassy Disclosure Schedule,
there is no claim, action, proceeding or investigation pending or, to Embassy's
knowledge, threatened against or affecting Embassy before or by any court,
arbitrator or governmental agency or authority which, in the reasonable judgment
of Embassy, could have a materially adverse effect on Embassy. There are no
decrees, injunctions or orders of any court, governmental department, agency or
arbitration outstanding against Embassy.

5.14 Compliance with Laws and Regulations. To its knowledge, Embassy is in
compliance, in all material respects, with all laws, rules, regulations, orders
and requirements (federal, state and local) applicable to it in all
jurisdictions in which the business of Embassy is currently conducted or to
which Embassy is currently subject, which may have a material impact on Embassy,
including, without limitation, all applicable civil rights and equal opportunity
employment laws and regulations, all state and federal antitrust and fair trade
practice laws and the Federal Occupational Health and Safety Act. Embassy does
not know of any assertion by any party that Embassy is in violation of any such
laws, rules, regulations, orders, restrictions or requirements with respect to
its current operations, and no notice in that regard has been received by
Embassy. To Embassy's knowledge, there is not presently pending any proceeding,
hearing or investigation with respect to the adoption of amendments or
modifications of existing laws, rules, regulations, orders, restrictions or
requirements which, if adopted, would materially adversely affect the current
operations of Embassy.

5.15 Compliance with Laws. (a) To its knowledge, the business operations,
property and assets of Embassy (and to the knowledge of Embassy, the business of
any sub-tenant or license which is occupying or has occupied any space on any
premises of Embassy and the activities of which could result in any material
adverse liability to Embassy) (i) conform with and are in compliance in all
material respects with all, and are not in material violation of any applicable
federal, state and local laws, rules and regulations, including, but not limited
to, CERCLA and RCRA, as well as any other laws, rules or regulations relating to
tax, product liability, controlled substances, product registration,
environmental protection, hazardous or toxic waste, employment, or occupational
safety matters; and (ii) have been conducted and operated in a manner such that,
to Embassy's knowledge, Embassy has no foreseeable potential liabilities for
environmental clean-up under CERCLA, RCRA or under any law, rule, regulation or
common or civil law doctrine.

(b) To its knowledge, no predecessor-in-title to any real property now or
previously owned or operated by Embassy, nor any predecessor operator thereof
conducted its business or operated such property in violation of CERCLA and RCRA
or any other applicable, federal, state and local laws, rules and regulations
relating to environmental protection or hazardous or toxic waste matters.

(c) Except as disclosed in the Embassy Disclosure Schedule, no suit,
action, claim, proceeding nor investigation review or inquiry by any Government
Entity (as defined in Section 4.9) concerning any such possible violations by
Embassy is pending or, to Embassy's knowledge, threatened, including, but not
limited to, matters relating to diagnostic tests and products and product
liability, environmental protection, hazardous or toxic waste, controlled
substances, employment, occupational safety or tax matters. Embassy does not
know of any reasonable basis or ground for any such suit, claim, investigation,
inquiry or proceeding.

5.16 Governmental Licenses, Permits, Etc. To its knowledge, Embassy has
all governmental licenses, permits, authorizations and approvals necessary for
the conduct of its business as currently conducted. All such licenses, permits,
authorizations and approvals are in full force and effect, and no proceedings
for the suspension or cancellation of any thereof is pending or threatened.

A-15
107

5.17 Brokers. Embassy has not made any agreement or taken any action with
any person or taken any action which would cause any person to be entitled to
any agent's, broker's or finder's fee or commission in connection with the
transactions contemplated by this Agreement.

5.18 Employee Plans. Except as listed in Embassy's SEC Reports, Embassy
has no employees, consultants or agents, and Embassy has no Employee Plans or
Compensation Arrangements.

5.19 Registration Statement and Proxy Statement. To its knowledge, the
Registration Statement and the Proxy Statement will comply with, and will be
distributed in accordance with, as applicable, the BCA, the Securities Act and
the Exchange Act and all rules and regulations of the SEC promulgated under such
acts, and state securities or blue sky laws. At the time that the Registration
Statement (or any registration statement included therein) becomes effective,
the Proxy Statement is first mailed to Embassy's shareholders and the meeting of
Embassy's shareholders takes place, as the case may be, neither the Registration
Statement nor the Proxy Statement will contain any untrue statement of a
material fact or omit to state a material fact required to be stated therein or
necessary in order to make the statements therein, in light of the circumstances
under which they were made, not misleading; provided, however, that this
representation shall not be deemed to apply to information included in the
Registration Statement or the Proxy Statement relating to Orthodontix which was
furnished by Orthodontix to Embassy for use in the Registration Statement and
the Proxy Statement and which was made in conformity with the information so
furnished.

5.20 Accounts. Embassy has previously disclosed to Orthodontix a list of
all banks and other institutions in which Embassy maintains an account
(including checking, savings, cash management, brokerage, money market or any
other type of account) or safe deposit box, the address and telephone of such
bank or other institution, the name of Embassy's contact person with respect to
such account or safe deposit box, the account number of each such account, and
the names of all person authorized to make draws on such accounts or who have
access to such safe deposit boxes.

5.21 OTC Bulletin Board. The Embassy Stock is quoted on the OTC Bulletin
Board (the "Bulletin Board") under the symbol "MBCA," and Embassy is in
compliance in all material respects with all rules and regulations of the
Bulletin Board applicable to Embassy and the inclusion for quotation of such
securities on the Bulletin Board.

5.22 Nasdaq SmallCap Market. Embassy shall prepare and file with the
Nasdaq Small Cap Market no later than the Effective Date, an application to have
the Embassy Stock listed for trading on Nasdaq SmallCap.

5.23 No Omissions or Untrue Statements. No representations or warranties
made by Embassy to Orthodontix in this Agreement or in any certificate of a
Embassy officer required to be delivered to Orthodontix pursuant to the terms of
this Agreement contains or will contain any untrue statement of a material fact,
omits or will omit to state a material fact necessary to make the statement
contained herein or therein not misleading as of the date hereof and as of the
Closing Date.

5.24 Embassy Disclosure Schedule Complete. Embassy shall promptly
supplement the Embassy Disclosure Schedule if events occur prior to the Closing
Date that would have been required to be disclosed had they existed at the time
of executing this Agreement. The Embassy Disclosure Schedule, as supplemented
prior to the Closing Date, will contain a true, correct and complete list and
description of all items required to be set forth therein. The Embassy
Disclosure Schedule, as supplemented prior to the Closing Date, is expressly
incorporated herein by reference. Notwithstanding the foregoing, any such
supplement to the Embassy Disclosure Schedule following the date hereof shall
not in any way affect Orthodontix's right not to consummate the transactions
contemplated hereby as set forth in Section 6.2 hereof.

VI. STOCKHOLDER APPROVAL; CLOSING DELIVERIES

6.1 Stockholder Approval. Embassy shall submit the Merger and this
Agreement to its shareholders for approval and adoption at the Meeting to be
held as soon as practicable following the date or this Agreement in accordance
with Section 3.7 hereof. Subject to the Merger and this Agreement receiving all
approvals of

A-16
108

Embassy and Orthodontix shareholders and regulatory approvals and the absence of
30% or more of the non-affiliated shareholders of Embassy (i) voting against the
Merger; and (ii) requesting redemption of their shares of Embassy Stock in the
manner to be set forth in the Proxy Statement, and subject to the other
provisions of this Agreement, the parties shall hold a closing (the "Closing")
no later than the fifth business day (or such later date as the parties hereto
may agree) following the later of (a) the date of the Meeting of Shareholders of
Embassy to consider and vote upon the Merger and this Agreement and the Name
Change or (b) the business day on which the last of the conditions set forth in
Articles VII and VIII hereof is fulfilled or waived (such later date, the
"Closing Date"), at 10:00 A.M. at the offices of Berman Wolfe & Rennert, P.A.,
or at such other time and place as the parties may agree upon.

6.2 Closing Deliveries of Orthodontix. At the Closing, Orthodontix shall
deliver, or cause to be delivered, to Embassy:

(a) a certificate dated as of the Closing Date, to the effect that the
representations and warranties of Orthodontix contained in this Agreement
are true and correct in all material respects at and as of the Closing Date
and that Orthodontix has complied with or performed in all material
respects all terms, covenants and conditions to be complied with or
performed by Orthodontix on or prior to the Closing Date;

(b) an opinion of Orthodontix's counsel, Atlas, Pearlman, Trop &
Borkson, P.A., in form and substance reasonably satisfactory to Embassy, in
a form to be mutually agreed to prior to the Closing;

(c) a certificate, dated as of the Closing Date, certifying as to the
Articles of Incorporation and Bylaws of Orthodontix, the incumbency and
signatures of the officers of each of Orthodontix and copies of the
directors' and shareholders' resolutions of Orthodontix approving and
authorizing the execution and delivery of this Agreement, and the
consummation of the transactions contemplated hereby;

(d) the First Union Consent (as defined in Section 7.9) as well as any
other applicable consents contemplated by the Orthodontix Disclosure
Schedule;

(e) an agreement, in a form reasonably satisfactory to Orthodontix and
to Embassy and in substantially the form as Exhibit "B" (the "Orthodontix
Lock-Up Agreement"), prohibiting, for a period of fifteen months from the
Effective Date, all holders of the outstanding shares of Orthodontix Stock,
exclusive of the shares issuable in connection with the Practice
Acquisitions, from selling, transferring or otherwise disposing of the
Embassy Stock received by each of them pursuant to the Merger (the "Embassy
Acquired Stock");

(f) a letter executed by an authorized representative of Orthodontix
listing those persons who may be deemed "affiliates" of Orthodontix within
the meaning of Rule 145 under the Securities Act of 1933; and

(g) such other documents, at the Closing or subsequently, as may be
reasonably requested by Embassy as necessary for the implementation and
consummation of this Agreement and the transactions contemplated hereby.

6.3 Closing Deliveries of Embassy. At the Closing, Embassy shall deliver
to Orthodontix:

(a) a certificate of Embassy, dated as of the Closing Date, to the
effect that the representations and warranties of Embassy contained in this
Agreement are true and correct in all material respects and that Embassy
has complied with or performed in all material respects all terms,
covenants and conditions to be complied with or performed by Embassy on or
prior to the Closing Date;

(b) a certificate, dated as of the Closing Date, executed by the
Secretary of Embassy, certifying the Articles of Incorporation, Bylaws,
incumbency and signatures of officers of Embassy and copies of Embassy's
directors' and shareholders' resolutions approving and authorizing the
execution and delivery of this Agreement and the consummation of the
transactions contemplated hereby;

(c) an opinion of Embassy's counsel, Berman Wolfe & Rennert, P.A., in
form and substance reasonably satisfactory to Orthodontix, in a form to be
mutually agreed to prior to the Closing;
A-17
109

(d) the written resignations of all officers, and all directors of
Embassy other than Halpryn and Dresnick.

(e) certificates representing the Embassy Stock issuable upon
consummation of the Merger;

(f) agreements, in form reasonably satisfactory to Orthodontix and to
Embassy and in substantially the form of Exhibits "C" and "D" attached
hereto (the "Embassy Lock-Up Agreements") prohibiting, for a period of six
months from the Effective Date (the "Six Month Period"), Dresnick, Halpryn,
Ronald M. Stein, Craig A. Brumfield and Andrew H. Marshak from selling,
transferring or otherwise disposing their shares of Embassy Common Stock,
and limiting the transfer or other disposition of the Embassy Common Stock
by Dresnick and Halpryn for a period of nine months following the Six Month
Period;

(g) the books and records of Embassy; and

(h) documentation satisfactory to Orthodontix evidencing the fact that
the signatories on all relevant bank accounts of Embassy have been changed
to signatories designated by Orthodontix.

VII. CONDITIONS TO OBLIGATIONS OF ORTHODONTIX

The obligation of Orthodontix to consummate the Closing is subject to the
following conditions, any of which may be waived by Orthodontix in its sole
discretion:

7.1 Compliance by Embassy. Embassy shall have performed and complied in
all material respects with all agreements and conditions required by this
Agreement to be performed or complied with by Embassy prior to or on the Closing
Date.

7.2 Accuracy of Embassy's Representations. Embassy's representations and
warranties contained in this Agreement (including the Embassy Disclosure
Schedule) or any schedule, certificate or other instrument delivered pursuant to
the provisions hereof or in connection with the transactions contemplated hereby
shall be true and correct in all material respects at and as of the Closing Date
(except for such changes permitted by this Agreement) and shall be deemed to be
made again as of the Closing Date.

7.3 Material Adverse Change. No material adverse change shall have
occurred subsequent to December 31, 1996 in the financial position, results of
operations, assets, liabilities or prospects of Embassy, nor shall any event or
circumstance have occurred which would result in a material adverse change in
the financial position, results of operations, assets, liabilities or prospects
of Embassy within the reasonable discretion of Orthodontix.

7.4 Documents. All documents and instruments delivered by Embassy to
Orthodontix at the Closing shall be in form and substance reasonably
satisfactory to Orthodontix and its counsel.

7.5 Capitalization. At the Closing Date, Embassy shall have, other than
with respect to the issuance of shares underlying the Embassy Warrants, not more
than 2,540,000 shares of Embassy Stock issued and outstanding.

7.6 Effectiveness of Registration Statement; No Stop Order. The
Registration Statement shall be effective under the Securities Act and shall not
be subject to a stop order or any threatened stop order.

7.7 Reorganization. The Merger shall qualify as a tax-free reorganization
under Section 368 of the Code.

7.8 Litigation. No litigation seeking to enjoin the transactions
contemplated by this Agreement or to obtain damages on account hereof shall be
pending or, to Orthodontix's knowledge, be threatened.

7.9 Certain Consents. Orthodontix shall have received from First Union
Bank (the "First Union Consent") (and any other applicable consents contemplated
by the Embassy Disclosure Schedule) a consent in writing, in form and substance
reasonably satisfactory to Embassy and its counsel, to Orthodontix's entry into
this Agreement and consummation of the Merger.

A-18
110

7.10 Nasdaq SmallCap Market. An application to have the shares of Embassy
Stock quoted for trading on the Nasdaq SmallCap Stock Market shall have been
filed by Embassy.

7.11 Cash Assets. Embassy shall have cash assets of no less than $7.2
million at the Closing, exclusive of any amounts payable in connection with the
Practice Acquisitions and inclusive of any redemption amounts payable to Embassy
shareholders.

VIII. CONDITIONS TO EMBASSY'S OBLIGATIONS

Embassy's obligation to consummate the closing is subject to the following
conditions, any of which may be waived by Embassy in its sole discretion:

8.1 Compliance by Orthodontix. Orthodontix shall have performed and
complied in all material respects with all agreements and conditions required by
this Agreement to be performed or complied with prior to or on the Closing Date.

8.2 Accuracy of Orthodontix's Representations. Orthodontix's
representations and warranties contained in this Agreement (including the
exhibits hereto and the Embassy Disclosure Schedule) or any schedule,
certificate or other instrument delivered pursuant to the provisions hereof or
in connection with the transactions contemplated hereby shall be true and
correct in all material respects at and as of the Closing Date (except for such
changes permitted by this Agreement) and shall be deemed to be made again as of
the Closing Date.

8.3 Material Adverse Change. No material adverse change shall have
occurred subsequent to December 31, 1996 in the financial position, results of
operations, assets, liabilities or prospects of Orthodontix taken as a whole,
nor shall any event or circumstance have occurred which would result in a
material adverse change in the business, assets or condition, financial or
otherwise, of Orthodontix taken as a whole, within reasonable discretion of
Embassy.

8.4 Litigation. No litigation seeking to enjoin the transactions
contemplated by this Agreement or to obtain damages on account hereof shall be
pending or, to Embassy's knowledge, be threatened.

8.5 Reorganization. The Merger shall qualify as a tax-free reorganization
under Section 368 of the Code and there are no material adverse tax consequences
to the Merger.

8.6 Documents. All documents and instruments delivered by Orthodontix to
Embassy at the Closing shall be in form and substance reasonably satisfactory to
Embassy and its counsel.

8.7 Practice Acquisitions. Immediately after the Merger has been effected,
on the Effective Date, Orthodontix shall have consummated the acquisition of
certain tangible and intangible assets of certain orthodontic practices, which,
in the aggregate, generated no less than $15.0 million in gross revenues for the
twelve month period ended December 31, 1996 (the "Practice Gross Revenue
Amount") in consideration for the delivery of cash (the "Practice Acquisition
Cash Amount"); and (ii) that number of shares of Orthodontix Stock equal to the
quotient obtained by (x) the difference between 1.2 times the Practice Gross
Revenue Amount and the Practice Cash Amount divided by (y) the Embassy Share
Value. For purposes of this calculation, the Embassy Share Value shall mean the
average over a period of 15 trading days of the closing prices of Embassy Stock
as reflected on the OTC Bulletin Board.

8.8 Liabilities. At the Closing Date, Orthodontix shall have no more than
$500,000 in total liabilities, exclusive of the Practice Acquisition Cash
Amount.

IX. INDEMNIFICATION

9.1 By Orthodontix. Subject to Section 9.4, Orthodontix shall indemnify,
defend and hold Embassy, its directors, officers, shareholders, attorneys,
agents and affiliates, harmless from and against any and all losses, costs,
liabilities, damages, and expenses (including legal and other expenses incident
thereto) of every kind, nature and description, including any undisclosed
liabilities (collectively, "Losses") that result from or arise

A-19
111

out of (i) the breach of any representation or warranty of Orthodontix set forth
in this Agreement or in any certificate delivered to Embassy pursuant hereto; or
(ii) the breach of any of the covenants of Orthodontix contained in or arising
out of this Agreement or the transactions contemplated hereby.

9.2 By Embassy. Subject to Section 9.4, Embassy shall indemnify, defend,
and hold Orthodontix its directors, officers, shareholders, attorneys, agents
and affiliates harmless from and against any and all Losses that arise out of
(i) the breach of any representation or warranty of Embassy set forth in this
Agreement or in any certificate delivered to Orthodontix pursuant hereto; or
(ii) the breach of any of the covenants of Embassy contained in or arising out
of this Agreement or the transactions contemplated hereby.

9.3 Claims Procedure. Should any claim covered by Sections 9.1 or 9.2 be
asserted against a party entitled to indemnification under this Article (the
"Indemnitee"), the Indemnitee shall promptly notify the party obligated to make
indemnification (the "Indemnitor"); provided, however, that any delay or failure
in notifying the Indemnitor shall not affect the Indemnitor's liability under
this Article if such delay or failure was not prejudicial to the Indemnitor. The
Indemnitor upon receipt of such notice shall assume the defense thereof with
counsel reasonably satisfactory to the Indemnitee and the Indemnitee shall
extend reasonable cooperation to the Indemnitor in connection with such defense.
No settlement of any such claim shall be made without the consent of the
Indemnitor and Indemnitee, such consent not to be unreasonably withheld or
delayed, nor shall any such settlement be made by the Indemnitor which does not
provide for the absolute, complete and unconditional release of the Indemnitee
from such claim. In the event that the Indemnitor shall fail, within a
reasonable time, to defend a claim, the Indemnitee shall have the right to
assume the defense thereof without prejudice to its rights to indemnification
hereunder.

9.4 Limitations on Liability. Neither Orthodontix nor Embassy shall be
liable hereunder as a result of any misrepresentation or breach of such party's
representations, warranties or covenants contained in this Agreement unless and
until the Losses incurred by each, as the case may be, as a result of such
misrepresentations or breaches under this Agreement shall exceed, in the
aggregate, $200,000 (in which case the party liable therefor shall be liable for
the entire amount of such claims, including the first $200,000).

X. TERMINATION

10.1 Termination Prior to Closing. (a) If the Closing has not occurred by
March 1, 1998, subject to a 30 day extension by Orthodontix, or any other
extension as agreed by the parties (the "Termination Date"), any of the parties
hereto may terminate this Agreement at any time thereafter by giving written
notice of termination to the other parties; provided, however, that no party may
terminate this Agreement if such party has willfully or materially breached any
of the terms and conditions hereof.

(b) Prior to the Termination Date either party to this Agreement may
terminate this Agreement following the insolvency or bankruptcy of the other, or
if any one or more of the conditions to Closing set forth in Article VI, Article
VII or Article VIII shall become incapable of fulfillment and shall not have
been waived by the party for whose benefit the condition was established, then
either party may terminate this Agreement.

(c) Notwithstanding anything contained herein to the contrary, Embassy
acknowledges that certain of the Practice Acquisitions which in the aggregate
had generated approximately no less than $5.2 million in gross revenues for the
twelve-month period ended December 31, 1996 are required to close on or prior to
March 1, 1998.

10.2 Consequences of Termination. Upon termination of this Agreement
pursuant to this Article X or any other express right of termination provided
elsewhere in this Agreement, the parties shall be relieved of any further
obligation to the others except as specified in Section 12.3. No termination of
this Agreement, however, whether pursuant to this Article X hereof or under any
other express right of termination provided elsewhere in this Agreement, shall
operate to release any party from any liability to any other party incurred
before the date of such termination or from any liability resulting from any
willful misrepresentation made in connection with this Agreement or willful
breach hereof.

A-20
112

XI. ADDITIONAL COVENANTS

11.1 Mutual Cooperation. The parties hereto will cooperate with each
other, and will use all reasonable efforts to cause the fulfillment of the
conditions to the parties' obligations hereunder and to obtain as promptly as
possible all consents, authorizations, orders or approvals from each and every
third party, whether private or governmental, required in connection with the
transactions contemplated by this Agreement. Without limiting the generality of
the foregoing, Orthodontix shall obtain, prior to the Closing, the consent of
all of the recipients of Orthodontix Stock in connection with the Practice
Acquisitions as a condition to closing the Practice Acquisitions.

11.2 Changes in Representations and Warranties of Orthodontix. Between the
date of this Agreement and the Closing Date, Orthodontix shall not, directly or
indirectly, except as contemplated in the Orthodontix Disclosure Schedule, enter
into any transaction, take any action, or by inaction permit an event to occur,
which would result in any of the representations and warranties of Orthodontix
herein contained not being true and correct at and as of (a) the time
immediately following the occurrence of such transaction or event or (b) the
Closing Date. Orthodontix shall promptly give written notice to Embassy upon
becoming aware of (i) any fact which, if known on the date hereof, would have
been required to be set forth or disclosed pursuant to this Agreement and (ii)
any impending or threatened breach in any material respect of any of the
representations and warranties of Orthodontix contained in this Agreement and
with respect to the latter shall use all reasonable efforts to remedy same.

11.3 Changes in Representations and Warranties of Embassy. Between the
date of this Agreement and the Closing Date, Embassy shall not, directly or
indirectly, enter into any transaction, take any action, or by inaction permit
an event to occur, which would result in any of the representations and
warranties of Embassy herein contained not being true and correct at and as of
(a) the time immediately following the occurrence of such transaction or event
or (b) the Closing Date. Embassy shall promptly give written notice to
Orthodontix upon becoming aware of (i) any fact which, if known on the date
hereof, would have been required to be set forth or disclosed pursuant to this
Agreement and (ii) any impending or threatened breach in any material respect of
any of the representations and warranties of Embassy contained in this Agreement
and with respect to the latter shall use all reasonable efforts to remedy same.

XII. MISCELLANEOUS

12.1 Expenses. Orthodontix and Embassy shall each pay its own expenses
incident to the negotiation, preparation and carrying out of this Agreement,
including all fees and expenses of its counsel and accountants for all
activities of such counsel and accountants undertaken pursuant to this
Agreement, whether or not the transactions contemplated hereby are consummated.

12.2 Survival of Representations, Warranties and Covenants. All statements
contained in this Agreement or in any certificate delivered by or on behalf of
Orthodontix or Embassy pursuant hereto or in connection with the transactions
contemplated hereby shall be deemed representations, warranties and covenants by
Orthodontix or Embassy, as the case may be, hereunder. All representations,
warranties and covenants made by Orthodontix and by Embassy in this Agreement,
or pursuant hereto, shall survive through the Closing Date.

12.3 Nondisclosure. Embassy will not at any time after the date of this
Agreement, without Orthodontix' consent, divulge, furnish to or make accessible
to anyone (other than to its representatives as part of its due diligence or
corporate investigation) any knowledge or information with respect to
confidential or secret processes, inventions, discoveries, improvements,
formulae, plans, material, devices or ideas or know-how, whether patentable or
not, with respect to any confidential or secret aspects (including, without
limitation, customers or suppliers) ("Confidential Information") of Orthodontix.

Orthodontix will not at any time after the date of this Agreement, without
Embassy's consent (except as may be required by law), use, divulge, furnish to
or make accessible to anyone any Confidential Information (other than to its
representatives as part of its due diligence or corporate investigation) with
respect to Embassy.
A-21
113

The undertakings set forth in the preceding two paragraphs of this Section
12.3 shall lapse if the Closing takes place as to Embassy and Orthodontix, but
shall not lapse as to the officers and directors of Embassy, individually.

Any information, which (i) at or prior to the time of disclosure by either
of Orthodontix or Embassy was generally available to the public through no
breach of this covenant, (ii) was available to the public on a non-confidential
basis prior to its disclosure by either of Orthodontix or Embassy or (iii) was
made available to the public from a third party, provided that such third party
did not obtain or disseminate such information in breach of any legal obligation
to Orthodontix or Embassy, shall not be deemed Confidential Information for
purposes hereof, and the undertakings in this covenant with respect to
Confidential Information shall not apply thereto.

12.4 Succession and Assignments; Third Party Beneficiaries. This Agreement
may not be assigned (either voluntarily or involuntarily) by any party hereto
without the express written consent of the other party. Any attempted assignment
in violation of this Section shall be void and ineffective for all purposes. In
the event of an assignment permitted by this Section, this Agreement shall be
binding upon the heirs, successors and assigns of the parties hereto. Except as
expressly set forth in this Section, there shall be no third party beneficiaries
of this Agreement.

12.5 Notices. All notices, requests, demands or other communications with
respect to this Agreement shall be in writing and shall be (i) sent by facsimile
transmission, (ii) sent by the United States Postal Service, registered or
certified mail, return receipt requested, or (iii) personally delivered by a
nationally recognized express overnight courier service, charges prepaid, to the
following addresses (or such other addresses as the parties may specify from
time to time in accordance with this Section):

(a) To Embassy:

Embassy Acquisition Corp.
1428 Brickell Avenue, Suite 105
Miami, Florida 33131
Attn: Glenn Halpryn, President

With a copy to:

Charles J. Rennert, Esq.
Berman Wolfe & Rennert, P.A.
NationsBank Tower At International Place
100 Southeast 2nd Street, 35th Floor
Miami, Florida 33131

(b) To Orthodontix:

Orthodontix, Inc.
2222 Ponce de Leon Blvd., PH
Coral Gables, Florida 33134
Attn: F.W. "Mort" Guilford

With a copy to:

Charles Pearlman
Atlas, Pearlman, Trop & Borkson, P.A.
New River Center, Suite 1900
200 East Las Olas Boulevard
Fort Lauderdale, Florida 33301

Any such notice shall, when sent in accordance with the preceding sentence,
be deemed to have been given and received on the earliest of (i) the day
delivered to such address or sent by facsimile transmission, (ii) the fifth
(5th) business day following the date deposited with the United States Postal
Service, or (iii) twenty-four (24) hours after shipment by such courier service.
A-22
114

12.6 Construction. This Agreement shall be construed and enforced in
accordance with the internal laws of the State of Florida without giving effect
to the principles of conflicts of law thereof, except to the extent that the
Securities Act or the Exchange Act applies to the Registration Statements and
the Proxy Statement.

12.7 Counterparts. This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original, but all of which shall
together constitute one and the same Agreement.

12.8 No Implied Waiver; Remedies. No failure or delay on the part of the
parties hereto to exercise any right, power or privilege hereunder or under any
instrument executed pursuant hereto shall operate as a waiver, nor shall any
single or partial exercise of any right, power or privilege preclude any other
or further exercise thereof or the exercise of any other right, power or
privilege. All rights, powers and privileges granted herein shall be in addition
to other rights and remedies to which the parties may be entitled at law or in
equity.

12.9 Entire Agreement. This Agreement, including the Exhibits and
Schedules attached hereto, sets forth the entire understandings of the parties
with respect to the subject matter hereof, and it incorporates and merges any
and all previous communications, understandings, oral or written, as to the
subject matter hereof, and cannot be amended or changed except in writing,
signed by the parties.

12.10 Headings. The headings of the Sections of this Agreement, where
employed, are for the convenience of reference only and do not form a part
hereof and in no way modify, interpret or construe the meanings of the parties.

12.11 Severability. To the extent that any provision of this Agreement
shall be invalid or unenforceable, it shall be considered deleted herefrom and
the remainder of such provision and of this Agreement shall be unaffected and
shall continue in full force and effect.

12.12 Public Disclosure. From and after the date hereof through the
Closing Date, Embassy shall not issue a press release or any other public
announcement with respect to the transactions contemplated hereby without the
prior consent of Orthodontix, which consent shall not be unreasonably withheld
or delayed. It is understood by Orthodontix that Embassy is required under the
Exchange Act to make prompt disclosure of any material transaction.

THE PARTIES TO THIS AGREEMENT HAVE READ THIS AGREEMENT, HAVE HAD THE
OPPORTUNITY TO CONSULT WITH INDEPENDENT COUNSEL OF THEIR OWN CHOICE, AND
UNDERSTAND EACH OF THE PROVISIONS OF THIS AGREEMENT.

A-23
115

IN WITNESS WHEREOF, the parties hereto have executed this Agreement the day
and year first above written.

EMBASSY ACQUISITION CORP.

By: /s/ GLENN L. HALPRYN
------------------------------------
Glenn L. Halpryn
President

ORTHODONTIX, INC.

By: /s/ F.W. MORT GUILFORD
------------------------------------
F.W. Mort Guilford
President

The undersigned agree to the
provisions of
Section 3.7(b) and Section 12.3
hereof:

/s/ GLENN L. HALPRYN
- --------------------------------------
Glenn L. Halpryn

/s/ RONALD M. STEIN
- --------------------------------------
Ronald M. Stein

/s/ CRAIG A. BRUMFIELD
- --------------------------------------
Craig A. Brumfield

/s/ STEPHEN J. DRESNICK, M.D.
- --------------------------------------
Stephen J. Dresnick, M.D.

/s/ ANDREW H. MARSHAK
- --------------------------------------
Andrew H. Marshak

A-24
116

APPENDIX B

RESTATED ARTICLES OF INCORPORATION
OF
EMBASSY ACQUISITION CORP.

Pursuant to Section 607.1007 of the Florida Business Corporation Act, the
undersigned corporation on this date hereby restates its Articles of
Incorporation by deleting therefrom in their entirety Article I through Article
XII and by substituting in their place Article I through Article XI below.

ARTICLE I

NAME

The name of the corporation is Orthodontix, Inc. (the "Corporation").

ARTICLE II

PURPOSE

The Corporation is organized for the purposes of transacting any or all
lawful business for which corporations may be organized under the laws of the
United States and the laws of the State of Florida.

ARTICLE III

CAPITAL STOCK

The Corporation is authorized to issue the following shares of capital
stock: (a) 100,000,000 shares of common stock, par value $.0001 per share (the
"Common Stock"); and (b) 100,000,000 shares of preferred stock, par value $.0001
per share (the "Preferred Stock"). The voting rights, the rights of redemption
and other relative rights and preferences of the Preferred Stock shall be
established by the Board of Directors.

The Board of Directors may authorize the issuance of such stock to such
persons upon such terms and for such consideration in cash, property or services
as the Board of Directors may determine and as may be allowed by law. The just
valuation of such property or services shall be fixed by the Board of Directors.
All such stock when issued shall be fully paid and exempt from assessment.

ARTICLE IV

REGISTERED OFFICE AND AGENT

The name of the registered agent of the Corporation and the street address
of the registered office of this Corporation is:

Berman, Wolfe & Rennert, P.A.
100 S.E. Second Street, 35th Floor
Miami, FL 33131
Attention: Charles J. Rennert, Esq.

ARTICLE V

CORPORATE MAILING ADDRESS

The principal office and mailing address of the Corporation is:

2222 Ponce de Leon, 3rd Floor
Coral Gables, FL 33134

B-1
117

ARTICLE VI

POWERS

The Corporation shall have all of the corporate powers enumerated under
Florida law.

ARTICLE VII

DIRECTOR-CONFLICTS OF INTEREST

No contract or other transaction between the Corporation and one or more of
its directors, or between the Corporation and any other corporation, firm,
association or other entity in which one or more of the directors are directors
or officers, or are financially interested, shall be either void or voidable
because of such relationship or interest or because such director or directors
are present at the meeting of the Board of Directors or a committee thereof
which authorizes, approves or ratifies such contract or transaction or because
his or her votes are counted for such purpose, if:

(a) The fact of such relationship or interest is disclosed or known to
the Board of Directors, or a duly empowered committee thereof, which
authorizes, approves or ratifies the contract or transaction by a vote or
consent sufficient for such purpose without counting the vote or votes of
such interested director or directors; or

(b) The fact of such relationship or interest is disclosed or known to
the shareholders entitled to vote and they authorize, approve or ratify
such contract or transaction by vote or written consent; or

(c) The contract or transaction is fair and reasonable as to the
Corporation at the time it is authorized by the Board, committee or the
shareholders.

A director of the Corporation may transact business, borrow, lend, or
otherwise deal or contract with the Corporation to the full extent and subject
only to the limitations and provisions of the laws of the State of Florida and
the laws of the United States.

Common or interested directors may be counted in determining the presence
of a quorum at a meeting of the Board of Directors or a committee thereof which
authorizes, approves or ratifies such contract or transaction.

ARTICLE VIII

NO ANTI-TAKEOVER LAW GOVERNANCE

The Corporation shall not be governed by Sections 607.0901 or 607.0902 of
the Florida Business Corporation Act or any laws related thereto.

ARTICLE IX

INDEMNIFICATION

The Corporation shall indemnify and shall advance expenses on behalf of its
officers and directors to the fullest extent permitted by law in existence
either now or hereafter.

ARTICLE X

FISCAL YEAR

The fiscal year of this Corporation shall be the calendar year, unless
otherwise established by the Board of Directors.

B-2
118

ARTICLE XI

DURATION

The duration of the Corporation is perpetual, unless sooner liquidated or
dissolved in accordance with law.

The foregoing Restated Articles of Incorporation were approved by unanimous
written consent of the Board of Directors and by a majority of the stockholders
at a special meeting of stockholders. The number of stockholder votes cast were
sufficient for approval of the Restated Articles of Incorporation.

The undersigned has executed these Restated Articles of Incorporation this
th day of , 199 .

EMBASSY ACQUISITION CORP.

By:
------------------------------------
Glenn L. Halpryn,
President

B-3
119
APPENDIX C

PROXY AND NOTICE OF ELECTION
EMBASSY ACQUISITION CORP.
1428 BRICKELL AVENUE, SUITE 105
MIAMI, FLORIDA 33131

THIS PROXY AND NOTICE OF ELECTION IS SOLICITED ON BEHALF OF THE BOARD OF
DIRECTORS

The undersigned hereby appoints Ronald M. Stein as proxy of the undersigned
(the "Proxy"), with power to appoint his substitute, and authorizes him to
represent and to vote, as specified below, all of the shares of the undersigned
held of record by the undersigned on March 24, 1998, at the Special Meeting of
Shareholders of Embassy Acquisition Corp. (the "Company") on April 16, 1998, and
at all adjournments thereof (the "Special Meeting"), on the matters set forth
below AND TO VOTE IN HIS DISCRETION FOR THE TRANSACTION OF SUCH OTHER BUSINESS
AS MAY COME BEFORE THE SPECIAL MEETING.

1. THE MERGER. To consider and vote upon the following interrelated matters
(collectively, the "Merger") as a single proposal:

(i) to approve and adopt a certain Agreement and Plan of Merger and
Reorganization, dated as of October 30, 1997, by and between the Company and
Orthodontix, Inc. a Florida corporation ("Orthodontix"), providing for, among
other things, the merger of Orthodontix Acquisition Corp., a Florida
corporation and wholly owned subsidiary corporation of the Company, with and
into Orthodontix; and

(ii) to approve an amendment to the Articles of Incorporation of the
Company to change the name of the Company to
"Orthodontix, Inc."

[ ] FOR [ ] AGAINST [ ] ABSTAIN

IF THE UNDERSIGNED VOTES "AGAINST" PROPOSAL 1, AND ELECTS TO REDEEM HIS
SHARES, PLEASE COMPLETE THE FOLLOWING:

THE UNDERSIGNED HEREBY ELECTS TO HAVE HIS SHARES REDEEMED

[ ] YES [ ] NO

(Continued and to be signed on other side)

(Continued from other side)

2. AUTHORIZATION TO ISSUE PREFERRED STOCK. To consider and vote upon a proposal
to amend and restate Articles of Incorporation of the Company to provide for
an authorized class of Preferred Stock consisting of 100,000,000 shares, par
value $.0001 per share, with rights, preferences and designations of such
shares to be determined by the Board of Directors of the Company.

[ ] FOR [ ] AGAINST [ ] ABSTAIN

3. 1997 STOCK OPTION PLAN. To consider and vote upon a proposal to approve the
1997 Embassy Acquisition Corp. Stock Option Plan.

[ ] FOR [ ] AGAINST [ ] ABSTAIN

4. OTHER BUSINESS. In his discretion, the Proxy is authorized to vote on such
other business as may properly come before the Special Meeting or any
adjournment or postponement thereof.

[ ] FOR [ ] AGAINST [ ] ABSTAIN

THE SHARES REPRESENTED BY THIS PROXY WILL BE VOTED AS SPECIFIED ABOVE. IF NO
SPECIFICATION IS MADE, THIS PROXY WILL BE VOTED "FOR" THE PROPOSALS 1, 2 AND 3.
A VOTE TO ABSTAIN WILL NOT BE COUNTED TOWARDS THE REQUISITE AFFIRMATIVE VOTE TO
APPROVE PROPOSALS 1, 2 AND 3.

Dated:

----------------------------------- ,1998

-----------------------------------
Signature

-----------------------------------
Signature if held jointly

Your signature should appear
exactly as your name appears in the
space at left. For joint accounts,
both should sign. When signing in a
fiduciary or representative
capacity, please give your full
title as such. If a corporation or
partnership, sign in full corporate
or partnership name by authorized
officer or partner.

PLEASE SIGN, DATE AND RETURN THIS PROXY IN THE ENCLOSED POSTAGE PAID ENVELOPE.